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Current psychotherapy outcome research: Focus on symptom reduction 
 
Goldfried and Wolfe (1996) have described three generations in the history of 
psychotherapy1 outcome research. The first generation of research was conducted in the 
1950s and 1960s, and it was aimed at the investigation of whether psychotherapy can 
elicit personality change or not. Little specification or differentiation of the different 
forms of psychotherapy and research methods occurred. The second generation of 
psychotherapy outcome research was conducted in the 1960s and 1970s. The research 
themes were much more specific than before, and the question was now if a specific 
treatment could reduce the symptoms of a specific disorder. Control conditions and 
randomization procedures were introduced into the research designs. The current 
generation of psychotherapy outcome research, as described by Goldfried and Wolfe, 
originated in the 1980s and is the most widely used paradigm in psychotherapy outcome 
research today. The research methodology is based upon the medical model and 
generally aimed at investigation of the effects of specific, manual-based treatments 
compared to other well-defined treatments and/or control groups. Patients with clearly 
defined DSM-IV diagnoses are typically assigned at random to an experimental 
treatment condition, alternative treatment conditions or control conditions. Treatments 
are conducted under optimal circumstances in order to test the best possible treatment 
effect. The therapists for instance, are carefully trained. This type of research is referred 
to as efficacy research. Over the years psychotherapy outcome research has thus ruled 
out as many sources of variance (i.e., patient, therapist, and treatment variation) as 
possible which were not part of the main research interest. The ultimate result, also 
stimulated by Division 12 of the American Psychological Association (APA), is that 
one can now speak of “empirically supported treatments” (ESTs). Examples of such are 
psychological treatments available today for anxiety disorders, mood disorders, 
somatoform disorders, substance abuse, and eating disorders (Carr, 2009; Chambless & 
Ollendick, 2001; Keijsers, van Minnen & Hoogduin, 2010; Roth & Fonagy, 2006).  
For the current generation of psychotherapy outcome research, the main question 
is whether a specific treatment effectively reduces symptoms of psychopathology. For 
patients with social phobia, for example, the question is to what extent a specific 
treatment reduces disorder specific symptoms such as fear of social and/or performance 
situations, the experienced anxiety when patients are exposed to such situations, and the 
level of avoidance of such situations, compared to another treatment or control group. In 
1998, the renowned Journal of Consulting and Clinical Psychology devoted a special 
issue to ESTs. Both advocates and critics of the EST presented their views on — among 
other issues — the use of randomized controlled clinical trials as the golden standard for 
efficacy research, the use of highly trained therapists, the advantages and disadvantages 
of strict patient selection, the use of treatment manuals, the transferability of the out-
                                                 
1 By psychotherapy, we understand all common varieties of psychological treatments  
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comes of controlled clinical trials to clinical practice, and the differences between 
efficacy and effectiveness research (see, among others, Beutler, 1998; Borkovec & 
Castonguay, 1998; Chambless & Hollon, 1998; Goldfried & Wolfe, 1998). Remarkably, 
almost no discussion of the definition of treatment outcome measure occurred. 
Sometimes explicitly but mostly implicitly, the authors seemed satisfied with the assess-
ment of the level of symptom reduction as the only outcome measure to establish the 
effects of ESTs. Only Chambless and Hollon mentioned the desirability to go beyond 
symptom assessment to examine the effects of treatment on more general measures of 
functioning, but they observed that only a very few studies included such measures. 
This one-sided view of symptom reduction as the only important outcome measure has 
become so pervasive in the present generation of outcome research that a treatment is 
now referred to as “effective” without further clarification that “effective” means with 
respect to symptom reduction.  
Underlying this symptom-focused approach, a specific and rather restricted 
notion of health and disease can be discerned, namely that the reduction of the 
symptoms of a mental disorder is sufficient to increase mental health. It is suggested, 
thus, that psychopathology and mental health are at the opposite ends of a single mental 
health continuum and that good mental health is the absence of symptoms of psycho-
pathology. However, various authors in the area of mental health care have taken issue 
with the focus of psychotherapy outcome measurement on solely symptom reduction 
(Hill & Lambert, 2004; Jacobson, Roberts, Berns, & McGlinchey, 1999, Mirin & 
Namerow, 1991; Perkins, 2001). Effective symptom reduction does not, for example, 
necessarily imply positive changes in the individual’s subjective sense of well-being, 
the quality of his or her social relationships (Mirin & Namerow), or an increased sense 
of control or greater engagement in activities (Perkins). Conversely, for a chronic 
mental illness such as schizophrenia, it is known that an increased sense of control and 
reduction of hopelessness can be realized without a change of negative symptoms 
(Shrivastava, Johnston, Shah, & Bureau, 2010; Strauss, 1994). Successful treatment 
typically yields a variety of positive effects and not just symptom reduction (Goldfried 
& Wolfe, 1996; Perkins; Wampold, 2001). 
The definition of effective treatment in terms of only symptom reduction also 
produces an overly narrow view of treatment from the perspective of patients. Most 
patients mention symptom reduction as a reason for entering into treatment, but Grosse 
Holtforth and Grawe (2002) found only a small minority of patients to mention symp-
tom reduction as the only or most important goal. Increased interpersonal functioning, 
well-being, and personal development were also frequently mentioned as goals for 
seeking treatment. Connolly and Strupp (1996), studying the literature on patients’ 
perceptions of change, found that changes in self-concept were reported in addition to 
symptom relief. More recently, Levitt, Butler, and Hill (2006) found symptom reduction 
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per se to be rarely mentioned by patients as an important outcome of treatment; relating 
better with others and feeling better about themselves were mentioned instead. 
The idea that the effects of therapy consist of more than symptom reduction is 
far from new. Already in 1948, the World Health Organization (WHO, p.1) stated that 
“[health is] a state of complete physical, mental and social well-being and not merely 
the absence of disease.” However, the number of studies on the underlying structure of 
mental health is limited. It was only in 2005, that Keyes showed measures of mental 
health and mental illness to constitute correlated but separate unipolar dimensions. In 
other words, a one-sided focus on symptom reduction, as is the case in most efficacy 
studies of psychological treatment, runs the risk of leaving an important part of mental 
health out of the discussion.  
The reason for the current emphasis on symptom reduction may lie in the world-
wide use of an a-theoretical classification system for psychopathology, namely the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) -III, -IV, and -IV-R 
(American Psychiatric Association, 1980, 1987, 1994). The uniform terminology 
offered by the DSM for the description of mental disorders provides a standardized 
system of symptom measurement and allows researchers to submit grant proposals that 
meet standard scientific criteria (Mayes & Horwitz, 2005). From the original DSM-III 
on, the medical model was adopted in the classification of psychopathology, and 
therewith the focus on symptoms.  
An additional practical reason for the current emphasis on symptom reduction 
may be that symptom reduction is also the most unequivocal means to determine the 
effects of treatment because symptom reduction is measured in a fairly similar manner 
by all kind of researchers and for all kind of treatments. Therefore, the outcomes of 
studies can be compared and incorporated, for example into meta-analyses (see, for in-
stance, Gould, Otto, & Pollack, 1995; Westen & Morrison, 2001). The one-sided focus 
on symptom reduction in psychotherapy outcome research might also, as already men-
tioned, be due to the equation made by many researchers of mental health with the 
absence of psychopathology. 
In previous years, the field of psychotherapy made tremendous improvements in 
classifying and treating a large variety of mental disorders. Nevertheless, there are 
unwanted consequences of the current one-sided focus on symptom reduction as the 
only measure of psychotherapy treatment outcome. To start with, this one-sided focus 
can actually hamper the implementation of evidence-based knowledge into clinical 
practice. That is, many clinicians do not sufficiently recognize elements of clinical 
practice or characteristics of their patients in today’s research paradigm. Clinicians 
perceive psychotherapy outcome research to be biased and thus of limited use for actual 
clinical practice (Hutschemaekers, 2003; Mirin & Namarow, 1991; Takens, 2004). 
According to the American Psychological Association (Presidential Task Force on 
Evidence Based Practice, 2006), for example, the inclusion of the subjectively lived 
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experiences of patients in psychotherapy outcome research is important because it can 
strengthen the relation between research and practice.  
A second unwanted consequence of the focus on solely symptom reduction is a 
neglect of the other treatment goals mentioned by patients. Patients mention change 
other than symptom reduction as the goal of their treatment but these goals of treatment 
are ignored in current research paradigms. 
A third unwanted consequence is that the current one-sided focus on symptom 
reduction possibly also leads to a biased selection of treatments. Little is known about 
the effects on important other outcomes. There is a possibility that certain treatments are 
incorrectly perceived as less effective when the evaluation is in terms of symptom 
reduction only. Broadening outcome research to include measures other than just 
symptom reduction that are valid and reliable as outcome measures, may produce a 
different picture of which treatments can be judged to be effective. In any case, the 
broadening of psychotherapy outcome research will certainly deepen the discussion of 
which treatments are effective.  
A fourth unwanted consequence of the evaluation of only symptom reduction is 
that negative side-effects of treatment are not considered. Treatment can make a patient 
dependent upon treatment or foster feelings of powerlessness on the part of a patient 
while nevertheless effectively reducing the symptoms of a specific disorder. With the 
one-sided focus on symptom reduction an overly optimistic picture of the effects of 
treatment can thus be painted at times. 
Fifth and finally, there are patient groups such as those with schizophrenia or 
somatization disorder for whom symptom reduction is virtually unattainable. In the 
current research tradition, these patients are considered minimally treatable. They can, 
however, show marked progress on other treatment outcomes and thus an increased 
sense of control and reduced hopelessness, for example, (Shrivastava, Johnston, Shah, 
& Bureau, 2010; Strauss, 1994). In other words, these patient groups may actually be 
judged to be treatable when a psychotherapy outcome measure other than symptom 
reduction is employed. 
 
 
In search of supplementary outcome measures 
 
In light of the above discussion of the shortcomings of the current generation of 
psychotherapy outcome research, a broader perspective on the measurement of 
psychotherapy outcome is clearly desirable. Let us examine what measure or measures 
can be employed in order to attain a more complete picture of psychotherapy outcome.  
This measure should describe positive change, which is not captured by the 
measurement of specific features of syndromes or specific symptoms. In the literature, 
there are various positive changes described. In the definition of health by the WHO, 
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both mental and social well-being are mentioned (WHO, 1948). Patients mention 
‘getting a grasp on their lives’, ‘having a more positive perspective on the future’, and 
‘learning to cope with difficulties’ (Boevink, Wolf, Nieuwenhuizen, & Schene, 1995). 
Researchers mention such concepts as subjective well-being, (Mirin & Namerow, 
1991), a sense of control, and engagement in activities (Perkins, 2001). The term quality 
of life is also mentioned when other treatment changes are discussed (Gladis, Gosch, 
Dishuk, & Crits-Christoph, 1999). The list can be broadened to include dozens of other 
concepts that refer to all kinds of changes that are realized apart from symptom 
reduction by effective treatments. All these concepts seem to focus on positive changes 
such as self-worth, well-being, and personal strength.  
Given the multitude of positive changes, it is far from evident which measure 
should be added to outcome research to broaden it. To keep out of the rivalries between 
different traditions and schools of thought, but also to enlarge the chances of the 
concept being relevant for various mental health patients, the concept should not be 
restricted to a particular psychotherapeutic tradition or specific patient populations. The 
concept should also gauge conditions that are known to change as a result of successful 
psychotherapy.  
Several concepts have been introduced over the years to describe positive effects 
that go beyond symptom reduction for psychotherapeutic treatment. In the field of 
social psychiatry, the concept of empowerment (Rogers, Chamberlin, Ellison, & Crean, 
1997) has been put forth. In certain psychotherapeutic traditions, the concepts of ego 
strength (Kernberg et al., 1972) and self-actualization (Maslow, 1970) are quite well-
known. However, the aforementioned concepts do not have a concise meaning outside 
the specific traditions in which they are embedded. The popular term quality of life is 
not limited to a specific tradition but lacks a clearly agreed upon definition (Gladis et 
al., 1999). The attempt of Katschnig (1997) to define quality of life is illustrative: “a 
loosely related body of work on psychological well-being, social and emotional 
functioning, health status, functional performance, life satisfaction, social support, and 
standard of living, whereby normative, objective, and subjective indicators of physical, 
and emotional functioning are all used” (p.6). The existence of hundreds of different 
instruments to measure quality of life further confirms the lack of a clearly agreed upon 
definition (Gladis et al.). 
When evaluating the classical theories about change of mental health care 
patients, the demoralization theory of Jerome Frank (1974) stands out. The concept of 
remoralization or the restoration of morale is of significance for not only different 
treatment approaches; there is also a good consensual definition. The question of 
whether it is a useful measure in outcome research has yet to be addressed, however. In 
the remainder of this general introduction, the concept of demoralization and its reverse, 
namely the concept of remoralization, will therefore be examined in greater detail and 
particularly with respect to their value as measures of psychotherapy outcome. 
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Thereafter, the relation between the measurement of remoralization and the measure-
ment of symptom reduction will be considered and the question of just how remora-
lization relates to symptom reduction in treatment outcome research in particular.  
The value of remoralization as an outcome measure  
In his book entitled Persuasion and Healing (1973), Frank states that people who enter 
into treatment for psychological problems typically suffer from not only a specific 
mental disorder (i.e., symptomatic burden) but also feel demoralized. According to 
Frank (1974), the painful experience of symptoms and the accompanying negative 
emotions over a longer period of time can lead to feelings of hopelessness and 
powerlessness, which are central to the state of demoralization. Demoralization thus 
results from the belief of not being able to solve current problems and is thus 
characterized by feelings of impotence, isolation, and despair. De Figueiredo and Frank 
(1982) have described demoralization as involving two dimensions: subjective 
incompetence and distress. Subjective incompetence is described as a feeling of 
inability to plan and initiate concerted action towards one or more goals, and the actions 
of demoralized individuals tend to lack direction as a result of this (de Figueiredo, 
2007). Distress is described as the incapacity of a person to adapt to stressful events by 
de Figueiredo and Frank, and it is characterized by feelings of discouragement, anger, 
and sadness.  
Subjective incompetence, by itself, and distress, by itself, can be seen as normal. 
Their overlap, however, can be very impairing and thus lead to a state of demora-
lization. To remoralize, subjective incompetence must therefore be resolved, on the one 
hand, and distress must be reduced, on the other hand (de Figueiredo, 2007). The first 
requires that the person again believe that he or she is competent. The latter requires 
coping with a particular stressor.  
 According to Howard, Lueger, Malin, and Martinovich (1993), remoralization is 
the enhancement of subjective well-being, and is realized early in treatment. When a 
treatment clarifies a patient’s problems, inspires hope, and provides experiences of 
success and mastery, it is likely to remoralize (Frank, 1973). According to Frank (1974), 
moreover, “[treatment should] heighten the patient’s sense of mastery over the inner and 
outer forces assailing him by labeling them and fitting them into a conceptual scheme, 
as well as by supplying success experiences” (p. 272). Slavney (1999) has similarly 
pointed out that a therapist should try to normalize a patient’s distress in order to 
remoralize the patient. That is, the patient’s mood and concerns should be attended to 
and the patient’s distress validated (i.e., acknowledged as normal for an individual 
responding under abnormally difficult) in order to promote remoralization. 
Although a state of demoralization may look like a major depressive disorder, 
researchers show that it is different and can be distinguished from depression (Clarke & 
Kissane, 2002; de Figueiredo, 1993; Mangelli et al., 2005). Depression is characterized 
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by anhedonia — diminished interest or pleasure in all, or almost all, activities — 
whereas demoralization is defined by de lack of looking forward to the future with 
pleasant anticipation. The individual who is demoralized can actually enjoy the present 
(de Figueiredo), but suffers from subjective incompetence due to uncertainty about what 
course of action to take; the depressed individual suffers from apathy even when action 
is called for and the type of action necessary is clear. In a study of psychiatric morbidity 
among medically ill patients, Clarke, Mackinnon, Smith, McKenzie, and Herrman 
(2002) found separate latent symptom structures of anhedonia and demoralization. 
Additionally, they found that suicidal ideation also associated differently with 
demoralization and depression. The states of depression and demoralization are known 
to frequently overlap but not be necessarily connected. While Mangelli et al. found 
some of their sample of medically ill patients to be both depressed and demoralized, 
44% of the depressed patients were not demoralized and 70% of the demoralized 
patients were not depressed.  
Remoralization can thus be viewed as a valuable candidate to supplement 
symptom reduction as a measure of psychotherapy outcome because it indeed appears to 
be an important outcome of psychotherapy, can be expected to change when treatment 
is effective, and it is not a feature of a specific syndrome or a specific symptom. In the 
following, how remoralization appears to relate to symptom reduction will therefore be 
considered further. 
The conceptual relation of remoralization to symptom reduction  
According to Frank (1973), people who enter into treatment suffer from not only 
symptomatic burden but also feel demoralized, which means that effective treatment 
must realize both remoralization and symptom reduction. Remoralization and symptom 
reduction are viewed as two distinguishable outcomes of treatment. At the same time, 
however, these two outcomes are expected to influence each other. As Frank (1974) 
stated, demoralization can aggravate symptoms and symptoms can aggravate 
demoralization. Similarly, de Figueiredo (2007) states that “An illness may set the stage 
for appearance of demoralization which, in turn, may worsen the prognosis of the 
illness.” (p131). From such a perspective, thus, remoralization and symptom reduction 
can be assumed to be interdependent but distinguishable.  
Another renowned theory that provides insight into the theoretical distinction 
between remoralization and symptom reduction is the phase model of psychotherapy 
outcome. Howard et al. (1993) designed the phase model to describe the different stages 
of change that characterize the course of psychotherapeutic treatment and not to provide 
information on the distinction between remoralization and symptom reduction, but the 
phase model nevertheless provides insight into the relations between remoralization and 
symptom reduction. In the phase model, psychotherapy is assumed to progress in a 
stepwise manner with each phase depending upon a previous phase and each phase 
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assumed to represent a different domain of psychotherapeutic change. The first phase in 
the model draws upon the demoralization theory of Frank and is therefore referred to as 
the remoralization phase. During this phase, patients overcome their state of demora-
lization, regain hope that their problems can be resolved, and experience an increased 
sense of subjective well-being as a result. The second phase addresses the symptoms of 
the patient and is referred to as the remediation phase. Coping is facilitated and im-
proved in order to bring about symptom relief. The third phase is the rehabilitation 
phase, which is “focused on the unlearning of troublesome, maladaptive, longstanding 
patterns and the establishment of new ways of dealing with various aspects of self and 
life” (Howard et al., p. 680).  
It is apparent from the description of the first two phases of the phase model that 
Howard et al. (1993) considered remoralization and remediation to constitute different 
phases in the process of psychotherapeutic change, and they thus considered different 
psychotherapeutic outcomes. In other words, remoralization and symptom reduction are 
two distinguishable effects of treatment. Considering de Figueiredo (2007), Frank 
(1974), and Howard et al., it is clear that remoralization and symptom reduction can be 
distinguished at a conceptual level. 
Remoralization, with respect to its theoretical content, is a valuable candidate to 
broaden the measurement of treatment outcome. However, to really be a valuable 
measure, remoralization must also have practical significance and it must be possible to 
operationalize the notion. The measurability of remoralization will thus be considered 
along with its empirical relation to symptom reduction in the following.  
 
 
Remoralization at an operational level 
The measurability of remoralization  
In order to measure remoralization in mental health patients, a reliable and valid 
instrument must be available. Three instruments appear to have some potential for the 
measurement of remoralization. The first is the Psychiatric Epidemiological Research 
Interview-Demoralization (PERI-D) from Dohrenwend, Shrout, Egri, and Mendelsohn 
(1980). However, the PERI-D has several disadvantages when considered for use as an 
outcome measure. First, it is an interview and therefore its administration is rather time-
consuming and complicates research logistics as opposed to a self-report instrument. 
Second, the PERI-D is a classification instrument (i.e., it produces a classification of the 
individual as demoralized or not), and is therefore not particularly well-suited to 
determine the level of demoralization following treatment. That is, the PERI-D may 
have a low level of sensitivity to change. In addition, the fact that the respondents are 
asked to estimate their demoralization for the entire past year also reduces the sen-
sitivity of the PERI-D to change. Third, the PERI-D contains a number of items that 
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concern symptoms of anxiety, depression, and psychosomatic problems, which makes it 
less suited to measure an outcome of treatment not captured by symptom reduction. 
Fourth, eight highly intercorrelated subscales provide information on the state of 
demoralization but their intercorrelations make things difficult to interpret. The last 
disadvantage of the PERI-D as a measure of demoralization is that de Figueiredo and 
Frank (1982) explicitly stated that the PERI-D does not encompass a broad concept-
tualization of demoralization as it only contains items that assess distress and not 
subjective incompetence.  
The second instrument is the Demoralization Scale (DS) from Kissane, Wein, 
Love, Lee, Kee, and Clarke (2004). The DS consists of 24 items and 5 highly correlated 
dimensions of demoralization: disheartenment, loss of meaning, non-specific dysphoria, 
helplessness, and sense of failure. Interpretation problems also thus occur because of the 
high correlations between the dimensions of demoralization. The high correlations raise 
the question of whether the DS is really a multidimensional scale. The DS aims to 
measure demoralization in somatic health care patients and it has only been validated 
using a relatively small (N = 100) and highly homogeneous sample of patients suffering 
from a chronic somatic illness (i.e., cancer) and no data has been collected on the test-
retest reliability of the scale or its underlying factor structure. The suitability of the DS 
for use with mental health patients and its psychometric properties when used with such 
patients are thus unknown. Finally, the DS measures a negative state and therefore 
emphasizes what is wrong (i.e., problems). This may be demoralizing in and of itself, 
particularly when the instrument is administered repeatedly throughout the course of 
treatment. 
The third instrument is the subjective well-being scale (SWS) from Howard et 
al. (1993). In addition to the original two-item form from Howard et al, a three-item 
form (Grissom, Lyons, & Lutz, 2002) and a four-item form have also been developed 
(Callahan, Swift, & Hynan, 2006). The SWS has been constructed to measure change in 
patients during the remoralization phase of treatment. The SWS is the only scale that is 
known in the literature to evaluate the positive process of remoralization. Therefore it 
has significance. At the same time there are several issues that might cause difficulties 
when this instrument is adopted to broaden current outcome research. The items on the 
original form were as follows: “At the present time, how well do you feel you are 
getting along emotionally and psychologically?” and “At the present time, how upset 
and distressed have you been feeling?” (Howard et al., p. 860). These items do not 
encompass Frank’s broader conceptualization of demoralization. The SWS is speci-
fically directed to the patients’ distress and lacks items concerned with subjective 
incompetence. Furthermore, the use of a scale with such a small number of items is 
methodologically limited; the reliability and the content validity of the scale can easily 
drop below acceptable values. Finally, in most of the current outcome research, 
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treatments for specific diagnostic groups of patients are evaluated. The subjective well-
being scale, in contrast, has only been used with heterogeneous patient samples.  
Despite the aforementioned concerns, studies using the SWS have all shown 
remoralization to change significantly and reliably for most patients (Callahan et al., 
2006; Hilsenroth, Ackerman, & Blagys, 2001; Howard et al. 1993; Joyce, Ogrodniczuk, 
Piper, & McCallum, 2002; Lutz, Lowry, Kopta, Einstein, & Howard, 2001; Martino-
vich, 1998). This is a promising result. 
In sum, there is no instrument that can be judged sufficiently appropriate to 
measure changes in remoralization as a result of treatment among mental health care 
patients available today. This is a practical difficulty for the addition of measures of 
remoralization to outcome research. 
Distinguishing remoralization from symptom reduction  
In addition to the measurability of remoralization, whether or not it can be empirically 
distinguished from symptom reduction and whether or not the measurement of remora-
lization thus has added value for psychotherapy outcome research must be determined. 
While Frank (1974) asserted that the process of remoralization can be theoretically 
differentiated from the process of symptom reduction, he — himself — never invest-
tigated this assertion empirically. Howard and colleagues (1993) similarly describe the 
changes in remoralization and symptom reduction as two distinguishable processes. 
And this has also been done in later studies (Barkham, Rees, Stiles, Shapiro, Hardy, & 
Reynolds, 1996; Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; Howard 
et al., Joyce et al., 2002; Kopta, Howard, Lowry, & Beutler, 1994; Lutz et al., 2001; 
Martinovich, 1998). None of these studies, however, explicitly investigated the relation 
between remoralization and symptom reduction or provided specific information on the 
relation between remoralization and symptom reduction. Their findings can nevertheless 
shed some light on the differentiation of remoralization from symptom reduction and 
the possibly added value of measuring remoralization in addition to symptom reduction.  
A total of five studies (Barkham et al., 1996; Hilsenroth et al., 2001; Howard et 
al., 1993; Kopta et al., 1994; Lutz et al., 2001) showed a larger percentage of their 
patients to improve more on remoralization than on symptom reduction. Whether or not 
symptom reduction (i.e., the remediation phase) actually constitutes a later phase of 
change than remoralization can, strictly speaking, not be deduced on the basis of this 
data, however. The ratio of patients who improved on remoralization to patients who 
improved on symptom reduction did not change over time. That is, the improvement 
ratio for remoralization relative to symptom reduction was stable across the course of 
treatment. Inspection of the figures depicting the percentages of patients improved for 
remoralization and the percentages of patients improved for symptom reduction over 
time (Barkham et al.; Howard et al.; Kopta et al.) also reveals virtually identical growth 
lines for the two measures. It is thus not clear that one measure actually changes earlier 
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than the other or one measure accelerates at a different point in time than the other. In 
the figures of Howard et al. and Kopta et al., moreover, the changes in remoralization 
are found to be largest during the first few treatment sessions, but this was also the case 
for symptom reduction. In other words, remoralization does not accelerate earlier than 
symptom reduction, which suggests that the changes in the two co-occur. 
Whether or not remoralization and symptom reduction are clearly separate or 
overlap considerably remains to be seen, thus. Related to this issue, we do not know if 
the measurement of changes in remoralization provides information that is supplemental 
and useful for the proper evaluation of treatment outcomes when employed in addition 
to symptom reduction.  
 
 
Aims and outline of the present dissertation 
 
Many authors have taken issue with the one-sided focus of current psychotherapy 
outcome research on symptom reduction. Despite these concerns, a valuable construct 
to be added to symptom reduction and thereby broaden the determination of treatment 
effects has yet to be identified. In the renowned demoralization theory of Jerome Frank 
(e.g., 1974) and the phase model of Howard et al. (1993), the construct of 
remoralization is put forward to describe an important psychotherapy outcome that 
occurs in addition to symptom reduction. While remoralization appears to be a 
promising measure in addition to symptom reduction, a suitable measurement 
instrument (i.e., measure to document changes in remoralization) is lacking. Whether or 
not remoralization can be empirically distinguished from symptom reduction is also not 
clear. Because of this, the question remains: Is remoralization a valuable outcome 
measure supplementary to measuring symptom reduction in psychotherapy outcome 
research? In the first three empirical chapters of the dissertation (Chapters 2, 3, and 4), 
critical aspects of the measurement of remoralization will therefore be considered in 
order to determine the added value of attention to remoralization. A related but 
somewhat different enterprise is undertaken in the fourth empirical chapter (Chapter 5) 
in order to determine the treatment implications of the phase model of psychotherapy 
outcome. 
Chapter 2. Development of the remoralization scale: An extension of contem-
porary psychotherapy outcome measurement 
In this chapter, the newly developed Remoralization Scale (RS) is introduced. The RS 
has been specifically developed for patients in mental health care. The results of five 
studies are described. First, the development of the RS, thereafter, the unidimensionality 
and scalar invariance of the RS; the reliability of the RS; the construct validity of the 
RS; and the sensitivity of the RS to therapeutic change are investigated. 
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Chapter 3. Utility of measuring remoralization in addition to symptoms in efficacy 
research: A preliminary study 
In this chapter, the results of a naturalistic study undertaken to investigate whether or 
not the measurement of remoralization is sensitive to changes at several points during 
the course of an empirically-supported treatment are reported. The relations between 
remoralization and symptom reduction are investigated in addition to the unique con-
tribution of measuring remoralization in addition to symptom reduction for the predict-
tion of change in health-related quality of life. This study was also designed to 
overcome the methodological drawbacks of earlier studies of the phase model of 
Howard and colleagues (1993). Patients suffering from a specific and well-defined 
disorder, namely panic disorder with agoraphobia, received an indicated, protocol-based 
EST. Changes in specific agoraphobic avoidance symptoms and agoraphobic 
cognitions, changes in remoralization, and changes in health-related quality of life were 
examined across the course of treatment.  
Chapter 4. The distinction between remoralization and symptom reduction: An 
experimental study  
The study reported on in this chapter was specifically designed to experimentally 
investigate the relations between remoralization and symptom reduction. Once again, 
patients suffering from panic disorder and agoraphobia were followed. Patients were 
randomly assigned to a waiting list control condition or one of two treatments. Both 
remoralization and specific panic symptoms were assessed. The effects of a brief 
treatment focused solely on remoralization versus the effects of a brief exposure in vivo 
treatment for the symptoms of the disorder were compared. This experimental research 
design was adopted in order to maximize the chances of distinguishing remoralization 
and symptom reduction. It was reasoned that, if remoralization and symptom reduction 
can really be distinguished as Frank (1974) and Howard et al. in the phase model (1993) 
both propose, the treatment aimed at remoralization should not lead to symptom 
reduction; conversely, the treatment aimed at remediation should not lead to increases in 
remoralization. 
Chapter 5. Treatment implication of the phase model of psychotherapy outcome: 
An experimental study  
The three preceding empirical studies were all designed to answer the question of 
whether the measurement of remoralization is valuable in addition to the measurement 
of symptom reduction in psychotherapy outcome research. The fourth empirical study 
addresses a different but related topic. Previous studies of the phase model (Barkham et 
al, 1996; Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; Howard et al., 
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1993; Joyce, et al., 2002; Kopta et al, 1994; Lutz et al., 2001; Martinovich, 1998) all 
suffer from an important shortcoming, namely: that all refrained from the provision of 
treatment in line with the content of the phase model. According to Howard et al. 
(1993), “certain classes of interventions are appropriate for different phases of therapy” 
(p. 679). In the phase model, it is indeed presumed that different topics should be 
addressed during different phases of therapy, but none of the studies testing the phase 
model to date — including that of Howard et al. — have either experimentally or quasi-
experimentally, tested this presumption.  
 The study described in Chapter 5 was designed to do just this and thus to 
experimentally investigate the treatment implications of the phase model. The study is 
an extension of the study described in Chapter 4. The patients in the treatment condition 
from the study described in Chapter 4 received a second brief treatment after initial brief 
treatment in such a manner that half of the patients in the treatment condition received 
remoralization treatment first and then exposure treatment; the other half received 
exposure treatment first and then remoralization treatment. It was reasoned that the 
treatment sequence that was in concordance with the sequence of the phase model (i.e., 
brief remoralization treatment followed by brief symptom reduction treatment) would 
be more effective than the treatment that was not in concordance with the sequence of 
the phase model (i.e., brief symptom reduction treatment followed by brief 
remoralization treatment). Effects were similarly measured in terms of both symptom 
reduction and remoralization.   
Chapter 6. Summery and general discussion  
In the final chapter of this dissertation, the overall results of the studies are summarized. 
Limitations and considerations, and the implication of the results in relation to the 
background of the dissertation are discussed. 
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Abstract 
 
Remoralization is the process of restoration of morale. Remoralization constitutes an 
important step in the therapeutic change process. Because no appropriate self-report 
instrument was available to indicate the level of morale in mental health care patients, 
the Remoralization Scale (RS) was developed. In a first study (299 outpatients), a pool 
of 69 items was examined to produce an initial scale of 16 items with a unidimensional 
factor structure. In a second study (199 outpatients, 192 non-patients), the 
unidimensionality and scalar invariance of the initial scale was tested. To make the RS 
as short and easy to complete as possible, 4 items with low factor loadings were 
removed. In a third study (124 students), the test-retest reliability (r = .89) and internal 
consistency (α = 0.91) of the RS were estimated. In a fourth study, the construct 
validity of the RS was investigated using a demoralization scale (r = .72) and scales 
which measure anxiety (r = .52), depression (r = .50), somatic symptoms (r = .36) 
and social dysfunction (r = .37). In a fifth study (24 panic outpatients), the sensitivity 
of the RS to therapeutic change was examined and found to be good. In closing, limita-
tions of the RS were discussed. 
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Introduction 
 
The designs of contemporary psychotherapy outcome studies draw heavily on medical 
treatment efficacy research. The effects of specific, manual-based treatments are typi-
cally compared to the effects of other, equally well-defined treatments or control 
groups. The outcome measures in efficacy research are usually measures of symptom 
reduction, especially in the large randomized controlled trials and meta-analyses (see, 
for instance, Gould, Otto, & Pollack, 1995; Westen & Morrison, 2001). Reduced 
symptomatology is often taken to be necessary and sufficient for the demonstration of 
psychotherapeutic treatment effects.  
More and more, however, various authors in the area of contemporary 
psychotherapy have taken issue with the fact that, in line with the medical model, the 
main focus is on symptom reduction (Hill & Lambert, 2004; Jacobson, Roberts, Berns, 
& McGlinchey, 1999). The frequent hopes of patients in psychotherapy for a wider 
range of treatment effects is insufficiently taken into account by the medical model 
(Grosse Holtforth & Grawe, 2002) and successful psychotherapeutic treatment often 
yields more than simply a reduction of symptoms (Goldfried & Wolfe, 1996; Perkins, 
2001; Wampold, 2001). Additionally, symptom reduction does not necessarily imply 
positive changes in, for example, the individual’s subjective sense of well-being or the 
quality of social relationships (Mirin & Namerow, 1991). Furthermore, for a chronic 
mental illness such as schizophrenia, it is known that an increased sense of control and a 
reduction of hopelessness can be brought about despite a lack of reduced symptom-
matology (Strauss, 1994).  
It seems clear that exclusive attention to symptom reduction is considered 
problematic. Other concepts that can be investigated in addition to symptom reduction 
in treatment outcome research are required. Several psychological concepts have been 
introduced over the years to describe the beneficial effects of psychotherapy besides 
symptom reduction. In social psychiatry, the concept of empowerment (Rogers, Cham-
berlin, Ellison, & Crean, 1997) has been put forth; in various psychotherapeutic tra-
ditions, the concepts of ego-strength (Kernberg et al., 1972) and self-actualization 
(Maslow, 1970) are well-known. However, these introduced concepts do not have a 
concise meaning outside the specific psychotherapeutic traditions in which they are 
embedded, which makes them less suitable as outcome measures in addition to 
symptom reduction. A rare exception is the concept of demoralization, introduced by 
Jerome Frank in 1974, which has significance across different psychotherapeutic 
approaches. Demoralization is a state of mind, resulting from a person’s belief that he or 
she is incapable of solving problems and thus characterized by feelings of impotence, 
isolation, and despair. Demoralized patients feel powerless and hopeless. Frank believed 
that the effectiveness of every form of psychotherapy depends upon its ability to restore 
a patient’s morale. In later work, Howard, Lueger, Maling, and Martinovich (1993) 
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referred to the restoration of a person’s morale as ‘remoralization’ and asserted that 
remoralization may actually constitute the first step in the process of therapeutic change. 
Remoralization encompasses a variety of beneficial treatment effects, which makes it 
attractive as an outcome measure in addition to the assessment of symptoms. 
Although remoralization, as is demoralization, has been discussed over the years 
as an interesting, promising concept, and despite the introduction of various instruments 
to measure demoralization and remoralization, it has barely influenced the efficacy and 
effectiveness outcome research. In 1980, Dohrenwend, Shrout, Egri and Mendelsohn 
developed the Psychiatric Epidemiological Research Interview-Demoralization. 
However, this instrument has several disadvantages when used as an outcome measure. 
First, it is an interview as opposed to an easy to administer self-report instrument. 
Second, it is a classification instrument which asks about demoralization during the past 
year, which makes it insensitive to change. Third, it contains a number of items 
concerned with symptoms of anxiety, depression and psychosomatic problems, which 
makes it less appropriate to be measured in addition to symptom assessment. In 1993, 
Howard et al. published a two-item scale to measure subjective well-being. However, 
this instrument does not encompass Frank’s broader conceptualization of 
demoralization. Furthermore, the use of a measurement scale with only two items is 
methodologically limited; the reliability and the content validity of the scale can easily 
drop below acceptable values. In 2004, the Demoralization Scale (Kissane, Wein, Love, 
Lee, Kee, & Clarke, 2004) was introduced. This scale was developed to measure 
demoralization in general health care patients. It was only tested on a relatively small (N 
= 100) and highly homogeneous sample of patients suffering from chronic somatic 
illnesses (cancer) for its validation and no data regarding the (test-retest) reliability of 
the scale or confirmation of its underlying factor structure are known. In addition to the 
fact that the Demoralization Scale measures demoralization as opposed to 
remoralization, its suitability and psychometric properties for use with patients in 
mental health care are unknown.  
To our knowledge, no appropriate instrument is available for the measurement 
of changes in remoralization as a result of treatment among mental health care patients. 
It was therefore decided to develop a new instrument. The Remoralization Scale (RS) is 
intended to be used during the treatment process to indicate the level of a patient’s 
morale at the time of administration. Given that remoralization is a process, multiple 
measure points are obviously needed over time to determine whether the patient’s 
morale is restoring or not. The instrument should, therefore, be an easy-to-use self-
report measure with only a small number of items to minimize response burden. In 
addition, the instrument should be unidimensional, reliable and valid. In the present 
article, we thus report on the results of five studies conducted to develop and document 
the RS. In Study 1, the development of the scale was undertaken. In Study 2, the factor 
structure underlying the scale was examined. In Study 3, the test-retest reliability and 
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internal consistency of the scale were documented. In Study 4, the construct and 
discriminative validity of the scale were determined. And in Study 5, the sensitivity of 
the scale to therapeutic change was examined. 
 
 
Study 1: Scale development 
 
In the literature, a state of demoralization has been shown to relate to such concepts as 
(1) feelings of low self-esteem (de Figueiredo & Frank, 1982), (2) feelings of impotence 
(3) and absence of a sense of mastery (Frank, 1974), and (4) pessimism (Howard et al., 
1993). Remoralization has been shown to relate to (5) a sense of inner control (Frank) 
and (6) restored hope (Kuyken, 2004). Obviously, these relationships are part of the 
conceptualizations of remoralization, rather than being established empirically. In fact, 
measures of the aforementioned concepts have been frequently used as proxies for the 
measurement of remoralization. Building upon this idea, we thus searched for 
instruments which measure the aforementioned concepts and expected the combination 
of these various instruments to provide a good starting point for the development of the 
RS. Whether or not a combination of such instruments measure one or more dimensions 
was also of interest. 
Method 
Several criteria were applied for the initial selection of the instruments. Substantively, 
each instrument had to measure one or more of the six aforementioned concepts which 
relate, according to the literature, to demoralization or remoralization. In addition, each 
instrument had to be (1) self-report, (2) brief and easy to complete and (3) sensitive to 
change. 
Measures. We found a total of five instruments to meet the selection criteria 
and, given that one of the instruments measured two of the aforementioned concepts, all 
six of the relevant concepts were addressed. The concepts with the corresponding 
measurement instruments were as follows. 
 Self-esteem using the Rosenberg Self-Esteem Scale (Rosenberg, 1965)  
 Personal empowerment and sense of mastery using the Empowerment Scale (Rogers 
et al., 1997) 
 General feelings of competence using the adapted Dutch version (Bosscher, Smit, & 
Kempen, 1997) of the General Self-efficacy Scale (Sherer et al., 1982)  
 Optimism, the opposite of pessimism, using the Optimism Subscale from the 
Positive Outcome Scale (Appelo, 2005) and sense of inner control using the 
Autonomy Subscale also from the Positive Outcome Scale 
 Hope using the State Hope Scale (Snyder et al., 1996)  
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The five instruments were next combined into a survey which contained a total of 69 
items. For all instruments, except for the State Hope Scale (Snyder et al., 1996), official 
Dutch items were available. For the State Hope Scale we followed the back-translation 
procedure to obtain the Dutch items.  
Participants and procedure. A sample of 750 patients, 18 years of age or older, 
was selected by a computerized random generator from the outpatient databases of the 
three main locations of De Gelderse Roos, a community mental health centre in the east 
part of The Netherlands. A package containing the survey, a demographic questionnaire, 
a questionnaire to inventorize reasons for seeking psychological help, and a return 
envelope was mailed to the selected individuals by secretaries from the different 
locations. No information which could possibly lead to identification of the selected 
patients was requested and the anonymity of the respondents was thus guaranteed. A 
total of 299 individuals returned sufficiently completed questionnaires (39.9%); 207 
were female (69%). The age of the respondents varied from 19 to 73 with a mean of 38 
years (SD = 11). Of the 299 respondents, 40 had not yet started treatment (13%), 190 
were currently receiving treatment (64%) and 47 had recently completed their treatment 
(16%). A total of 169 respondents reported seeking treatment for feeling depressed 
(57%), 110 for feeling anxious (37%) and 93 for feeling tense (31%). Intake for about 
25% of the respondents was more than 32 months prior to questionnaire administration. 
The distribution of the amount of time between intake and administration of the 
questionnaire is skewed to the right (skewness = 3.55) with a median of 12 months. 
Results  
Single-factor principal components analyses were first conducted on each of the 
measurement instruments separately in order to select those three items which best 
represented the concept in question. It was decided a priori to select the three items 
loading highest per instrument in order to avoid possible overrepresentation in the RS of 
scales with a relatively larger number of items. This was also a step towards mini-
mization of the number of items in the RS. The resulting set of 18 items contained two 
items with a strong overlap in their wording: ‘I have a positive attitude towards myself’ 
(Empowerment Scale) and ‘I take a positive attitude towards myself’ (Rosenberg Self-
Esteem Scale). It was therefore decided to omit the item from the Empowerment Scale.  
Next, an exploratory factor analysis was conducted on the set of 17 remaining 
items using maximum likelihood estimation to determine the number dimensions 
measured. When the scree plot was examined (Floyd & Widaman, 1995), an elbow was 
fairly apparent and thus showed a one-factor solution to yield the best fit. The factor has 
an eigenvalue of 6.77 and explanation of 42.30 % of the variance in the item scores. 
‘When I have something unpleasant to do, I stick to it until the task is finished’ (Self-
Efficacy Scale) was omitted following the rule of thumb which requires items with a 
loading under .40 to be discarded (Guadagnoli & Velicer, 1988). The Cronbach’s alpha 
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used to assess the internal consistency of the scale was .92 (n = 266). In the next step in 
the development process (Study 2), confirmatory factor analyses were undertaken to 
show that the 16 items indeed formed a unidimensional scale.  
 
 
Study 2: Scale confirmation 
 
Study 2 had two objectives. The first objective was to show the 16 items from Study 1 
to again load on a single factor. The second objective was to see if the RS measures the 
same construct in the same way for both patients and non-patients. Ideally, patients are 
non-patients by the end of their treatment (Jacobson et al., 1999) and the RS should be 
applicable throughout the treatment process to document changes in morale. That is, it 
should be possible to compare RS scores over time (i.e., from the very start of treatment 
to the end of treatment). Both objectives are met by a multi-group confirmatory factor 
analysis.  
Method 
Participants and procedure for the patient sample. A total of 199 outpatients 
from either De Gelderse Roos community mental health centre (no overlap with the 
sample in Study 1) or the GGZ Nijmegen community mental health centre (Nijmegen, 
The Netherlands) volunteered to participate in the present study after being invited to do 
so at intake (participation rate of 88.5%). The age of the participants varied from 21 to 
60 years with a mean of 38 (SD = 11); 121 participants were female (61%). With the 
exception of the patients requiring outpatient mental health care, no exclusion criteria 
were applied. Those patients who agreed to participate were asked to provide some 
demographic information and complete the RS16. As in Study 1, participants were 
anonymous to the researchers. 
In order to be sure that the sample consisted of patients suffering from mental 
health problems at the time of data collection, assessment was undertaken immediately 
following intake. Given that the original five measurement instruments employed 
different response formats, a single response format was provided for the 16 items. That 
is, a four-category scale ranging from totally disagree to totally agree was used by the 
participants to respond.  
Participants and procedure for the non-patient sample. A ‘snowball 
sampling’ procedure (Faugier & Sargeant, 1997) resulted in 192 participants, not 
seeking mental health care, referred in the present study as non-patients. Snowball 
sampling relies upon referrals from initial subjects to generate additional subjects. This 
technique was used on account of time and money constraints. The age of the non-
patients varied from 18 to 91 years with a mean of 37.32 (SD = 13.57); 124 participants 
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were female (65%). Three of the non-patients reported a somatic illness (1.6%) and six 
reported having a mental illness (3.2%).  
 Individuals received an e-mail letter in which the aims of the study were 
described and the recipient was invited to participate in the study. The participants were 
mailed a survey packet which consisted of a demographic questionnaire, the RS16 and 
two other self report instruments being used to validate the RS (see Study 3).  
  Data analyses. Given that the RS is to be used across time to track changes in 
the level of morale, the scale should be scalar invariant. We tested for this using a 
procedure suggested by Meredith (1993). The procedure starts with the most simple 
form of invariance (factorial and metric) and ends with the most strict form of in-
variance (scalar). While the current practice is to evaluate model fit using fit indices and 
the RMSEA in particular, recent studies have shown fit indices with fixed critical values 
(e.g., the RMSEA, GFI) are not able to control for type I and type II errors (Marsh, Hau, 
& Wen, 2004; Saris, Satorra, & van der Veld, 2009). An alternative procedure, namely 
the detection of misspecifications (Saris et al.), was therefore adopted to evaluate the fit 
of the model developed. The procedure departs from fit indices to evaluate model fit 
and returns to exact tests while controlling for type I and type II errors. The idea behind 
the procedure is that each constrained model parameter can be a misspecification. The 
traditional procedure used to determine if a constrained parameter is perhaps a mis-
specification, the use of the modification index, is sensitive to the power of a test. For 
this reason, we controlled for that. The power of the test to detect a misspecification of 
size delta or larger can be computed using a special formula (Saris et al.). The size of 
delta depends upon the size of the misspecification one wants to detect with high power 
and can thus be set by the researcher. Whether or not a constrained parameter is a 
misspecification is judged from the combination of the power, which can be high or 
low, and the modification index, which can be significant or not. There is a mis-
specification when either the power is low and the modification index is significant or 
the power is high, the modification index is significant and the expected parameter 
change is larger than delta. Other combinations indicate no misspecification or a lack of 
power to detect a misspecification. For the current analyses, we set the alpha level at 
.05, the power at .80 and the delta at .10.  
Results 
The factorial invariance of the RS16 was first evaluated. The model contained many 
large misspecifications (RMSEA = .10, 2 = 529, df = 208). We improved the model in a 
stepwise manner by deleting those items with a standardized loading lower than .40 
from either the patient or the non-patients sample. If no such items occurred further but 
major misspecifications were still found, correlated errors, which could be given 
substantive meaning and were present in both the patient sample and the non-patient 
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sample, were introduced. Following these rules, four items had to be removed from the 
RS, which produced an acceptable model (RMSEA = .07, 2 = 183, df = 100). The final 
form of the RS thus contained 12 items and is presented in the Appendix. This form of 
the RS also showed metric invariance (RMSEA = .07, 2 = 204, df = 111). Finally, 
whether or not the final version of the RS is scalar invariant was also tested. The model 
contained one important misspecification which was fixed. The resulting model was 
good (RMSEA = .07, 2 = 232, df = 121). It can be concluded that patients and non-
patients understand the items of the RS similarly. As a consequence, their scores can be 
compared.  
 
 
Study 3: Scale reliability 
 
Study 3 had two objectives. The first objective was to investigate the test-retest 
reliability of the RS. The changes to be tracked by the RS over time should be clearly 
the result of actual changes in the level of morale and not due to random measurement 
error. A high level of test-retest reliability is thus required. This was tested for with a 
student sample for which no systematic changes in morale could be expected, 
particularly within a brief period of time; any changes detected using the RS could thus 
be attributed to random error.  
The second objective was to assess the internal consistency of the RS. The 
Cronbach’s alpha for the initial RS (i.e., the RS16) was .92 (n = 266). In Study 2, four 
items were omitted, but the internal consistency should not decrease too much as a 
result of such deletion.  
Method 
Participants and procedure. For determination of the test-restest, a sample of 
124 psychology students was recruited and asked to complete the RS at the end of a 
seminar on two consecutive occasions with one week in between the administrations. 
The mean age of the respondents was 22 years (SD = 3.2), and 102 respondents were 
female (82%).  
The Cronbach’s alpha for the psychology students described above and for the 
patients and non-patients described in Study 2 were estimated. 
Results 
The Pearson correlation between the first and second administrations of the RS in the 
student sample was estimated. The test-retest reliability of the RS was found to be .89 (p 
< .01, n = 124, time 1: M = 3.11, SD = 0.39; time 2: M = 3.10, SD = 0.39), which is 
good.  
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The Cronbach’s alphas for the patient sample, the non-patient sample and the 
student sample were .91 (n = 177), .91 (n = 166) and .87 (n = 123), respectively. The 
internal consistency of the RS was thus high and similar across different samples. In 
addition, the removal of the four items as described in Study 2 was found to have only a 
negligible to marginal effect on the internal consistency of the RS.  
 
 
Study 4: Scale validity 
 
Study 4 was conducted to investigate the validity of the RS. To start with, the capacity 
of the RS to differentiate between patients and non-patients was examined. That is, the 
levels of remoralization for the different groups were investigated and compared.  
 Second, the construct validity of the RS was investigated by examining the 
relations of the RS to other relevant concepts for mental health care patients. The 
following concepts were chosen for this purpose: demoralization, somatic symptoms, 
social dysfunction, anxiety and depression. Remoralization is described in the 
introduction as the reduction of demoralization and we hence expect a strong negative 
correlation to occur between the constructs of remoralization and demoralization. 
Somatic symptoms and social dysfunction were expected to be related to, but never-
theless clearly distinguishable from, the level of remoralization; that is, moderate 
negative correlations were expected to occur with the RS. Demoralization and 
remoralization are intrapsychic, just as feelings of anxiety and depression. Highly 
anxious or depressed people often feel quite demoralized (Frank, 1974). Conversely, 
being demoralized can make people more fearful of losing control and going crazy 
which may then, in turn, make them more vulnerable to depression and other dysphoric 
emotions (Frank). For this reason, strong negative correlations were expected to occur 
between remoralization, anxiety and depression. In this light, several scholars have 
questioned whether depression and demoralization can be treated as distinct concepts 
because they both accompany symptoms of distress, despair, impotence, hopelessness 
and loss of meaning (Mangelli et al., 2005). However, it has been shown that 
demoralization and depression can indeed be clearly distinguished (Clarke, McLeod, 
Smith, Trauer, & Kissane, 2005; Mangelli et al.).  
Method 
Participants and procedure. See Study 2.  
Measures. The Demoralization Scale (DS) of Kissane and colleagues (2004) 
consists of 24 items to be scored along a five-point scale. The following five dimensions 
of demoralization are distinguished: disheartenment, loss of meaning, non-specific 
dysphoria, helplessness and sense of failure. DS total score is an addition from all items 
of the DS. High scores on the DS indicate strong demoralization. The Dutch adaptation 
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(Koeter & Ormel, 1991) of the General Health Questionnaire (GHQ; Goldberg, 1972) 
measures somatic symptoms, social dysfunction, anxiety and depression. The GHQ 
consists of 28 items to be evaluated along a four-point scale. High GHQ scores indicate 
high levels of psychopathology. 
Results  
We tested whether the mental health patients produced, on average, lower RS scores 
than the non-patients in an ANOVA. The results showed the patients to be significantly 
less remoralized (M = 2.37, SD = 0.57) than the non-patients (M = 3.33, SD = 0.45), F 
(1, 356) = 309.74, p < .001, Cohen’s d = 1.87.  
Pearson correlations were calculated between the RS, the DS and the subscales 
of the GHQ. The estimates confirmed our expectations. According to the conventions of 
Cohen (1987) for the interpretation of correlations: r > .30 is moderate and r > .50 is 
high. The RS showed high negative correlations with the DS (r = .72), GHQ anxiety (r 
= .52) and GHQ depression (r = .50). The RS showed moderate negative correlations 
with GHQ somatic symptoms (r = .36) and GHQ social dysfunction (r = .37).  
 
 
Study 5: Sensitivity to change 
 
A longitudinal study was undertaken in order to investigate the sensitivity to change of 
the RS among 24 patients suffering from a panic disorder with agoraphobia. 
Method 
Participants and procedure. A total of 42 patients from the outpatient clinic for 
anxiety disorders of the Pro Persona Centre for Anxiety Disorders Overwaal were 
invited at intake to participate in the present study when they met below mentioned 
criteria. After referral for treatment, two intake sessions were conducted conform 
normal procedure. The Mini International Neuropsychiatric Interview (Lecrubier et al., 
1997) was examined in order to classify the problems of the patients in terms of DSM-
IV diagnoses. Inclusion and exclusion criteria for the present study were determined at 
this time in line with the usual criteria of efficacy studies on PDA (Westen & Morrison, 
2001). The inclusion criteria were: (1) a present classification of panic disorder with 
agoraphobia (PDA), and (2) age between 18 and 65 years. The exclusion criteria were: 
(1) receipt of other psychological treatment, (2) use of effective antidepressant 
medication or (3) a present diagnosis of schizophrenia, mental retardation, suicidal 
ideation, alcohol or psychoactive substance abuse or dependence. Since a reduction of 
symptoms in depressed patients could erroneously be attributed to an increase in 
remoralization, patients meeting the DSM-IV criteria for a mood disorder were also 
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excluded. When selected for inclusion in the study, the participants were asked to 
provide their informed consent and a postal address. Survey packets containing the 
instruments, a demographic questionnaire and a return envelope were mailed to the 
selected individuals prior to the initiation of their treatment. After 28 weeks, a second 
survey packet was mailed.  
The usual procedure followed at the outpatient clinic for patients taking 
antidepressant medication which is proving ineffective, is to discontinue medication 
under supervision of a psychiatrist. After a washout period of two weeks and prior to 
the start of other treatment, such patients were asked to participate in the present study. 
Patients taking benzodiazepines were asked to adhere to a set daily dosage during the 
course of the present study. Of the patients initially approached, 11 did not participate 
further due to refusal to participate or because they wanted to continue with their 
ineffective antidepressant medication or refused to set their benzodiazepine use. A total 
of 31 patients enrolled in the study. Of these, 6 used benzodiazepines and agreed to 
adhere to a fixed dose. During the study, 7 patients dropped out for reasons of being too 
busy or failed to return the questionnaire and could not be contacted thereafter (23%). 
Of the 24 completers, 17 were female (71%). The age of the respondents varied from 22 
to 50 years with a mean of 32 (SD = 9.29).  
Treatment. Patients received evidence-based treatment which drew upon the 
Dutch multidisciplinary guidelines for anxiety disorders (Landelijke Stuurgroep 
Multidisciplinaire Richtlijnontwikkeling in de GGZ, 2003). This could be either (a) 
panic control treatment (PCT; Craske & Barlow, 1993) or (b) treatment with Citalopram 
which is a Selective Serotonin Reuptake Inhibitor in combination with supportive 
consults with a psychiatrist.  
 Measures. In addition to the utilization of the RS, the effectiveness of the 
treatment being followed for the reduction of the symptoms of PDA was checked using 
the Mobility Inventory Avoidance when Alone (Chambless, Caputo, Jasin, Gracely, & 
Williams, 1985).  
Results  
When the effectiveness of treatment was examined with respect to symptom 
reduction, the results showed the patients to be significantly less avoidant at week 28 (M 
= 1. 78, SD = 0.68) than at the start of the study (M = 2.70, SD = 0.83), F (1, 23) = 
35.46, p < .001, Cohen’s d = 1.21. The next question, of course, was whether an 
effective treatment for a panic disorder could also foster remoralization as well, and this 
was in fact found to be the case. The change in the RS scores was found to be 
significant: M = 2.64 (SD = 0.36) at the start of study as opposed to M = 3.30 (SD = 
0.50) after 28 weeks (F [1, 23] = 56.93, p < .001, Cohen’s d = 1.51). These data suggest 
that the RS is indeed sensitive to therapeutic change.  
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General discussion 
 
In a series of empirical studies, the RS was developed and tested. The initial pool of 
items used for this purpose was derived from already available instruments with content 
related to remoralization or demoralization. In the five studies presented here, the RS 
was shown to be unidimensional self-report instrument with high internal consistency, 
excellent test-retest reliability, both good construct validity and discriminative validity 
for patients versus non-patients and sensitivity to therapeutic change. With only 12 
items, the RS is brief and easy to interpret. The unidimensional structure of the RS 
suggests that it indeed measures a single concept which was initially documented for a 
large group of mental health patients in an exploratory factor analysis and later 
confirmed for both mental health patients and non-patients.  
The RS further showed a strong negative correlation (-.72) with the DS (Kissane 
et al., 2004), indicating considerable overlap between the two instruments. This raises 
the question — in retrospect — of whether the DS might be used to meet the same aims 
as the RS. When the nature of the two measurement instruments is compared more 
carefully, it should first be noted, as written in the introduction, that the DS was tested 
in one study using only preliminary data of somatic care patients. The RS, in contrast, 
has been tested extensively in the five studies presented here, using several samples 
including a wide variety of mental health care patients as well as non-patients. Second, 
the RS is unidimensional and contains only 12 items which makes it easy to administer 
in repeated measures outcome research. The DS, in contrast, contains twice as many 
items and is multidimensional with five highly correlated dimensions (in the present 
data ranging from .36 p < .01 to .71 p < .01). This makes the DS more difficult to 
administer and interpret in actual practice than the RS. Finally, the DS measures a 
negative state and therefore emphasizes what is wrong. This may work demoralizing in 
and of itself, particularly when the instrument is administered repeatedly during the 
course of treatment. The RS, in contrast, measures a positive state.  
One possible limitation on the present series of studies concerns the selection of 
items for inclusion in the original item pool. It was decided a priori to include those 
three items which best represented each of the concepts measured by six scales judged 
to be of relevance for remoralization in the original RS item pool. This decision was 
based on both theoretical and practical considerations. One can argue, however, that a 
factor analysis on the 69 items from the original scales combined, as opposed to per 
scale, with subsequent selection of those items with the highest factor loadings from the 
total, might have been a more appropriate method for item selection. We determined 
whether the same 12 RS items would be included when a factor analysis was conducted 
on the original 69 items together and those 18 items with the highest factor loadings 
then selected for further consideration. Of the 12 items constituting the RS, 11 would 
again be selected. Furthermore, examination of the scree plot for the factor analysis on 
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the original 69 items together also showed a one-factor solution to best fit the data. This 
finding suggests that patients do not construe the concepts of self-esteem, 
empowerment, self-efficacy, optimism, autonomy and hope — as reflected by the 
original 69 items — as highly different. In addition, it was argued in the introduction 
that the concept of remoralization captures an interesting variety of beneficial treatment 
effects other than symptom reduction. The present findings appear to provide support 
for this argument: The concepts of self-esteem, empowerment, self-efficacy, optimism, 
autonomy and hope are not only theoretically but also empirically related to the concept 
of remoralization. 
Some other possible limitations on the present studies concern the manner of 
data collection. For reasons of anonymity, the avoidance of interference in the treatment 
process of participation in the research, we had no direct contact with the patients in 
Studies 1 and 2. This allowed only limited insight into the demographic and psychiatric 
characteristics of the patients. In Study 1, the secretaries from De Gelderse Roos mailed 
the instruments to the patients. Without any obligation to respond and no follow-up 
steps for non-response, the response rate stagnated at less than 40%. This limits the 
generalizability of the present results to other outpatients in mental health care. The 
participants, moreover, completed the instruments in an uncontrolled setting with 
possible assistance and/or influence from others. Future research on the RS should thus 
adopt a more sophisticated data collection procedure to overcome some of these 
problems.  
The snowball sampling procedure which was used to select the non-patients of 
Study 2 suffers from the same disadvantages as mentioned above. However, the 
disadvantages are less important here because it was not our intention to test the RS in a 
representative nonclinical sample. Our main interest was to see if non-patients 
understand the items similarly to the patients and whether the former score higher on 
the RS than the latter. Scalar invariance tests indicate the comparability of the non-
patients and patients, which makes comparisons of the mean scores for such groups 
valid and meaningful. In addition, the non-patients showed higher mean scores than the 
patients. 
In Study 5, we showed the RS to be sensitive to therapeutic change for a small 
group of patients suffering from panic disorder with agoraphobia. Whether the RS is 
similarly sensitive to therapeutic change, and thus useful, for other groups of patients 
obviously requires further investigation. For now, the RS appears to be clearly sensitive 
to change, also because it discriminated between patients and non-patients.  
The analyses and results presented here are tentative to some extent, but show 
the RS to be a promising instrument for the assessment of remoralization in mental 
health care patients receiving psychotherapy. The next step in our research is to examine 
the relations between symptom reduction and remoralization as a result of psycho-
therapy. As argued in the introduction, contemporary outcome research tends to focus 
Remoralization Scale 
 37
heavily on the reduction of symptoms as a means to document the effectiveness of 
psychotherapeutic treatment. There is nevertheless good reason to believe that 
successful treatment also realizes remoralization. And only when additional treatment 
effects are taken sufficiently into account can the effects of psychotherapeutic treatment 
be fully appreciated. 
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Abstract 
 
Remoralization as an outcome measure for psychotherapy was compared to symptom 
reduction (agoraphobic avoidance and -cognitions). Twenty-four patients with panic 
disorder and agoraphobia received empirically-supported treatment and were followed 
across multiple time-points for 28 weeks. Treatment resulted in reduced symptoms and 
enhanced remoralization (Cohen's ds 1.19 to 1.45). Slopes of symptoms and 
remoralization were obtained from latent growth model analyses. The slopes correlated 
highly (r = .50 to .55), which indicates similar patterns of change over time. The 
slope of remoralization also correlated with a number of aspects of health-related 
quality of life, while the slope of symptom reduction did not. Though strongly related to 
symptom reduction, the measurement of remoralization is expected to provide unique 
information for treatment efficacy research.  
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Introduction 
 
Since the first edition of Persuasion and Healing by Jerome Frank in 1961, therapists 
have grown to appreciate the essential features of the demoralization theory. The many 
reprints of Persuasion and Healing show how successful the message was. 
Demoralization theory states that people who enter into treatment for psychological 
problems do not only suffer from a specific mental disorder (i.e., symptomatic burden) 
but typically feel demoralized as well. Frank (1974) believed that the painful experience 
of symptoms and accompanying negative emotions over longer periods of time, leads to 
feelings of hopelessness and powerlessness, central to the state of demoralization. 
Demoralization results from an individual’s belief of being incapable of solving current 
problems and is thus characterized by feelings of impotence, isolation, and despair. 
According to Frank the effectiveness of every form of psychotherapy depends upon its 
ability to restore a patient’s morale. In writings of Howard, Lueger, Maling, and 
Martinovich (1993), the expression remoralization refers to the process of restoration of 
morale and is believed to take place in an early phase in psychotherapy. In this phase 
the problems of the patients are acknowledged, the therapist offers an understanding of 
the patients’ suffering and instils hope by showing that there are ways in reducing it. 
These ingredients of the first psychotherapy sessions lead to remoralization by 
stimulating positive growth, an increase of hope, a sense of mastery, and an increase of 
subjective well-being.  
Given the impact of the work of both Frank (1973) and Howard et al. (1993) on 
academic views of psychotherapy, one would expect remoralization to be a valuable 
measure as part of the assessment of treatment outcome in psychotherapy outcome 
research. However, in the current research generation, in which well-documented 
treatments are evaluated on their effects on specific disorders (see e.g., Godfried & 
Wolfe, 1996), remoralization is no part of the assessment. In this, so called efficacy 
research, remoralization is rarely used as an outcome measure. And the question is, of 
course, why?  
Perhaps the most important reason for the lack of attention to remoralization as 
outcome measure is that the added value of measuring remoralization in addition to the 
measurement of symptom reduction has remained unclear. Symptom reduction has been 
the primary outcome measure in efficacy research over the past few decades. In large 
randomized controlled trials and meta-analyses, symptom reduction is considered the 
only relevant outcome (see, for instance, Gould, Otto, & Pollack, 1995; Westen & 
Morrison, 2001). And while Frank (1974) asserted that the process of remoralization 
can be theoretically differentiated from the process of symptom reduction, he — himself 
— never investigated this assertion empirically. Howard and colleagues similarly 
described changes in remoralization and symptom reduction as two distinguishable 
processes, and a number of studies were conducted along these lines (e.g. Callahan, 
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Swift, & Hynan, 2006; Grissom, Lyons, & Lutz, 2002; Hilsenroth, Ackerman, & 
Blagys, 2001; Howard et al., 1993; Lutz, Lowry, Kopta, Einstein, & Howard, 2001, 
Lutz, Martinovich, & Howard, 1999), but these studies did not directly investigate, nor 
provide specific information on the relationship (correlation) between remoralization 
and symptom reduction. Further, most of the these studies have used unspecified patient 
samples, unspecified treatments or treatments directed on all kind of problems and 
syndromes, and/or general symptom checklists which were insufficiently suited to 
separate symptom reduction from remoralization. Hence, it is unclear whether remora-
lization and symptom reduction might considerably overlap or might be two, maybe 
somewhat related, but rather different measures of outcome.  
Presently, we do not know whether measuring change in remoralization ads 
extra information that is useful, or even highly desirable, for the proper evaluation of 
psychotherapy outcome in efficacy research, when measured in addition to symptom 
reduction. To fill in this gap of knowledge, a study was undertaken in which patients 
suffering from panic disorder with agoraphobia were given indicated, manual-based, 
empirically-supported treatment (EST) and then followed to assess their treatment 
outcome. Changes in specific agoraphobic avoidance and agoraphobic cognitions symp-
toms, changes in remoralization, and changes in health-related Quality of Life (QoL) 
were measured. The first aim of the study was to investigate whether or not the 
measurement of remoralization is sensitive to change when administered at several 
points during the course of the EST and thereby gain insight into the manner in which 
remoralization may change over time (e.g., whether increases in remoralization are 
linear and relatively stable over time). Given the paucity of data regarding the 
relationship between symptom reduction and change of remoralization as a result of 
treatment, the second aim of the present study was to investigate this relationship 
empirically. Based on the assumption that ESTs will generally lead to reduced symp-
tomatology, the question is whether increase in remoralization will be similarly paced as 
symptom reduction. The third and main aim of this study was to determine if the 
measurement of remoralization in addition to symptom reduction offers unique infor-
mation with regard to the change on health-related QoL or, in other words, the extent to 
which the daily life functioning of a patient is hampered by his or her problems. Given 
that remoralization refers to a state of mind that results from an individual’s belief of 
being incapable of solving current problems, we expected changes in remoralization to 
be more strongly associated with changes in health-related QoL than symptom 
reduction is found to be.  
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Method 
Participants and procedure  
A total of 42 patients from the outpatient clinic for anxiety disorders at the Pro Persona 
Centre for Anxiety Disorders Overwaal, were invited at intake to participate in the 
present study. In order to asses the DSM-IV classification of their disorders, the Mini 
International Neuropsychiatric Interview (MINI; Lecrubier et al., 1997) was admin-
istered to all of the patients. The inclusion criteria for the present study were: a present 
classification of panic disorder with agoraphobia (PDA) and an age between 18 and 65 
years. The exclusion criteria were: current receipt of other psychological treatment, use 
of antidepressant medication, or a present diagnosis of schizophrenia, mental retar-
dation, suicidal ideation, alcohol or psychoactive substance dependence or abuse. Given 
that a reduction of symptoms on the part of depressed patients in particular can 
erroneously be attributed to an increase in remoralization, patients meeting the DSM-IV 
criteria for a mood disorder were also excluded. In accordance with standard procedure 
at the outpatient clinic, a multidisciplinary intake team assigned the patients to either 
panic control treatment (PCT) or medication treatment (MT; see Treatments and 
therapists section for details), in which the treatment preference of the patients was 
taken into account.  
When selected for inclusion in the study, the participants were asked to provide 
their informed consent and a postal address. The participants were next administered a 
number of measures every four weeks across a period of 28 weeks (see Measures for a 
description of the measures). That is, assessment was undertaken prior to treatment (i.e., 
in week 0) and was repeated in weeks 4, 8, 12, 16, 20, 24, and 28. Survey packets 
containing the symptomatology and remoralization measurement instruments and a re-
turn envelope were thus mailed to the participants; a demographic questionnaire was 
also included in the packet for week 0; and a measure of health-related QoL was 
included in the packets for weeks 0 and 28 (see Measures).  
The usual procedure at the outpatient clinic for patients taking antidepressant 
medication that is proving ineffective is to discontinue the medication under the super-
vision of a psychiatrist. After a washout period of two weeks and prior to the start of the 
treatment, such patients could thus be asked to participate in the present study. Patients 
taking benzodiazepines were asked to adhere to a set daily dosage during the course of 
the present study.  
Of the 42 patients initially approached, 11 did not participate either because they 
did not want to participate, they wanted to continue with their ineffective antidepressant 
medication, or they refused to set their benzodiazepine use. A total of 31 patients thus 
participated in the study (17 assigned to PCT and 14 assigned to MT). During the study, 
of seven participants (23%; in PCT: 3 [18%]; in MT: 4 [29%]) we had missing data 
because they stopped returning the measurement packets. Some reported they were too 
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busy to fill in any measurements, others, could not be contacted thereafter. Twenty-four 
patients completed the 28 weeks of the study. Note, however, that in five casus 
treatment was ended before the period of 28 weeks (the distribution was as follows: for 
PCT 1 by week 16, 1 by week 20, 2 by week 24, and 1 by week 28) because the patients 
concerned had already achieved recovery. There were no treatment dropouts from MT 
and no treatment dropouts from PCT due to other reasons. 
Of the 24 completers, 14 received PCT and 10 received MT. Seventeen 
participants were female (71%; in PCT: 8 [57%]; in MT: 9 [90%]). The age of the 
participants varied from 22 to 50 years with a mean of 32.38 years (SD = 9.29; in PCT: 
M = 29.07, SD = 7.27; in MT: M = 37.00, SD = 10.18). Fourteen participants (58%; in 
PCT: 8 [57%]; in MT: 6 [60%]) were living together with a partner or were married, 
nine participants (38 %; in PCT: 6 [43 %]; in MT: 3 [30 %]) were living alone, one 
participant (4 %; in MT: 1 [10 %]) was divorced and living alone. Two participants (8 
%; in MT: 2 [20 %]) had low education, 9 participants (38 %; in PCT: 2 [14 %]; in MT: 
7 [70 %]) had middle education, 7 participants (29 %; in PCT: 5 [36 %]; in MT: 2 [20 
%]) had higher education, and 6 participants (25 %; in PCT: 5 [36 %]; in MT: 1 [10 %]) 
had university. Of the completers, 12 (50 %, in PCT: 8 [57 %]; in MT: 4 [40 %]) were 
fulltime or part-time employed, 6 (25 %; in PCT: 4 [29 %]; in MT: 2 [20 %]) were 
studying, 3 (13 %; in PCT: 2 [14 %]; in MT: 1 [10 %]) were unemployed (i.e. without a 
job or disabled); for 3 participants (13 %; in MT: 3 [30 %]) employment status was 
unknown.  
Since panic onset, the average duration of panic symptoms was 5.45 years (SD = 
6.92, range from 0.30 to 20.00; in PCT: M = 4.99, SD = 6.47, range from 0.42 to 20; in 
MT: M = 6.71, SD = 8.99, range from 0.30 to 20.00). Fourteen participants (58%; in 
PCT: 9 [64 %]; in MT: 5 [50 %] ) had no other DSM-IV classification than DPA. Ten 
participants (42 %) had at least one DSM-IV Axis-I co-morbid diagnosis. The 
distribution was: generalized anxiety disorder 4 (3 in PCT, 1 in MT), hypochondria 3 (1 
in PCT; 2 in MT), social phobia 1 (MT), specific phobia 1 (PCT), adjustment disorder 1 
(MT). Further, no one had a co-morbid personality disorder. Three participants (13 %; 
in PCT: 1 [7 %]; in MT: 2 [20 %]) were using benzodiazepines and adhered to a set 
daily dosage.  
Measures 
In order to examine change of symptomatic burden, agoraphobic avoidance and 
agoraphobic cognitions were measured. Agoraphobic avoidance was assessed with the 
Dutch translation of the Mobility Inventory Avoidance when Alone (MI-AAL; 
Chambless, Caputo, Jasin, Gracely, & Williams, 1985). It consists of 25 situations 
typically avoided or endured with severe distress by agoraphobics. Patients rate the 
degree of avoidance on a five-point scale, when exposed to the situation being alone. 
The MI-AAL, and also the Dutch translation, have good test-retest reliability (rs range 
Remoralization in Addition to Symptom Reduction 
 45
from .70 to .90), high internal consistency (αs range from .91 to .97), and reasonable 
concurrent validity (de Beurs, 1993; Chambless et al.). 
Agoraphobic cognitions were assessed with the Dutch translation of the 
Agoraphobic Cognitions Questionnaire (ACQ; Chambless, Caputo, Bright, & Gallager, 
1984). This questionnaire contains 14 catastrophic thoughts such as ‘having a heart 
attack’ or ‘losing control.’ Patients rate the frequency of being troubled by these 
thoughts when they are anxious on a five-point scale. Internal consistency (Cronbach’s 
αs range from .72 to .84), test-retest reliability (rs range from .71 to .80) of the ACQ 
and Dutch translation are good (de Beurs, 1993).  
The Remoralization Scale (RS; Vissers, Keijsers, van der Veld, de Jong, & 
Hutschemaekers, in press) was used to measure remoralization. The RS is a psycho-
metrically sound, self-report instrument that measures growth of hope, subjective well-
being, and sense of mastery. Patients rate on a four-point scale the extent to which they 
agree with each of 12 statements. Internal consistency (Cronbach’s α = .91) and test-
retest reliability (r = .89) are excellent (Vissers et al.). 
The RAND-36 (van der Zee & Sanderman, 1994) was used to measure health-
related QoL. The 36-item RAND-36 encompasses the following eight subscales: 
physical functioning, social functioning, role limitations due to physical problem (i.e., 
problems with work or other daily activities as a result of physical health problems), 
role limitations due to emotional problem (i.e., problems with work or other daily 
activities as a result of emotional problems), mental health, vitality (i.e., feelings of 
energy/tiredness), bodily pain, and general health perception. Internal consistency 
(Cronbach’s αs range from .71 to.92) is good and test-retest reliability (rs range from 
.58 to .82) is reasonable (van der Zee & Sanderman). 
Treatments and therapists 
For our purposes we wanted to investigate patients receiving an empirically supported 
treatment for patients suffering from PDA to ensure a reduction of symptoms. Two 
treatments, Panic Control Treatment (PCT; Craske & Barlow, 1993) and medication 
treatment (MT) with a Selective Serotonin Reuptake Inhibitor (SSRI), are found highly 
and equally effective (e.g., Oei, Llamas, & Devilly, 1999; van Balkom et al., 1997). 
Both treatments are recommended as first choice treatments according to the Dutch 
national multidisciplinary guidelines for the treatment of anxiety disorders (DMG-AD; 
Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ, 2003). Of 
the 24 completers, 14 received PCT and 10 received MT, consisting of prescription of 
citalopram (which is an SSRI). For PCT, the therapists were experienced psychologists 
(MSc level) who were cognitive behavior therapists, and graduate students in clinical 
psychology working as trainees at the outpatient clinic. They all had been extensively 
trained in the PCT. Throughout the study period the therapists were weekly supervised 
by senior therapists certified as supervisors by the Dutch Association for Behavioural 
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and Cognitive Therapy to safeguard adequate application of the PCT techniques and 
adherence to the manual. Per session the therapists recorded which PCT components 
had been addressed and discussed these and any deviations from the manual with their 
supervisors. Adaptation to the intervention to meet a patient’s specific circumstances 
were allowed if they were not in conflict with the manual. Patients received weekly 
sessions of 45 minutes. For MT, patients received monthly consults of 20 minutes by a 
licensed and experienced psychiatrist.  
 
 
Results 
 
We first performed a one-way MANOVA to test whether PCT and MT produced 
systematically different pre-post (Week 0 - Week 28) outcomes for the three dependent 
variables. The overall test yielded no significant Wilks’ Lambda, F (2, 23) = 0.31, p = 
.82. The two treatment alternatives were therefore further taken to constitute a single 
EST in the analyses and interpretation of the data. An alpha level of .05 was used for all 
statistical tests. Whether or not treatment reduced symptomatology and promoted 
remoralization was examined to start with. The findings in Table 1 show the parti-
cipants to be significantly less avoidant, have significantly fewer agoraphobic 
cognitions, and be significantly more remoralized, when the results in week 28 were 
compared to those in week 0 (i.e., prior to the start of the EST). The effect sizes (Co-
hen’s d = [M0 – M28]/SDpooled; SDpooled = [(SD² + SD²)/2]) showed the changes to be 
robust.  
 
 
Table 1  
Means, Standard Deviations, F-statistics, and Effect Sizes for Pre- and Post-measure-
ment (Week 0 vs. Week 28), n = 24.  
Measure  Mweek0 
(SD) 
Mweek28 
(SD) 
F df p Cohen’s d
MI-AAL 2.70 (0.83) 1.78 (0.68) 35.46 23 < .001 1.21 
ACQ  2.17 (0.60) 1.52 (0.49) 32.03 23 < .001 1.19 
RS 2.64 (0.36) 3.27 (0.50) 56.93 23 < .001 1.45 
Note. MI-AAL = Mobility Inventory - Avoidance when Alone, ACQ = Agoraphobic Cognition Questionnaire, and 
RS = Remoralization Scale. 
 
 
Recall that the first aim of the present study was to investigate the sensitivity of 
a measure of remoralization to therapeutic change over time. Latent growth models 
(LGMs; Curran & Hussong, 2003; Duncan & Duncan, 2004) were used for this purpose 
because LGMs simultaneously examine changes in the variances, covariances, and 
mean values of factors over time. More information is thus incorporated into a LGM 
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than into such traditional statistical measures as a repeated measures ANOVA. LGMs 
also allow us to track individual changes as well as aggregate changes over time. Mplus 
(Muthén & Muthén, 2007) was used to estimate the LGMs. The sample size imposes 
constraints on the power of the test, however, Muthén and Muthén (2002) showed that a 
sample of 40 cases with four measures over time, yielded enough power. We have more 
measures over time (i.e. eight), therefore we estimated 24 casus to be enough to obtain 
sufficient power. 
 
 
Table 2 
Means, Variances, and Fit Measures for the Slopes and Intercept Factors for the MI-
AAL, ACQ, and RS.  
 Intercept factor Slope factor          Fit Measures 
 M Variance M Variance ² dfa 
MI-AAL 2.66* 0.74* 0.13* 0.02* 50.50 31 
ACQ 2.03* 0.29* 0.07* 0.01* 28.10 30 
RS 2.64* 0.10*   0.09* 0.00* 46.50 30 
Note. RS = Remoralization Scale, MI-AAL = Mobility Inventory - Avoidance when Alone, and ACQ = Agoraphobic 
Cognition Questionnaire.  
aThe number of df for the random effects model was 31, however, for ACQ and RS an extra correlated error had to be 
introduced, consuming one df.  
*p < .05 
 
 
A random effects model was initially adopted to assess linear growth. The fit 
measures presented in Table 2 indicate that the random effects model fits reasonably 
well (p > .01). The change in RS (i.e., the mean for the slope factor) was significant, 
which shows remoralization to be sensitive to the changes that occur across multiple 
time points. Agoraphobic avoidance (MI-AAL) and agoraphobic cognitions (ACQ) also 
showed significant change over time. In addition, significant differences between the 
individual participants were indicated by significant variances of the intercept factors. 
We have addressed the issue of power by using JRule (Saris, Satora, & van der 
Veld, 2009) and found for all means of the slope factors the power to detect a 
misspecification of .10 was .75 or higher. For the variance of the slope factors, the 
power to detect a misspecification of .01 was .99. Hence, our estimation that 24 casus 
was enough, seemed justified. 
Due to the limitations of a small sample size on the number of parameters that 
can be estimated in a conditional LGM, the LGM could not be used to investigate the 
second and third research questions in the present study. The factor scores of the growth 
factors — intercept and slope — were therefore saved as new variables for the analyses 
to follow. However, because our main interest is change we only used the slope factor 
scores in subsequent analysis. 
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The second aim of this study was to investigate the strength of the relation 
between changes in remoralization, on the one hand, and symptomatology, on the other 
hand. The changes in remoralization, agoraphobic avoidance and agoraphobic 
cognitions were all linear. The slope of the RS scores strongly correlated with the slope 
of the MI-AAL scores (r = .50, p < .01) and the slope of the ACQ scores (r = .55, p < 
.05), which shows remoralization to change at a pace that is similar to the pace of 
change found for the symptom variables. The slopes of the MI-AAL and ACQ scores 
also correlated highly (r = .66, p < .01).   
The third and main aim of the present study was to investigate the unique value 
of measuring remoralization in addition to symptom reduction. Linear regression 
analyses were undertaken to determine just how well changes in remoralization, 
changes in agoraphobic avoidance and changes in agoraphobic cognitions predicted 
change in health-related QoL (all subscales of the RAND). Eight multiple linear 
regression analyses (method Enter) were conducted for this purpose: one for each of the 
RAND-36 subscale difference scores (i.e. the score at week 28 minus the score at week 
0), with the slopes of the MI-AAL, ACQ, and RS entered as predictor variables. The 
results are presented in Table 3.  
 
 
Table 3 
Standardized Regression Coefficients of the Slope Factors of the RS, MI-AAL, and 
ACQ, and explained variance on the RAND-36 Subscale Difference Scores. 
 Predictors: Slope factor  
Dependent variables MI-
AAL 
ACQ  RS R² 
RAND-36 subscales difference scoresa     
  General health perception   .10   .34  .62* .27*
  Physical functioning .28   .28  .02 .06*
  Mental health   .10 .12  .53* .30*
  Bodily pain   .45 .00  .63* .28*
  Role limitations due to emotional problem   .37 .16  .56* .26*
  Role limitations due to physical problem   .07 .06  .45 .19*
  Social functioning   .11 .26  .23 .13*
  Vitality   .07 .15  .38 .18*
Note. The RS partly suppresses the relation between the RAND-36 subscale difference scores and the slope factors of 
MI-AAL and ACQ. Therefore, the presented standardized coefficients do not always have the same direction. 
Inspection of the correlations shows that the slope factor of MI-AAL and ACQ are correlated negatively and the 
slope factor of the RS is correlated positively with the RAND-36 subscale scores, as should be expected. RS = 
Remoralization Scale, MI-AAL = Mobility Inventory - Avoidance when Alone, and ACQ = Agoraphobic Cognition 
Questionnaire.  
aThe difference scores for the RAND-36 subscales were calculated to provide change over four-week intervals, so 
that change in the outcome is expressed over the same time interval as the predictors are. So difference scores for the 
RAND-36 subscales were calculated as follows: score at week 28 minus score at week 0 divided by 7 (i.e., number of 
four-week intervals). 
*p < .05. 
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Change of remoralization significantly and strongly predicted change on the 
following RAND-36 subscale scores: general health perception, mental health, bodily 
pain, and role limitations due to emotional problem. Changes in the symptom measures 
did not significantly predict changes in the RAND-36 subscale scores. The amount of 
variance explained showed the three predictor variables together to explain a reasonable 
part of the variance in the RAND-36 subscales change scores. These results indicate, 
although tentative, that the measurement of RS has added value above and beyond the 
measurement of the MI-AAL and ACQ. 
 
 
Discussion 
 
The aim of the present study was to investigate the utility of remoralization as a 
supplemental outcome measure for the evaluation of treatment. We followed patients 
with PDA receiving a standard, indicated EST. As expected, the treatment was effective 
with respect to the symptoms: After 28 weeks, large decreases in agoraphobic 
avoidance and agoraphobic cognitions were observed. The effect sizes (Cohen’s ds were 
1.21 for MI-AAL and 1.19 for ACQ) were comparable with the effect sizes from meta-
analyses on the treatment of panic disorder with agoraphobia (Cohen’s ds varying from 
.91 to 1.25; see van Balkom et al., 1997; Oei et al., 1999). There were missing data for 7 
participants (23 %), but no dropouts from treatment, save those who reported to have 
improved already. Our attrition rates, therefore, were lower than those commonly found 
in panic disorder patients treated with PCT or SSRI (see for instance: Keijsers, 
Kampman, & Hoogduin, 2001; Barlow, Gorman, Shear, & Woods, 2000). Meta-
analyses generally suggest that that PCT and SSRIs are equally effective, and, although 
largely irrelevant for the research questions we were interested in, there were no 
differences in treatment efficacy between both treatments in our study also. With regard 
to the sensitivity of remoralization measurement change over time, we found a linear 
pattern of change: in every four week interval patients were more remoralized than in 
the interval before. The treatment was not only effective with respect to symptoms, but 
also with respect to remoralization. Its effect size (Cohen’s d was 1.45) was even larger 
than those found for the two symptom measures.  
When the changes over time in agoraphobic avoidance, agoraphobic cognitions 
and remoralization were compared, similar patterns were found. Despite the use of a 
homogeneous group of patients with one specific syndrome in a study with treatment 
aimed specifically at alleviation of the relevant symptoms, the course of remoralization 
showed a pattern similar to that for the course of the symptoms. This leads us to 
conclude that the symptoms of PDA patients change in a similar manner and at a similar 
pace as their remoralization and vice versa.  
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To determine if measuring remoralization has also a unique value, we examined 
whether remoralization of patients was more strongly related to health-related QoL 
(RAND-36 subscales) than changes in the symptoms of the patients did. This was 
indeed found to be the case for the following RAND-36 subscales: general health 
perception, mental health, bodily pain, and role limitations due to emotional problem. 
Contrary to these findings, agoraphobic avoidance and agoraphobic cognitions 
exhibited only a minimal unique relationship to the RAND-36 subscales. When patients 
experience remoralization during the course of treatment, they are also more likely to 
report a better overall feeling of health, less limitations on their work and daily 
activities, less bodily pain, and a better general health status. A high health-related QoL 
is, moreover, reported in the literature to be associated with less absenteeism from work 
(Hanebuth, Meinel, & Fischer, 2006), better social and global functioning, and better 
coping (de Vries & van Heck, 1997).  
The present study is, to our knowledge, the first to actually investigate the utility 
of measuring remoralization as part of the evaluation of the outcome effects of disorder 
directed treatments. Furthermore, it is the first study that directly investigated the 
relationship between remoralization and symptom reduction, and the unique 
contribution of remoralization in relation to symptom reduction with regard to health 
related QoL. Although the present study is small and preliminary, it is innovative 
because it included patients with well-defined symptoms, the receipt of a standard 
indicated EST, and measurement of symptom reduction using instruments specifically 
selected for this purpose. In doing the latter, changes in remoralization and symptoms 
could more easily be distinguished. In the present research, moreover, we focused on 
the relationships between the patterns of change for remoralization and symptoms over 
time as opposed to their relationships at a single point in time. The present study thus 
overcomes some of the drawbacks on the research conducted on remoralization to date 
(e.g. Callahan, Swift, & Hynan, 2006; Grissom, Lyons, & Lutz, 2002; Hilsenroth, 
Ackerman, & Blagys, 2001; Lutz, Lowry, Kopta, Einstein, & Howard, 2001).  
Our findings that remoralization and patient symptoms show a strongly 
correlated course for PDA patients receiving EST are not in concordance with the 
demoralization theory of Frank (1974) or the ideas of Howard and colleagues (1993) in 
which changes in remoralization are assumed to be distinguished from symptom 
reduction. The exact significance of the high correlations between symptom reduction 
and remoralization in the present study, is not completely clear, however. It is possible, 
for example, that symptom reduction enhances remoralization, remoralization leads to 
reduced symptomatology, or that the treatment offered simultaneously prompted 
remoralization and reduced symptomatology. Experimental study with treatment 
focused solely on the symptoms of a disorder versus treatment focused solely on 
remoralization should be undertaken to help unravel the relations between changes in 
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remoralization and the symptoms of a disorder as a consequence of psychotherapeutic 
treatment. 
The present results nevertheless suggest that Frank and Howard were right about 
the fact that measuring remoralization as part of treatment outcome evaluation is 
valuable because remoralization, as being related to patients’ estimates of being healthy 
in general, being mentally healthy, suffering no pain, and experiencing no daily 
limitations, contributes to a broader view of treatment enhancement — a view that 
includes more than just the assessment of symptom reduction. In sum and despite the 
preliminary nature of the present study, there is reason to believe that remoralization is a 
valuable measure to include in treatment efficacy research.  
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Abstract 
 
Objective: Previous studies that tested the phase model of psychotherapy outcome 
(Howard, Lueger, Maling, & Martinovich, 1993) were not able to confirm the assump-
tions underlying the phase model. They do not appear to have been able to sufficiently 
differentiate between remoralization and symptom reduction (i.e., the outcomes of the 
first two phases). Whether or not remoralization and symptom reduction can be 
distinguished was therefore investigated experimentally in the present study. Method: 
Patients suffering from panic disorder with agoraphobia (N = 78; mean age: 36.99 yrs 
[SD = 12.5]; 28 male) were randomly assigned to a 4-week remoralization treatment 
(RT), which was strictly focused on remoralization, a 4-week exposure treatment (ET), 
which was strictly focused on symptoms, or a 4-week waiting list. The Subjective Well-
being Scale (Howard et al.) was used to measure pre/post remoralization change and the 
Panic-Agoraphobia Scale (Bandalow, 1995) was used to measure pre/post panic 
symptoms. Results: Significant improvement was found for the intended effects of the 
treatments. RT increased remoralization significantly (ES = 0.70) and ET reduced 
symptoms significantly (ES = 0.72). In addition, unintended effects of the treatments 
were found as well. RT significantly affected symptom reduction (ES = 0.55) and ET 
significantly affected remoralization (ES = 0.76). Conclusions: It is unlikely, at least for 
patients suffering from panic disorder with agoraphobia, that remoralization and 
symptom reduction can be distinguished empirically. This difficulty may explain why 
earlier studies on the phase model have not been able to confirm the assumptions 
underlying the phase model.  
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Introduction 
 
The process of change during psychotherapy can be viewed as the cornerstone of 
clinical practice and meta-theories as the renowned phase model of psychotherapy 
outcome (phase model; Howard, Lueger, Malin, & Martinovich, 1993), in which the 
process of change in psychotherapy are unfolded, are of central interest. In this model, 
psychotherapy is assumed to progress in a stepwise manner with each phase depending 
upon a previous phase and each phase representing a different domain of 
psychotherapeutic change. The first phase in the model draws upon the demoralization 
theory of Frank and Frank (1991) and is therefore referred to as the remoralization 
phase. During this phase, patients overcome their state of demoralization, regain hope 
that their problems can be resolved, and experience an increased sense of subjective 
well-being. The second phase addresses the symptoms of the patient and is referred to 
as the remediation phase. Coping is facilitated and improved in order to bring about 
symptom relief. The third phase is the rehabilitation phase, which is “focused on the 
unlearning of troublesome, maladaptive, longstanding patterns and the establishment of 
new ways of dealing with various aspects of self and life” (Howard et al., p. 680).  
Given the simplicity and transparency of the phase model in addition to its 
detailed description of the phases, the model proved attractive and theoretically valuable 
for clinicians. Clinicians recognize the phases for all kind of patients from their own 
professional practices (Joyce, Ogrodniczuk, Piper, & McCallum, 2002). But how well 
has the phase model been validated empirically? At first sight, the model seems 
empirically validated because six early studies—including four by the research team of 
Howard—have confirmed the assumptions underlying the phase model (Barkham, Rees, 
Stiles, Shapiro, Hardy, & Reynolds, 1996; Hilsenroth, Ackerman, & Blagys, 2001; 
Howard et al., 1993; Kopta, Howard, Lowry, & Beutler, 1994; Lutz, Lowry, Kopta, 
Einstein, & Howard, 2001; Martinovich, 1998). At the same time, doubts can be raised 
about the empirical validation of the phase model because three later studies, (Callahan, 
Swift, & Hynan, 2006; Holloway, 2004; Joyce et al., 2002) did not yield further 
confirmation for the assumptions underlying the phase model.  
Let us scrutinize the assumptions of the phase model. In the phase model, it is 
assumed that patients in psychotherapy improve on a number of outcome measures in a 
systematic manner but not at the same time. According to Howard et al. (1993), 
psychotherapeutic change is not random but follows a customary sequence. 
Demoralization decreases within the first few sessions. After the establishment of 
remoralization, the patient moves into the phase of remediation in which actual 
symptom reduction takes place. Most patients terminate treatment after this phase. 
Those patients who continue with treatment progress to the last phase: rehabilitation. 
The assumption of a temporal relation between the different phases of psychothera-
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peutic change is thus the first basic assumption underlying the phase model of psycho-
therapy outcome. 
The second basic assumption underlying the phase model is the so-called 
conditional relation of the phases. Significant improvement in the preceding phase is a 
necessary condition for the occurrence of improvement in the next phase. In other 
words, remoralization must take place before symptom reduction can occur. And symp-
tom reduction must take place before rehabilitation can occur. 
In the following, we will consider the empirical evidence for the two basic 
assumptions underlying the phase model. We will focus on the first two phases of the 
model because only a minority of patients receiving psychotherapeutic treatment are 
expected to stay in therapy long enough to enter the third phase (Howard et al., 1993).  
Assumption 1: The temporal relation of the phases 
In a total of five studies (Barkham et al., 1996; Hilsenroth et al., 2001; Howard et al., 
1993; Kopta et al., 1994; Lutz et al., 2001), the amount of change in remoralization and 
symptom reduction for patients receiving treatment was dichotomized as “improved” or 
“non-improved” in order to examine the temporal sequence of the first two phases in the 
phase model. The authors compared the percentages of patients who had improved on 
remoralization (referring to the first phase), and on symptom reduction (referring to the 
second phase) at different points across the period of treatment, which could range from 
pre-treatment to an average of 16 sessions (for Kopta et al. and Lutz et al. to as many as 
52 sessions). The results showed a larger percentage of the patients to improve for 
remoralization than for symptom reduction. This finding led the authors of the five 
studies to conclude that remoralization of patients in psychotherapy occurs faster than 
symptom reduction and that psychotherapeutic change thus occurs in the stepwise 
manner as proposed by the phase model. 
This conclusion is open to debate, however. Whether or not symptom reduction 
(i.e., remediation) actually constitutes a later phase of change than remoralization 
cannot be deduced on the basis of the data analyzed in these studies. This is because the 
ratio of patients improved on remoralization to patients improved on symptom reduction 
did not change over time; that is, the ratio was stable across the different points in time. 
There was no difference for the earlier versus later sessions, although this might be 
expected on the basis of the phase model. Inspection of the figures depicting the 
percentages of improved patients for remoralization and symptom reduction over time 
(Barkham et al., 1996; Howard et al., 1993; Kopta et al., 1994), moreover, shows 
virtually no different growth line in either measure. It is thus not clear that one measure 
actually changes earlier than the other or that the measures start to accelerate at 
different points in time. In the figures of Howard et al. and Kopta et al., the change in 
remoralization can be seen to be largest in the first few treatment sessions, but this can 
also be seen to be the case for symptom reduction as well. Remoralization does not 
Distinction Remoralization and Symptom Reduction 
 57
accelerate earlier than symptom reduction. The reported data, thus, do not provide 
conclusive evidence for the first assumption of the phase model, the temporal relation of 
the phases. The unpublished findings of Martinovich (1998) may point in a different 
direction, but they could not be retrieved for inspection.  
Moreover, the five studies taken to provide support for the temporal sequence of 
the phase model (Barkham et al., 1996; Hilsenroth et al., 2001; Howard et al., 1993; 
Kopta et al., 1994; Lutz et al., 2001) suffer from several methodological problems. The 
use of dichotomized data to indicate improvement is likely to have resulted in a 
significant loss of information (Cohen, 1990). An increase in the likelihood of 
erroneous conclusions may occur as a result of this loss of information. General 
symptom checklists were used to measure symptom reduction (Hilsenroth et al.; 
Howard et al.; Kopta et al.; Lutz et al.), but these instruments are designed to measure 
general feelings of discomfort as opposed to specific symptoms. These instruments are 
less suited to distinguish the remediation phase (with reduction of symptoms) from the 
remoralization phase (with increase of remoralization). In addition, the studies used 
heterogeneous or unclear patient samples, and either the type of treatment was 
unspecified or the treatment was aimed at such a wide array of syndromes and problems 
that it is unclear what the observed effects of treatment should be ascribed to. 
As opposed to the other studies Barkham et al. (1996) studied a uniform patient 
population using a symptom-specific instrument. Unfortunately, Barham et al. used the 
same instrument to measure both, symptom reduction and remoralization, which makes 
it difficult to pinpoint those changes that belong to remoralization and those changes 
that belong to remediation. Both Joyce et al. (2002) and Holloway (2004) have failed to 
find empirical proof for the assumption of the temporal relation of the phases of the 
phase model. Drawing upon observational data, these studies did not suffer from a 
potential loss of information due to the dichotomization of data. However, proper pre-
treatment assessments did not take place. First assessment of Joyce et al. took place 
after session four; first assessment of Holloway took place after session one or two. 
Note that important changes in remoralization might have already occurred prior to 
initial assessment. A clear conclusion regarding the assumption of a temporal relation of 
the phases cannot, thus, be drawn as yet. 
Assumption 2: The conditional relation of the phases 
Three studies were particularly aimed at examining the assumption that improvement of 
remoralization is a condition for the remediation phase (Callahan et al., 2006; Joyce at 
al., 2002; Howard et al., 1993). Crosstabs and chi-square analyses were undertaken to 
compare the numbers of improved versus non-improved patients. That is, how many 
patients showed improved remoralization in combination with non-improved symptom 
reduction, versus non-improved remoralization in combination with improved symptom 
reduction at particular points in time? If the phases are conditionally related, the first 
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should show greater numbers than the latter. However, only Howard et al. has detected 
such a distribution. Callahan et al. and Joyce et al. did not find the expected distribution 
at most of the points that they analyzed.  
Joyce et al. (2002) also investigated the pre-condition assumption by examining 
the two sequences, remoralization preceding symptom reduction, and symptom 
reduction preceding remoralization. Both sequences were found to occur, and no one 
sequence occurred more often than the other.  
The—at best—ambiguous evidence regarding the conditional relation of the 
phases appears to stem at least in part from the previously discussed concerns related to 
dichotomization of data, the use of general symptom checklists, unspecified patient 
samples, unspecified or general treatments, and—in the case of Joyce et al. (2002)—a 
lack of proper pre-treatment assessment. Therefore we could not draw any definite 
conclusions about the pre-condition assumption.  
New studies 
In a recent study of the added value of measuring remoralization in addition to symptom 
reduction in outcome research, patients suffering from panic disorder and agoraphobia 
were given indicated, empirically supported treatments (Vissers, Keijsers, van der Veld, 
Hendriks, & Hutschemaekers, 2010). The treatments were well-defined, symptom-
directed, and undertaken with a homogeneous sample of patients. To assess 
remoralization and symptoms over time, separate and specific instruments were used. 
This means that this study should have been able to better distinguish changes in 
remoralization from changes in remediation than in previous studies. Both strong 
remoralization and strong symptom effects were found. Contrary to the expectations, 
however, the courses of remoralization and symptom reduction were highly correlated. 
That is, the timing and degree of change for the remoralization and remediation phases 
of psychotherapeutic change overlapped considerably. These findings together with the 
findings of the previously discussed studies can be explained in two manners. First, it is 
possible that the naturalistic study designs allowed for too much noise and that this 
noise masked any underlying differences between the remoralization and remediation 
phases of psychotherapeutic change. It is, alternatively, possible that the supposition 
underlying Howard’s phase model (and underlying the two described assumptions) that 
remoralization and symptom reduction are two distinguishable processes, simply does 
not hold.  
Greater empirical insight into the relations between remoralization and symptom 
reduction should be gathered before further research on the phase model is conducted. 
In the present study, we therefore compared the effects of treatment focused solely on 
remoralization versus treatment focused solely on the symptoms of the disorder. This 
experimental research design was adopted in order to maximize the likelihood of dis-
tinguishing the remoralization and remediation phases (i.e., the differences predicted by 
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the phase model). It was reasoned that, if remoralization and symptom reduction can 
really be distinguished, as the phase model proposes, the treatment aimed at remora-
lization should not lead to clear symptom reduction; and conversely, the treatment 
aimed at remediation should not lead to clear increases in remoralization. 
 
 
Method 
Design 
In an experimental study, patients with panic disorder with agoraphobia (PDA) were 
randomly allocated to one of three conditions: brief remoralization treatment (RT), brief 
exposure treatment (ET), or a four-week waiting list (WL). Time 1 measurement (T1) 
took place prior to randomization. Time 2 measurement (T2) took place 5 weeks later. 
This meant that the patients in the treatment conditions had completed their fourth and 
final session.  
A total of 30 patients per condition was judged to be required for a statistical 
power of 80%, an α < .05, and comparison of the treatment conditions with WL with an 
estimated Effect Size (ES) of 0.80 for the reduction of panic symptoms and 0.70 for 
remoralization (Cohen, 1992). De Beurs, van Balkom, Lange, Koele, and van Dyck 
(1995) reported an ES of 1.32 for a six-session exposure-in-vivo treatment of panic 
disorder patients. We thus presumed an ES of .80 to be feasible within the context of the 
present study (i.e., four as opposed to six sessions of exposure in-vivo). Remoralization 
effects with an ES of 0.38 were found for students receiving a single session of 
relaxation treatment (Ermers, 2005). In the current study, it was thus expected that these 
remoralization effects could be doubled ( i.e. ES of 0.70) because we included patients 
as opposed to students (patients are expected to be more demoralized) and because 
sharp increases in remoralization following the first four sessions of treatment have 
been previously reported (Howard et al., 1993; Lutz et al., 2001).  
The study was approved by the Dutch Central Committee for Human Related 
Research (i.e., ethical research committee).  
Participants and procedure  
A total of 150 patients from an outpatient clinic, the Pro Persona Centre for Anxiety 
Disorders Overwaal, was invited at intake to participate in the present study when they 
met the inclusion criteria. The intake at the clinic entailed two sessions. The Mini 
International Neuropsychiatric Interview (Lecrubier et al., 1997) was administered by 
independent assessors in order to determine the DSM-IV classification for the patients’ 
disorders. The inclusion and exclusion criteria for the present study were in line with 
criteria of efficacy studies on the treatment of panic disorder with agoraphobia (Westen 
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& Morrison, 2001) and were as follows: a present DSM-IV classification of PDA and 
an age of 18 to 65 years. The exclusion criteria were: receipt of other psychological 
treatment, meeting the DSM-IV criteria for a severe mood disorder with or without 
psychotic features, schizophrenia, mental retardation, suicidal ideation, or alcohol or 
psychoactive substance abuse or dependence.  
 When judged to be eligible for inclusion in the study, the patients were given 
written information about the study and asked to provide permission to be contacted by 
phone. Those patients who agreed to be contacted were called within one week after the 
second intake session; the study was explained in greater detail; and the patients were 
invited to participate in the present study while awaiting for their formal treatment to 
begin. The waiting time from intake to initiation of outpatient treatment was an average 
of 5.5 months at the time of the start of the present study.  
A total of 95 patients agreed to participate. At T1, the patients were asked to 
provide their written informed consent. They were then administered three self-report 
scales to determine their state of remoralization and symptoms (see Measures). At the 
end of T1, the patients were randomly assigned to one of the conditions (i.e., a three-
arm parallel trial design was followed). Randomization was carried out for successive 
blocks of 15 subjects (5 ET, 5 RT and 5 WL) in order to arrive at equal numbers of 
patients per condition. Additionally, stratification was adopted for the use of anti-
depressant medication. 
 One week after T1, weekly treatment sessions were initiated with the patients in 
the two treatment conditions. At the end of the fourth and final treatment session, the 
patients were asked by an independent assessor to again complete the three self-report 
scales (T2). The patients in the WL condition were invited to the clinic to again 
complete the three self-report scales 5 weeks (T2) after initial assessment.  
Seventy-eight patients completed the study and the demographic characteristics 
of the population who completed the study are summarized in Table 1. In addition to a 
DSM-IV axis I disorder, three of the patients also had a co-morbid DSM-IV axis II 
disorder: one in RT and two in WL. Of the 34 patients taking antidepressants, 29 had 
SSRIs and 5 tricyclic or other antidepressants. Of the 30 patients taking benzo-
diazepines, 11 were taking an antidepressant as well. All of the patients taking psycho-
tropic medication were asked to adhere to the set daily dosage during the course of the 
study.  
Treatment conditions 
General aspects. Both treatment conditions involved four weekly treatment 
sessions with a duration of 45 minutes each, that were described in detail in a manual. 
After each session, homework was assigned. And each treatment condition was piloted 
on five PDA patients.  
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All sessions were audiotaped for supervision purposes and to check for treatment 
integrity. With regard to the latter, 15% of the audiotaped sessions were selected at 
random. A graduate teaching assistant, who was naive with regard to the content and 
goals of the present study, listened to the audiotapes and used a checklist to rate whether 
or not he recognized the main features of the two brief treatments. This resulted in a 100 
% correct classification (i.e. either RT or ET) for all of the selected sessions. 
Brief exposure treatment (ET). Development of agoraphobia is seen as an 
aggravation and complication of panic disorder and often considered the most impairing 
aspect of PDA (Barlow, 1988; de Beurs & Widenfelt, 2004). For this reason, exposure 
in-vivo, directly aimed at the agoraphobia, was decided upon as the course of treatment 
for the symptoms of PDA in the present study. The exposure in-vivo component is one 
of the four components of the repeatedly tested and clearly effective Panic Control 
Treatment (PCT) of Craske and Barlow (1993; van Balkom, Bakker, Spinhoven, 
Blaauw, Smeenk, & Ruesink, 1997). This component has been shown to clearly 
contribute to the effectiveness of PCT (de Beurs et al., 1995).  
In the first ET session, psycho-education about anxiety and avoidance behavior 
was undertaken and, together with the therapist, the patient constructed a hierarchy of a 
large variety of relevant phobic situations. The patient was then given the assignment to 
expose him of herself, guided by the hierarchy of phobic situations, to complete for the 
second, third, and fourth treatment sessions. The exposure assignments were evaluated 
and discussed during the treatment sessions. In the ET sessions, no problems other than 
the patient’s agoraphobic avoidance were discussed. If a patient started to talk about 
other problem areas, the therapist politely brought the focus back to the exposure 
assignment and hierarchy. The therapist took a supportive, coaching stance and 
encouraged the patients to perform the exposure assignments. 
Brief remoralization treatment (RT). A four-session remoralization treatment 
was derived from the work of Rijnders (2004) who developed a brief therapy aimed at 
remoralization of patients. Rijnders’ brief therapy, which involves seven or eight 
sessions, is strongly based upon Frank’s demoralization theory and contains elements of 
strategic psychotherapy, behavior therapy, and solution-focused therapy. Hakkaart-van 
Roijen, van Straten, Rutten, & Donker (2006) showed this therapy to be just as effective 
as cognitive behavior therapy.  
In the RT condition, attention was not paid to specific PDA symptoms but, 
rather to the explanation of the problems experienced by the patient in terms of failed 
problem solving and inadequate coping strategies. The RT was aimed at identification 
of the patient’s competencies and stimulation of these competencies via step-by-step 
problem solving. The goal was not to reduce symptoms but to elicit perspective and 
hope. In the first session, a hypothesis about the relationship between the patient’s 
problems and his or her circumstances was sought. As homework assignment, the 
patient was then instructed to think and talk about the circumstances that appear to make 
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his or her usual problem-solving strategies fail. In the second session, the patient’s 
hypothesis was extended to include his or her personal coping style: The patient’s 
problems can be seen as a result of his or her particular circumstances and specific 
manner of coping. In the remainder of the sessions, behavior-change experiments were 
proposed, discussed, and carried out by the patient. Although the therapists in the RT 
condition had to acknowledge the suffering of the patients at times, they refrained from 
intervening to directly reduce the incidence of symptoms.  
Therapists and assessors 
Therapists were graduate students in clinical psychology who were fulfilling their 
practical internship at the Pro Persona Centre for Anxiety Disorders Overwaal and at an 
university outpatient clinic. All of the therapists received a two-day training on ET and 
a two-day training on RT. Throughout the study, the therapists were supervised on a 
weekly basis by two experienced clinical psychologists: one who is specialized in 
exposure treatment and one who is specialized in remoralization treatment, to ensure 
that the therapists adhered to the treatment manuals. Audiotaped-recordings of the 
sessions were used in these supervision sessions.  
The assessors on the T1 and T2 measurement occasions were also graduate 
students in clinical psychology who were fulfilling their practical or research internship, 
different than the therapists, and blind to the treatment conditions for the patients being 
assessed.  
Measures 
Remoralization was measured using two instruments. The Subjective Well-being Scale 
(SWS; Grissom, Lyons, & Lutz, 2002) is a 3-item adaptation of the original instrument 
used by Howard et al. (1993) to assess remoralization. The three items constituting the 
SWS are responded to using Likert scales with a range of 1 to 4, 1 to 5, and 1 to 6, 
respectively. The SWS has good internal consistency and validity. High scores indicate 
strong remoralization. The SWS is treated as the primary measure of remoralization in 
the present study because it corresponds most to the measures used in the original 
studies of the phase model. However, the usefulness of the SWS is unknown for cases 
of PDA. The Remoralization Scale (RS; Vissers, Keijsers, van der Veld, de Jong, & 
Hutschemaekers, in press), a measure of remoralization that has been recently 
developed and tested on a population of patients with PDA, was therefore included as a 
secondary measure of remoralization in the present study. The RS assesses changes in 
remoralization as a result of treatment. The RS is a psychometrically sound, self-report 
instrument that measures growth of hope, subjective well-being, and sense of mastery. 
Patients are required to rate on a four-point scale the extent to which they agree with 
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each of 12 statements, with higher RS scores indicating greater remoralization. Internal 
consistency and test-retest reliability are excellent (Vissers et al.). 
The Panic and Agoraphobia Scale (PAS; Bandelow, 1995) was used to measure 
symptoms of panic and agoraphobia. The PAS is a psychometrically sound instrument 
that requires respondents to respond to 13 items using a four-point Likert scale. The 
incidence of panic attacks, avoidance behavior, anticipatory anxiety, disability, and 
worries about health is assessed. A higher PAS score indicates more symptoms of panic 
and agoraphobia.  
Data analyses 
Analyses were conducted on the data for completers (ET, n = 28; RT, n = 26; WL, n = 
24). We decided on this approach as opposed to an intention-to-treat analysis because 
the present study was not concerned with demonstration of treatment efficacy. For the 
main analyses of the data change scores (i.e., T1 minus T2) were calculated. Each 
change score was entered separately into a one-way ANCOVA — one for SWS, one for 
RS and one for PAS — with three conditions (ET, RT, WL) and the T1 scores as the 
covariate. After checking for a main effect of condition, planned contrasts were 
undertaken (Maxwell & Delaney 2004): The change scores for ET were compared to 
those for WL, and the change scores for RT were compared to those for WL. Bonferroni 
adjustments were made to control for the inclusion of three dependent variables. An 
alpha of .05 divided by the 3 thus resulted in an alpha level of .017. 
There were no missing data for the primary measures (SWS and PAS). Due to a 
logistic failure, 17 % of the data of the secondary remoralization measure was missing 
completely at random. For this reason, we used multiple imputation (Little & Rubin, 
1990; Rubin, 1987). That is, we imputed 10 data sets and averaged predictions and SEs 
for uncertainty due to imputation.  
 
 
Results 
Attrition 
As can be seen from Figure 1, 150 patients were found to be potentially eligible for 
inclusion in the study and 126 met the inclusion criteria. A total of 95 agreed to 
participate and were randomly assigned to one of three conditions at T1. Immediately 
thereafter, 4 patients dropped out. An additional 13 patients dropped out just before T2. 
When the scores on the two measures of remoralization and the scores on the measure 
of symptoms at T1 were compared for the dropouts versus the completers, no 
significant differences were found.  
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Time 1 Measurement
and randomization
(n = 95)
 
Assessed for eligibility
(n = 150)
Started ET (n = 33)
Discontinued ET (n = 5)
-no symptoms anymore (n = 3)
-too busy (n = 1)
-could not be reached (n = 1)
Started RT (n = 28)
Discontinued RT (n = 2)
-refused to continue (n = 1)
-family circumstances (n = 1)
Started WL (n = 30)
Discontinued WL (n = 6)
-refused to continue (n = 3)
-could not be reached (n = 2)
-didn't want to wait (n = 1)
Allocated to ET (n = 34)
Did not receive ET (n = 1)
-refused to participate (n = 1)
Allocated to RT (n = 31)
Did not receive RT (n = 3)
-refused to participate (n = 2)
-had a stroke (n = 1)
Allocated to WL (n = 30)
Finished ET and Time 2
measurement (n =28)
Finished RT and Time 2
measurement (n = 26)
Finished WL and Time 2
measurement (n = 24)
Refused (n = 31)
-refused to participate (n = 23)
-didn't want to be randomized (n = 5)
-could not be reached (n = 3)
Excluded (n = 24)
-not meeting inclusion criteria (n = 24)
 
Figure 1. Overview of patient participation and dropout. ET = brief exposure treatment, 
RT = brief remoralization treatment, WL = waiting list control. 
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The study was conducted between December 2005 and November 2008. While 
the required sample sizes had yet to be obtained by November 2008, the average 
waiting time for the outpatient clinic had dropped to less than five weeks, which 
rendered inclusion in our study impossible.  
Preliminary analyses 
The ET, RT, and WL groups did not differ with regard to any of the demographic 
characteristics (see Table 1).  
 
 
Table 1 
Demographic and Clinical Characteristics of Patients. 
Variable ET n = 28 RT n = 26 WL n = 24 Test value (df) p 
Age, years (SD) 33.4 (11.1) 37.8 (13.1) 40.3 (13.6) F (2,75) = 2.00 .14 
      
Male, % (n) 35.7 (10)      23.1 (6) 50.0 (12) ² (2) = 3.93 .14 
      
Education, years (SD) 12.3 (2.2) 11.7 (2.7) 11.8 (3.1) F (2,73) = 0.48 .62 
      
Marital or living status:    ² (4) = 3.56 .47 
Never married, % (n) 46.4 (13) 38.5 (10) 34.8 (8)   
Divorced, % (n) 00.0 (0) 11.5 (3) 08.7 (2)   
Married or living with 
partner, % (n) 
 
53.6 (15) 
 
50.0 (13) 
 
56.5 (13) 
  
      
Employed, % (n) 66.7 (16) 54.2 (13) 45.5 (10) ² (2) = 2.13 .35 
      
Panic symptoms,  
years (SD) 
 
05.0 (6.2) 
 
05.8 (8.0) 
 
07.3 (10.5) 
 
F (2,71) = 0.47 
 
.63 
      
Co-morbidity, % (n) 64.3 (18) 42.3 (11) 37.5 (9) ² (2) = 4.35 .11 
      
Sort co-morbidity:      
Depression, % (n) 21.4 (6) 11.5 (3) 08.3 (2)   
Hypochondria, % (n) 17.9 (5) 11.5 (3) 04.2 (1)   
Social phobia, % (n) 14.3 (4) 07.7. (2) 12.5 (3)   
GAD, % (n) 10.7 (3) 07.7. (2) 12.5 (3)   
Specific phobia, % (n) 14.3 (4) 03.8 (1) 08.3 (2)   
OCD, % (n)  10.7 (3) 03.8 (1) 04.2 (1)   
Other, % (n) 07.2 (2) 11.5 (3) 00.0 (0)   
      
Antidepressant, % (n) 42.9 (12) 46.2 (12) 41.7 (10) ² (2) = 0.11 .95 
      
Benzodiazepine, % (n) 28.6 (8) 42.3 (11) 45.8 (11) ² (2) = 1.87 .39 
Note. ET = brief exposure treatment, RT = brief remoralization treatment, WL = waiting list control. GAD = 
generalized anxiety disorder, OCD = obsessive compulsive disorder, AD = adjustment disorder.  
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In Table 2, the baseline and post-treatment scores on the three outcome measures and 
the estimated effect sizes for the three groups are presented. After checking for the basic 
assumptions of multivariate normality and homogeneity of variance, we tested whether 
the three groups differed from baseline on the SWS, RS, and PAS. The overall 
MANOVA did not yield a significant Wilks’ Lambda, F (6, 148) = 1.59, p = .15. 
 
 
Table 2  
Descriptive Statistics for Outcome Measures at Times 1 and 2. 
Measure/condition (n) MTime1 (SD) MTime2 (SD) ESa (95 % CI) 
Subjective Well-being Scale    
 ET (28) 3.10 (0.58) 3.58 (0.66) 0.76 (0.22, 1.30) 
 RT (26) 2.76 (0.66) 3.30 (0.85) 0.70 (0.14, 1.26) 
 WL (24) 2.69 (0.75) 2.79 (0.92) 0.12 (0.68, 0.45) 
Remoralization Scale    
 ET (28) 2.64 (0.43) 2.85 (0.51) 0.47 (0.06, 1.00) 
 RT (26) 2.56 (0.52) 2.90 (0.38) 0.74 (0.17, 1.30) 
 WL (24) 2.44 (0.54) 2.47 (0.61) 0.05 (0.62, 0.51) 
Panic and Agoraphobia Scale    
 ET (28) 1.71 (0.71) 1.20 (0.69) 0.72 (0.18, 1.26) 
 RT (26) 1.68 (0.79) 1.23 (0.83) 0.55 (0.01, 1.10) 
 WL (24) 2.00 (0.86) 1.97 (1.03) 0.03 (0.53, 0.60) 
Note. ET = brief exposure treatment, RT = brief remoralization treatment, WL = waiting list control, CI = Confidence 
Interval. 
aEstimated effect size was calculated as Hedges’ g (M1 – M2)/SDpooled; SDpooled = ([(n1 – 1)SD1² + (n2 – 
1)SD2²]/n1 + n2 - 2).  
 
Intended treatment effects 
After checking that the basic assumptions of normality, homogeneity of variance, and 
homogeneity of regression were met, our main ANCOVA’s were conducted. The 
covariate SWS at T1 did not relate significantly to the change scores for SWS, F(1, 74) 
= 3.40, p = .07. A significant effect of condition on the SWS change scores was, 
however, apparent, F(2, 74) = 4.60, p = .013. Planned contrasts showed RT to elicit 
significantly greater increases in SWS than WL (i.e., no treatment), t(74) = 2.63 , p = 
.010. The covariate RS at T1 related significantly to the change scores for RS, F(1,74) = 
7.04, p = .013. There was a significant effect of condition on the RS change scores as 
well, F(2, 74) = 7.67, p = .001. Planned contrasts showed RT to elicit significantly 
greater increases in RS than WL, t(74) = 3.82 , p = .001. The covariate PAS at T1 was 
significantly related to the change scores for PAS, F(1, 74) = 7.99, p = .006. A 
significant effect of condition on the PAS change scores was found, F(2, 74) = 5.71, p = 
.005. Planned contrasts showed ET to elicit significantly greater decreases in PAS than 
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WL, t(74) = 3.10 , p = .003. Both treatments thus realized those effects that they were 
intended on.  
Unintended treatment effects 
Recall that the main aim of the current research was to investigate whether RT also 
resulted in symptom reduction and whether ET resulted in remoralization as well. Given 
that the progress of a patient with respect to remoralization and symptom reduction 
should be distinct according to the phase model (Howard et al., 1993), it was 
hypothesized that ET should not lead to significant increases in SWS or RS and that RT 
should not lead to significant decreases in PAS. Planned contrasts showed ET to elicit 
significantly greater increases in SWS than WL, t(74) = 2.66, p = .010, and marginally 
greater increases in RS than WL, t(74) = 2.22, p = .019. Planned contrasts showed RT to 
elicit significantly greater decreases in PAS than WL, t(74) = 2.79, p = .007. 
In other words, both treatments — which were aimed only at one effect — 
elicited changes on the measure of the unintended effect as well. 
 
 
Discussion 
 
The aim of the present study was to investigate whether the treatment effects of 
remoralization could be distinguished from the treatment effects of symptom reduction. 
An experimental research design in which the effects of treatment for PDA on patients 
who were randomly assigned to one of three conditions was adopted. The conditions 
were brief exposure treatment (ET), designed to strictly reduce symptoms of patients, 
brief remoralization treatment (RT), designed strictly to remoralize patients, or a 
waiting list (WL) control. The research design and decisions made with respect to the 
selection of outcome measures, treatment approach, and patient sample were all aimed 
at maximizing the a priori chances of finding distinct effects for remoralization and 
symptom reduction.  
As expected, both of the treatment conditions elicited the intended outcome 
effects respectively. After only four sessions, ET significantly reduced symptoms of 
panic and agoraphobia (ES = 0.72) and RT significantly increased remoralization (ES = 
0.70 for SWS; ES = 0.74 for RS). These effects were moderately large and comparable 
to those reported for the reduction of panic symptoms (de Beurs et al., 1995) and 
increase of remoralization (Ermers, 2005) with (very) brief mono-treatment. 
We were particularly interested in the possibly unintended effects of the 
different brief treatments. Our reasoning was as follows. If both treatments produce not 
only intended effects but also unintended effects, then it is difficult to maintain that 
remoralization and symptom reduction can be distinguished. That is, our data can show 
either the two outcomes to be distinguishable or to co-occur. The latter suggests that one 
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effect may prompt the other to occur and vice versa. In the present study, both brief 
treatments showed significant unintended outcome effects: RT produced not only 
remoralization but also a reduction of symptoms (ES = 0.55); ET produced not only 
symptom reduction but also increased remoralization (ES = 0.76 for SWS; ES = 0.47 for 
RS).  
The attrition rate of 18% from T1 (i.e., the moment of allocation) to T2 (i.e., 
post-treatment measurement) is comparable or lower than the rates commonly reported 
for panic disorder patients (see, for instance, Barlow, Gorman, Shear, & Woods, 2000; 
Keijsers, Kampman, & Hoogduin, 2001). Once treatment started, the dropout rates were 
not equal across the three conditions. More patients dropped out of the WL and ET 
conditions than the RT condition (6, 5, and 2, respectively). Speculation that RT may be 
easier for the patient to continue than no treatment or ET is tentative, considering the 
small number of patients and because three out of six patients who dropped out from ET 
mentioned they had no symptoms left as reason for their drop out.  
Although the present study is small and the present findings must therefore be 
considered preliminary, it is innovative because it definitely was not aimed at 
demonstrating treatment efficacy of the applied treatments, but it was designed instead 
to experimentally investigate whether two treatment effects could be manipulated 
separately. The treatment effects were evaluated according to the sophisticated 
standards for randomized clinical trials. The brief treatments that were intentionally 
designed to be brief, specific and strictly manualized, produced the pre/post changes 
they were designed for. The brief treatments were designed along the lines of treatment-
analogous laboratory manipulations, which means that the methodological 
sophistication of laboratory experiments was combined with the ecological validity of 
undertaking real treatment with real patients. One can object that the design had little 
ecological validity but, in our opinion, such a treatment-analogous laboratory design 
was necessary to maximize the a priori change to unravel the relation between 
remoralization and symptom reduction.  
Despite our research design, it is still possible that the ET may have been 
inadvertently aimed at remoralization of the patient or, conversely, the RT may have 
inadvertently urged the patient to deal with his or her agoraphobic avoidance. In 
addition, the fact that the therapists were trained to administer both types of treatment 
might have blurred the boundaries between the two forms of treatment provided. 
However, a correct treatment classification of 100% in the integrity analyses points in 
the opposite direction. As a significant distinction between remoralization and symptom 
reduction using a well-controlled research design cannot be demonstrated, the question 
can be raised whether this distinction, if it exists, is of relevance for clinical practice.  
With the use of a specific patient population (i.e., patients with PDA), we were 
able to investigate symptom reduction specifically and validly. This approach also 
methodologically enlarged the a priori chances of detecting a distinction between 
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remoralization and symptom reduction. However, the use of this patient population, in 
hindsight, may have masked an actual distinction between remoralization and symptom 
reduction. Patients with PDA are known to improve quite well with psychotherapy (e.g. 
Oei, Llamas, & Devilly, 1999; van Balkom et al., 1997). In the present research, 
relatively large effects for only four treatment sessions were indeed the case. For patient 
populations with more chronic syndromes, such as schizophrenia, the distinction be-
tween remoralization and symptom reduction may be more clear and symptom reduc-
tion may indeed be less likely to occur than remoralization in such cases (Shrivastava, 
Johnston, M., Shah, & Bureau, 2010; Strauss, 1994). However, the phase model is 
expected to apply to all kinds of patients and particularly patients who may benefit from 
the remediation phase (Howard et al., 1993); patients with PDA, for example. 
The original studies of the phase model (Barkham et al., 1996; Callahan et al., 
2006, Hilsenroth, 2001; Howard et al., 1993; Holloway, 2004, Joyce, et al., 2002; Kopta 
et al., 1994; Lutz et al., 2001) did not provide a conclusive answer for the question of 
whether the assumptions of temporal and conditional relation of the first two phases of 
the phase model are empirically valid. Based on the present findings, we are inclined to 
think that these studies also failed to distinguish between remoralization and symptom 
reduction during the process of psychotherapeutic change.  
Frank (1974) and Howard et al. (1993) were right in their assumption that 
successful psychotherapy produces multiple effects: symptom reduction, on the one 
hand, and remoralization, on the other hand. In line with the results of previous studies, 
however, we were not able to empirically distinguish these two outcome effects from 
each other. While our study was not designed to test the assumptions about the temporal 
and conditional relations between the phases of psychotherapeutic change, our results 
do not point in the direction of confirmation of these assumptions.  
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Abstract 
 
The phase model (Howard, Lueger, Maling, & Martinovich, 1993) presumes that 
different topics should be addressed during different phases of therapy. Studies testing 
this model, however, have not tested this presumption. The present study 
experimentally investigated whether a treatment that focused on remoralization first and 
on symptom reduction second, in line with the phase model, was more effective than a 
treatment that focused on symptom reduction first and on remoralization second. 
Patients suffering from panic disorder with agoraphobia (N = 72) were randomly 
assigned to one of the 8-session treatments or a waiting list. The two treatments proved 
equally effective for remoralization and symptom reduction. The treatment in line with 
the phase model was no more effective than the other treatment.  
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Introduction 
 
The process of change during psychotherapy can be viewed as the cornerstone of 
clinical practice and such meta-theories as the renowned phase model of psychotherapy 
outcome (phase model; Howard, Lueger, Malin, & Martinovich, 1993), in which the 
process of change in psychotherapy is described, are of central interest. In the phase 
model psychotherapy is assumed to progress in a stepwise manner with each phase 
depending upon a previous phase and each phase representing a different domain of 
psychotherapeutic change. The first phase in the model draws upon the demoralization 
theory of Frank and Frank (1991) and is therefore referred to as the remoralization 
phase. During this phase, patients overcome their state of demoralization, regain hope 
that their problems can be resolved, and experience an increased sense of subjective 
well-being. The second phase addresses the symptoms of the patient and is referred to 
as the remediation phase. Coping is facilitated and improved in order to bring about 
symptom relief. The third phase is the rehabilitation phase, which is “focused on the 
unlearning of troublesome, maladaptive, longstanding patterns and the establishment of 
new ways of dealing with various aspects of self and life” (Howard et al., p. 680).  
Let us scrutinize the basic assumptions of the phase model. In the phase model, 
it is assumed that patients in psychotherapy improve on a number of outcome measures 
in a systematic manner but not at the same time. According to Howard et al. (1993), 
psychotherapeutic change is not random but follows a customary sequence. 
Demoralization decreases within the first few sessions. After the establishment of 
remoralization, the patient moves into the phase of remediation in which actual 
symptom reduction takes place. Most patients terminate treatment after this phase. 
Those patients who continue with treatment progress to the last phase: rehabilitation. 
The temporal relation between the different phases of psychotherapeutic change is thus 
a basic assumption underlying the phase model of psychotherapy outcome. Another 
basic assumption concerns the conditional relation between the phases: Significant 
improvement in the preceding phase is assumed to be a necessary condition for 
improvement in the next phase. In other words, remoralization must take place before 
symptom reduction can occur, and symptom reduction must take place before 
rehabilitation can occur. 
Given the simplicity and transparency of the phase model in addition to its 
detailed description of the phases of psychotherapeutic change, the model has proved 
attractive and theoretically valuable for clinicians. Clinicians recognize the phases for 
all kinds of patients (Joyce, Ogrodniczuk, Piper, & McCallum, 2002). The question, of 
course, is whether the phase model has been shown to be empirically valid or not. At 
first sight, the model appears to be empirically valid because six early studies — 
including four by the research team of Howard — have confirmed the basic 
assumptions underlying the phase model (Barkham, Rees, Stiles, Shapiro, Hardy, & 
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Reynolds, 1996; Hilsenroth, Ackerman, & Blagys, 2001; Howard et al., 1993; Kopta, 
Howard, Lowry, & Beutler, 1994; Lutz, Lowry, Kopta, Einstein, & Howard, 2001; 
Martinovich, 1998). Three later studies, however, have not yielded further confirmation 
of the assumptions underlying the phase model (Callahan, Swift, & Hynan, 2006; 
Holloway, 2004; Joyce et al., 2002).  
In the following, the empirical evidence for aforementioned basic assumptions 
underlying the phase model will be considered in greater detail. Only the first two 
phases of the model will be considered in doing this because only a minority of patients 
undergoing psychotherapeutic treatment are expected to stay in therapy long enough to 
enter the third phase of psychotherapeutic change (Howard et al., 1993).  
Previous studies  
In a total of five studies (Barkham et al., 1996; Hilsenroth et al., 2001; Howard et al., 
1993; Kopta et al., 1994; Lutz et al., 2001), the amount of change in remoralization and 
symptom reduction for patients receiving treatment was dichotomized as “improved” or 
“non-improved” in order to examine the temporal relation of the first two phases in the 
phase model. The authors compared the percentages of patients who had improved for 
remoralization (i.e., the first phase) and for symptom reduction (i.e., the second phase) 
at different points across the course of treatment. The period of treatment could range 
from pre-treatment to an average of 16 sessions for Kopta et al. and Lutz et al. to as 
many as 52 sessions. The results showed that a larger percentage of patients improved 
on remoralization than on symptom reduction. This finding led the authors of the five 
studies to conclude that remoralization of patients in psychotherapy occurs faster than 
symptom reduction and that psychotherapeutic change thus occurs in the stepwise 
manner proposed by the phase model. 
However, this conclusion appears to have been rather rash. Whether or not 
symptom reduction (i.e., remediation) actually constitutes a later phase of change than 
remoralization cannot be deduced on the basis of the data analyzed in these studies. This 
is because the ratio of patients improved on remoralization to patients improved on 
symptom reduction did not change over time; that is, the ratio was stable across the 
course of treatment. As far as we can ascertain, the ratio of patients improving for 
remoralization to patients improving for symptom reduction did not differ for earlier 
versus later sessions although a changed ratio might be expected on the basis of the 
phase model. The reported data, thus, do not provide conclusive evidence for the 
assumption of a temporal relation of phases underlying the phase model. Unpublished 
findings from Martinovich (1998) may point in a different direction, but they could not 
be retrieved for inspection.  
In three studies that were particularly aimed at examining the assumption that 
remoralization is a pre-condition for remediation (i.e., symptom reduction), crosstabs 
and chi-square analyses were undertaken to compare the numbers of improved versus 
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non-improved patients during the course of treatment (Callahan et al., 2006; Joyce at al., 
2002; Howard et al., 1993). The question was just how many patients showed improved 
remoralization without symptom reduction versus no remoralization but clear symptom 
reduction at a given point in treatment. If the remoralization and remediation phases of 
the phase model are conditionally related, the first (i.e. improved remoralization and 
non-improved symptom reduction) should show greater numbers than the latter (non-
improved remoralization and improved symptom reduction). However, only Howard et 
al. found such a distribution of improvement and non-improvement. Neither Callahan et 
al. nor Joyce et al. found the expected distribution for the majority of the treatment 
points that they analyzed. Given these contradictory findings, definite conclusions 
cannot thus be drawn about the pre-condition assumption underlying the phase model.  
For all studies of the phase model, a number of methodological concerns must 
be addressed also. In the studies by Barkham et al. (1996), Callahan et al. (2006), 
Hilsenroth et al. (2001), Howard et al. (1993), Joyce et al. (2002), Kopta et al. (1994), 
and Lutz et al. (2001) the use of dichotomized data to indicate improvement may have 
led to a significant loss of information (Cohen, 1990). And as a result of this loss of 
information, an unnecessary increase in the likelihood of erroneous conclusions may 
thus have occurred. In addition, general symptom checklists were used to measure the 
reduction of symptoms in a number of the studies (i.e., Callahan et al.; Hilsenroth et al.; 
Howard et al.; Joyce et al.; Kopta et al.; Lutz et al.). However, such checklists are 
designed to measure general feelings of discomfort as opposed to specific symptoms. 
The question, thus, is whether these instruments were suited to distinguish the 
remediation (i.e., symptom reduction) phase from the remoralization phase. Finally, the 
studies have used heterogeneous or unclear patient samples and the type of treatment 
was either unspecified or the treatment was aimed at a wide array of syndromes and 
problems, which leaves what the observed effects of treatment should be ascribed to 
unclear. 
As opposed to the other prior studies of the phase model, Barkham et al. (1996) 
examined a uniform patient population using a symptom-specific instrument. 
Unfortunately, the same instrument was used to measure both symptom reduction and 
remoralization, which makes it difficult to pinpoint the changes that belong to 
remoralization and the changes that belong to remediation. Both Joyce et al. (2002) and 
Holloway (2004) collected observational data, which meant that these studies did not 
suffer from a potential loss of information due to the dichotomization of data. Empirical 
proof for the assumption of a temporal relation of the phases in the phase model was not 
found, but proper pre-treatment assessment did not take place. Initial assessment only 
took place after the fourth treatment session in the Joyce et al. study, and initial 
assessment only took place after one or two treatment sessions in the Holloway study. 
In other words, important changes in remoralization might have already occurred prior 
to initial assessment in these studies.  
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In light of the contradictory findings and methodological drawbacks of the 
previous studies of the phase model, clear conclusions regarding the assumptions of a 
temporal relation and conditional relation between the phases cannot be drawn as yet. 
Current study 
In addition to the aforementioned contradictory findings and methodological 
drawbacks, previous studies of the phase model all refrained from the provision of 
treatment in line with the content of the phase model. According to Howard et al. 
(1993), “certain classes of interventions are appropriate for different phases of therapy” 
(p. 679). In the phase model, it is indeed presumed that different topics should be 
addressed during different phases of therapy, but none of the studies testing the phase 
model to date — including that of Howard et al. — have either experimentally or quasi-
experimentally, tested this presumption. The present study was therefore specifically 
designed to do just this: To experimentally investigate the treatment implications of the 
phase model. 
In order to investigate the treatment implications of the phase model, treatment 
was divided into two components: a brief treatment strictly focused on remoralization 
and a brief treatment strictly focused on the reduction of symptoms of a specific 
disorder. The brief treatments were then offered in either a sequence reflecting the phase 
model (i.e., treatment aimed at remoralization first and then treatment aimed at 
symptom reduction) or in a sequence deviated from the phase model (i.e., treatment 
aimed at symptom reduction first and then treatment aimed at remoralization). It was 
expected that, if the phase model is a valid model of psychotherapeutic change, 
treatment in line with the phase model should be more effective than treatment deviated 
from the model.  
Many of the problems associated with the previous studies of the phase model 
are avoided in the present study. A homogeneous sample of patients suffering from 
panic disorder with agoraphobia is studied. Patients are randomly assigned to one of 
two treatment conditions or a waiting list. Treatment effects are assessed using 
observational as opposed to dichotomized data. And instruments are used to measure 
specifically remoralization and specific symptoms of panic with agoraphobia.  
 
 
Method 
Design 
In an experimental study, patients with panic disorder with agoraphobia (PDA) were 
randomly allocated to one of three conditions: 8 weeks of treatment consisting of a 4-
session remoralization module followed by a 4-session exposure module directed at the 
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patients symptoms (RT-ET), 8 weeks of treatment consisting of a 4-session exposure 
module followed by a 4-session remoralization module (ET-RT), or an 8-week waiting 
list (WL). Given that the 8-week treatment periods involved two separate treatment 
components, the term “module” is used to refer to the different components. 
Measurement was undertaken at Time 1 (T1), prior to randomization; at Time 2 (T2), 5 
weeks later, which meant that all of the patients in the treatment conditions had 
completed their fourth treatment session; and at Time 3 (T3), 9 weeks after T1, which 
meant that all of the patients in the treatment conditions had completed their eighth and 
final treatment session.  
We investigated whether RT-ET produced larger increase of remoralization and 
a larger reduction of panic symptoms than ET-RT at T3. The comparison of the T1 and 
T2 data of the present sample is outlined in greater detail elsewhere in order to answer 
another set of research questions (Vissers, Keijsers, Kampman, Hendriks, & Rijnders, 
2010). The study was approved by the Dutch Central Committee for Human Related 
Research (i.e., ethical research committee).  
Participants and procedure 
A total of 150 patients from an outpatient clinic, the Pro Persona Center for Anxiety 
Disorders Overwaal, was invited at intake to participate in the present study when they 
met the inclusion criteria. The intake at the clinic involved two sessions. The Mini 
International Neuropsychiatric Interview (Lecrubier et al., 1997) was administered by 
independent assessors in order to determine the DSM-IV classification for the patients’ 
disorders. The inclusion and exclusion criteria for the present study were, in line with 
the criteria used in efficacy studies for the treatment of panic disorder with agoraphobia 
(Westen & Morrison, 2001), as follows: a present DSM-IV classification of PDA and an 
age of 18 to 65 years. The exclusion criteria were: receipt of other psychological 
treatment, meeting the DSM-IV criteria for a severe mood disorder with or without 
psychotic features, schizophrenia, mental retardation, suicidal ideation, and alcohol or 
psychoactive substance abuse or dependence.  
 When judged to be eligible for inclusion in the study, the patients were given 
written information about the study and asked to provide permission to be contacted by 
phone. Those patients who agreed to be contacted were called within one week after the 
second intake session. The study was explained in greater detail. The patients were 
invited to participate in the study while awaiting for their formal treatment to begin. The 
waiting time from intake to initiation of outpatient treatment was an average of 5.5 
months at the time of the start of the present study.  
A total of 95 patients agreed to participate. At T1, the patients were asked to 
provide their written informed consent. They were then asked by an independent 
assessor to complete three self-report scales to determine their state of remoralization 
and symptoms (see Measures). At the end of T1, the patients were randomly assigned to 
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one of three conditions (i.e., a three-arm parallel trial design was followed). 
Randomization was carried out for successive blocks of 15 subjects (5 ET-RT, 5 RT-
ET, and 5 WL) in order to arrive at equal numbers of patients per condition. 
Stratification was adopted for the use of antidepressant medication. 
 One week after T1, weekly treatment sessions were initiated with the patients in 
the two treatment conditions. At the end of the fourth session (T2) and at the end of the 
eighth session (T3), the patients were again asked to complete the three self-report 
scales. The patients in WL were invited to the clinic to also complete the three self-
report scales 5 weeks (T2) and 9 weeks (T3) after initial assessment.  
In the end, 72 patients completed the study; the demographic characteristics are 
summarized in Table 1. In addition to a DSM-IV axis I disorder, two of the patients also 
had a co-morbid DSM-IV axis II disorder: one in RT-ET and one in WL. Of the 30 
patients taking antidepressants, 26 had SSRIs and 4 had a tricyclic or other 
antidepressant. Of the 26 patients taking benzodiazepines, 10 were taking an 
antidepressant as well. All of the patients taking psychotropic medication were asked to 
adhere to the set daily dosage throughout the study.  
Treatment modules  
General aspects. The patients in RT-ET and ET-RT all received two treatment 
modules but in a different sequence. Both modules involved four weekly sessions with a 
duration of 45 minutes each; the individual sessions were outlined in a manual. After 
each session, homework was assigned. Each module was piloted on five PDA patients. 
The treatment was provided by two therapists: one for each treatment module.  
All of the sessions were audiotaped for supervision purposes and to check for 
treatment integrity. With regard to the latter, 15% of the audiotaped sessions were 
selected at random. A graduate teaching assistant, who was naive with regard to the 
content and goals of the present study, listened to the audiotapes and used a checklist to 
indicate if the main features of the two modules were present or not. This resulted in a 
100 % correct classification (i.e. either RT or ET) for all of the selected sessions.  
Remoralization treatment module (RT). The four-session remoralization 
treatment module was derived from the work of Rijnders (2004) who has developed a 
brief therapy aimed at the remoralization of patients. Rijnders’ brief therapy involves 
seven or eight sessions and is strongly based upon Frank’s demoralization theory but 
also contains elements of strategic psychotherapy, behavior therapy, and solution-
focused therapy. Hakkaart-van Roijen, van Straten, Rutten, and Donker (2006) have 
shown this therapy to be just as effective as cognitive behavior therapy and also care as 
usual (i.e., a therapy from a wide range of options). 
In the RT module, attention was not paid to specific PDA symptoms but, rather, 
to the explanation of the problems experienced by the patient in terms of failed problem 
solving and inadequate coping strategies. The RT was aimed at identification of the 
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patient’s competencies and stimulation of these competencies via step-by-step problem 
solving training. The goal of the RT was not to reduce symptoms but to elicit 
perspective and hope. In the first session, a hypothesis about the relationship between 
the patient’s problems and his or her circumstances was sought. The patient was then 
instructed to think and talk about the circumstances that appear to make his or her usual 
problem-solving strategies fail as a homework assignment. In the second session, the 
patient’s hypothesis was extended to include his or her personal coping style: The 
patient’s problems can be viewed as a result of his or her particular circumstances and 
specific manner of coping. In the remainder of the sessions, behavior-change 
experiments were proposed, discussed, and carried out by the patient. Although the 
therapists in the RT module had to acknowledge the suffering of the patients at times, 
they refrained from directly intervening to reduce the incidence of symptoms.  
Exposure treatment module (ET). Development of agoraphobia is seen as an 
aggravation and complication of panic disorder and often considered the most impairing 
aspect of PDA (Barlow, 1988; de Beurs & Widenfelt, 2004). For this reason, exposure 
in-vivo, directly aimed at the agoraphobia, was decided upon as the course of treatment 
for the symptoms of PDA in the present study. The exposure in-vivo component is one 
of the four components of the repeatedly tested and clearly effective Panic Control 
Treatment (PCT) of Craske and Barlow (1993; van Balkom, Bakker, Spinhoven, 
Blaauw, Smeenk, & Ruesink, 1997). This component has been shown to clearly 
contribute to the effectiveness with respect to symptoms of PCT (de Beurs, van Balkom, 
Lange, Koele, & van Dyck, 1995).  
In the first ET session, psycho-education about anxiety and avoidance behavior 
was undertaken and, together with the therapist, the patient constructed a hierarchy of 
relevant phobic situations. The patient was then given the assignment to expose 
him/herself to a phobic situation, guided by the hierarchy of these situations, before the 
next session (i.e., the second, third, or fourth treatment session). The exposure 
assignment was then evaluated and discussed during the next treatment session. In the 
ET sessions, no problems other than the patient’s agoraphobic avoidance were 
discussed. If a patient started to talk about other problem areas, the therapist politely 
brought the focus back to the exposure assignment and hierarchy of phobic situations. 
The therapist took a supportive, coaching stance and encouraged the patients to perform 
the exposure assignments. 
Therapists and assessors 
Therapists were graduate students in clinical psychology fulfilling their practical 
internship at the Pro Persona Centre for Anxiety Disorders Overwaal or at a university 
outpatient clinic. All of the therapists received a two-day training in ET and a two-day 
training in RT. Throughout the study, the therapists were supervised on a weekly basis 
by two experienced clinical psychologists: one who is specialized in exposure treatment 
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and one who is specialized in remoralization treatment. In such a manner, adherence to 
the treatment manuals was ensured. Audiotaped recordings of the sessions were used for 
the supervision sessions.  
The assessors at T1, T2 and T3 were also graduate students in clinical 
psychology fulfilling their practical or research internship but different from the 
therapists. The assessors were blind to the treatment conditions for the patients being 
assessed.  
Measures 
Remoralization was measured using two self-report instruments. The Subjective Well-
being Scale (SWS; Grissom, Lyons, & Lutz, 2002), which is a three-item adaptation of 
the original instrument used by Howard et al. (1993) to assess remoralization. The three 
items constituting the SWS are responded to using Likert scales with a range of 1 to 4, 1 
to 5, and 1 to 6, respectively. The SWS has good internal consistency and validity. High 
scores indicate strong remoralization. The SWS is treated as the primary measure of 
remoralization in the present study because it corresponds most to the measures used in 
the original studies of the phase model. However, the usefulness of the SWS is 
unknown for cases of PDA. The Remoralization Scale (RS; Vissers, Keijsers, van der 
Veld, de Jong, & Hutschemaekers, in press), which is a measure of remoralization 
recently developed and tested on a population of patients with PDA, was therefore 
included as a secondary measure of remoralization in the present study. The RS assesses 
changes in remoralization as a result of treatment. The RS is a psychometrically sound 
instrument that measures growth of hope, subjective well-being, and sense of mastery. 
Patients are required to rate on a four-point scale the extent to which they agree with 
each of 12 statements, with higher RS scores indicating greater remoralization. Internal 
consistency and test-retest reliability are excellent (Vissers et al.). 
The Panic and Agoraphobia Scale (PAS; Bandelow, 1995) was used to measure 
symptoms of panic and agoraphobia. The PAS is a psychometrically sound self-report 
instrument that requires respondents to respond to 13 items using a four-point Likert 
scale. The incidence of panic attacks, avoidance behavior, anticipatory anxiety, 
disability, and worries about health is assessed. A higher PAS score indicates more 
symptoms of panic and agoraphobia. 
Data analyses 
Analyses were conducted on the data for completers (ET-RT, n = 27; RT-ET, n = 26; 
WL, n = 19). For the main analyses of the data, change scores were calculated (i.e., T1 
minus T3). Each change score was entered separately into a one-way ANCOVA — one 
for SWS, one for RS, and one for PAS — with three conditions (ET-RT, RT-ET, WL) 
and the T1 scores as the covariate. After checking for a main effect of condition, 
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planned contrasts were undertaken (Maxwell & Delaney 2004): The change scores for 
ET-RT were compared to those for WL, and the change scores for RT-ET were 
compared to those for WL. Thereafter, the main question, whether RT-ET was indeed 
more effective than ET-RT, was investigated using again three separate ANCOVAs 
with three conditions (RT-ET, ET-RT, WL). Planned contrasts were directly 
undertaken: change scores for ET-RT were compared to those for RT-ET. 
There were no missing data for the primary measures (SWS and PAS). Due to a 
logistic failure, 25% of the data for the secondary remoralization measure was missing 
but completely at random. For this reason, we used multiple imputation (Little & Rubin, 
1990; Rubin, 1987). That is, we imputed 10 data sets and averaged predictions and SEs 
for uncertainty due to imputation.  
 
 
Results 
Attrition 
As can be seen from Figure 1, 150 patients were found to be potentially eligible for 
inclusion in the study and 126 met the inclusion criteria. A total of 95 agreed to 
participate and were randomly assigned to one of the three conditions at T1. 
Immediately thereafter, 4 patients dropped out. An additional 13 patients dropped out 
just before T2 and 6 before T3. When the scores on the two measures of remoralization 
and the scores on the measure of symptoms at T1 were compared for the dropouts 
versus the completers, significant differences did not occur.  
Data collection was conducted between December 2005 and November 2008. 
While the required sample sizes had yet to be obtained by November 2008, the average 
waiting time for the outpatient clinic had dropped to less than nine weeks, which 
rendered inclusion in our study impossible.  
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Time 1 Measurement  and
randomization
(n = 95)
 
Assessed for eligibility
(n = 150)
Started ET (n = 33)
Discontinued ET (n = 5)
-no symptoms anymore (n = 3)
-too busy (n = 1)
-could not be reached (n = 1)
Started RT (n = 28)
Discontinued RT (n = 2)
-refused to continue (n = 1)
-family circumstances (n = 1)
Started WL (n = 30)
Discontinued WL (n = 6)
-refused to continue (n = 3)
-could not be reached (n = 2)
-didn't want to wait (n = 1)
Allocated to ET-RT (n = 34)
Did not start ET (n = 1)
-refused to participate (n = 1)
Allocated to RT-ET (n = 31)
Did not start RT (n = 3)
-refused to participate (n = 2)
-had a stroke (n = 1)
Allocated to WL (n = 30)
Finished ET and Time 2
measurement, started RT
(n = 28)
Discontinued RT (n = 1)
-refused to continue (n = 1)
Finished RT and Time 2
measurement, started ET
(n = 26)
Finished Time 2 measurement,
continued next 4 weeks WL
(n = 24)
Discontinued WL (n = 5)
-didn't want to wait (n = 5)
Refused (n = 31)
-refused to participate (n = 23)
-didn't want to be randomized (n = 5)
-could not be reached (n = 3)
Excluded (n = 24)
-not meeting inclusion criteria (n = 24)
Finished RT and Time 3
measurement (n =27)
Finished ET and Time 3
measurement (n = 26)
Finished WL and Time 3
measurement (n = 19)
 
Figure 1. Overview of patient participation and dropout. ET-RT = exposure treatment 
module followed by remoralization treatment module, RT-ET = remoralization 
treatment module followed by exposure treatment module, ET = exposure treatment 
module, RT = remoralization treatment module, WL = waiting list control. 
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Preliminary analyses 
ET-RT, RT-ET, and WL groups did not differ with regard to demographic 
characteristics (see Table 1). 
 
 
Table 1. 
Demographic and Clinical Characteristics of Patients.  
Variable ET-RT  
n = 27 
RT-ET  
n = 26 
WL  
n = 19 
Test value (df) p 
Age, years (SD) 33.2 (11.3) 37.8 (13.1) 29.9 (14.0) F (2,69) = 1.71 .19 
      
Male, % (n) 33.3 (9) 23.1 (6) 47.4 (9) ² (2) = 2.92 .23 
      
Education, years (SD) 12.2 (2.1) 11.7 (2.7) 12.1 (3.2) F (2,68) = 0.29 .75 
      
Marital or living status:    ² (4) = 3.48 .48 
Never married, % (n) 48.1 (13) 38.5 (10) 36.8 (7)   
Divorced, % (n) 00.0 (0) 11.5 (3) 06.9 (2)   
Married or living with 
partner, % (n) 
 
51.9 (14) 
 
50.0 (13) 
 
52.6 (10) 
  
      
Employed, % (n) 69.6 (16) 54.2 (13) 55.6 (10) ² (2) = 1.37 .51 
      
Panic symptoms,  
years (SD)  
 
05.1 (6.3) 
 
05.8 (8.0) 
 
07.6 (11.5) 
 
F (2,66) = 0.47 
 
.63 
      
Co-morbidity, % (n) 66.7 (18) 42.3 (11) 42.1 (8) ² (2) = 4.04 .14 
      
Sort co-morbidity:      
Depression, % (n) 22.2 (6) 11.5 (3) 05.3 (1)   
Hypochondria, % (n) 18.5 (5) 11.5 (3) 05.3 (1)   
Social phobia, % (n) 14.8 (4) 07.7. (2) 15.8 (3)   
GAD, % (n) 11.1 (3) 07.7. (2) 15.8 (3)   
Specific phobia, % (n) 14.8 (4) 03.8 (1) 10.5 (2)   
OCD, % (n)  11.1 (3) 03.8 (1) 05.3 (1)   
Other, % (n) 07.4 (2) 11.5 (3) 00.0 (0)   
      
Antidepressant, % (n) 40.7 (11) 46.2 (12) 36.08 (7) ² (2) = 0.41 .82 
      
Benzodiazepine, % (n) 25,9 (7) 42.3 (11) 42.1 (8) ² (2) = 1.94 .38 
Note. ET-RT = exposure treatment module followed by remoralization treatment module, RT-ET = remoralization 
treatment module followed by exposure treatment module, WL = waiting list control. GAD = generalized anxiety 
disorder, OCD = obsessive compulsive disorder, AD = adjustment disorder. 
 
 
In Table 2, the T1, T2, and T3 scores for the three outcome measures and the estimated 
effect sizes for the three groups of patients are presented. After checking for the basic 
assumptions of multivariate normality and homogeneity of variance, whether or not the 
three groups differed from baseline on the SWS, RS, and PAS measures was tested. The 
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overall MANOVA did not yield a significant Wilks’ Lambda, F (6, 136) = 1.39, p = .22. 
An alpha level of .05 was used for all statistical tests. 
 
 
Table 2.  
Descriptive Statistics for Outcome Measures at T1, T2, and T3. 
Measure/ 
condition (n) 
 
T1 M (SD) 
 
T2 M (SD) 
 
T3 M (SD) 
ESa 
T1-T2 
ESa 
T2-T3 
ESa 
T1-T3 
SWS       
ET-RT (27) 3.11 (0.58) 3.59 (0.68) 3.52 (0.72) 0.75 0.10b 0.61 
RT-ET (26) 2.76 (0.66) 3.30 (0.85) 3.41 (0.80) 0.70 0.13 0.88 
WL (19) 2.79 (0.76) 2.91 (0.81) 2.84 (0.83) 0.15 0.08 b 0.06 
RS       
ET-RT (27) 2.65 (0.43) 2.86 (0.51) 2.86 (0.52) 0.43 0.00 0.43 
RT-ET (26) 2.56 (0.52) 2.90 (0.38) 2.82 (0.48) 0.75 0.18 b 0.52 
WL (19) 2.42 (0.50) 2.48 (0.56) 2.44 (0.52) 0.10 0.06 b 0.04 
PAS       
ET-RT (27) 1.68 (0.70) 1.17 (0.68) 1.06 (0.70) 0.73 0.16 0.87 
RT-ET (26) 1.68 (0.79) 1.23 (0.83) 1.13 (0.87) 0.55 0.11 0.65 
WL (19) 1.89 (0.80) 1.80 (0.93) 1.70 (0.78) 0.11 0.11 0.24 
Note. SWS = Subjective Well-being Scale, RS = Remoralization Scale, PAS = Panic and Agoraphobia Scale, ET-RT 
= exposure treatment module followed by remoralization treatment module, RT-ET = remoralization treatment 
module followed by exposure treatment module, WL = waiting list control group. 
aEstimated effect size was calculated as Hedges’ g (M1 – M2)/SDpooled; SDpooled = ([(n1 – 1)SD1² + (n2 – 
1)SD2²]/n1 + n2 - 2). 
bMinus signs indicate an effect size for T2-T3 in the opposite direction of the effect size for T1-T2. 
 
 
ANCOVAs were conducted next. Each of the covariates (i.e., measures at T1) 
for the three outcome measures were significantly related to the change scores: SWS: 
F(1, 68) = 6.76, p = .011, RS: F(1,68) = 7.14, p = .010, and PAS: F(1, 68) = 11.14, p = 
.001. For all three measures, the condition effect was significant: SWS: F(2, 68) = 5.14, 
p = .008, RS: F(2, 68) = 4.23, p = .021, and PAS: F(2, 68) = 4.15, p = .020. Planned 
contrasts showed ET-RT compared to WL to elicit significantly greater changes in the 
SWS (t[68] = 2.35, p = .022), the RS (t[68] = 2.46 , p = .018), and the PAS (t[68] = 
2.74, p = .008). Planned contrasts similarly showed RT-ET compared to WL to elicit 
significantly greater changes in the SWS (t[68] = 2.13, p = .003.), the RS (t[68] = 2.73, 
p = .011), and the PAS (t[68] = 2.33, p = .023). Both ET-RT and RT-ET thus resulted in 
increased remoralization and decreased in panic-disorder symptoms.  
Treatments compared 
Recall that the main aim of the current research was to determine if RT-ET was more 
effective than ET-RT as might be expected on the basis of the phase model. Planned 
contrasts showed RT-ET to not elicit significantly stronger increases relative to ET-RT 
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for SWS, t(68) = 0.80, p = .426, for RS, t(74) = 0.31, p = .741, or for PAS, t(68) = 0.43, 
p = .668. There were no significant differences between the two treatments with respect 
to the amount of change for the three outcome measures. 
 
 
Discussion 
 
The aim of the present study was to investigate whether a treatment designed in line 
with the phase model (RT-ET) of Howard et al. (1993), was more effective than a 
treatment designed to clearly deviate from this model (ET-RT). In an experimental 
design, the two different treatments were compared in terms of their effects on remora-
lization and symptom reduction in patients with PDA. The different treatments were 
also compared to a waiting list control condition (WL).  
The results showed both treatments to increase remoralization (SWS and RS) 
and reduce panic disorder symptom (PAS) relative to WL. These effects were mode-
rately large, but in line with those reported for remoralization (Ermers, 2005) and panic 
symptoms (de Beurs et al., 1995) when brief treatment modules have been offered. 
When the two treatments in the present study were directly compared, RT-ET 
was not found to be more effective than ET-RT. These findings held for not only the 
measures of remoralization but also the measure of symptom reduction. 
The lack of differential effects for RT-ET and ET-RT might, of course, be due to 
the RT and ET modules not being sufficiently distinct. This does not, however, appear 
to be the case as the check for treatment integrity was 100% correct, which indicates 
that two clearly distinct treatment modules were indeed administered to all patients in 
the treatment conditions, but in different orders. Should the present findings be 
replicated, it can then be concluded that treatment that immediately starts with 
addressing patients’ symptoms is just as effective as treatment that first considers the 
patient’s state of hopelessness in order to provide some perspective and thereby hope, 
that is, as far as panic disorder patients are concerned. 
 In order to explain why RT-ET fails to be more effective than ET-RT, several 
explanations are possible and one of these is particularly likely in our opinion. While 
two distinct treatment modules were constructed and administered with 100% treatment 
integrity in the present study, it is nevertheless possible that the psychological processes 
associated with remoralization and symptom reduction co-occur and co-vary. Akin to 
thunder and lightning, it is thus possible that remoralization and symptom reduction are 
different psychological processes but cannot be experienced separate of each other. It is 
possible, for example, that symptom reduction cannot take place without remoralization 
and, conversely, remoralization cannot take place without symptom reduction. Reduced 
fear, less avoidance, and fewer panic attacks can certainly foster a more realistic 
perspective on the part of a patient and thereby foster hope; conversely, greater 
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perspective and hope can reduce symptoms of anxiety and ease the negative impact of 
such to at least a certain degree. 
Calculation of the correlations between the changes in the remoralization 
measures (T1-T3) and the changes in the symptom measures (T1-T3) yielded a mean of 
.54 (range: .52 to .57), which shows 29% of the change in one measure to be 
explained by changes in the other measure. This is a considerable amount of explained 
variance. In other words, remoralization and symptom reduction may indeed co-occur 
and co-vary.  
The effect sizes presented in Table 2 show the largest proportion of change to be 
realized by the first module in both of the treatments. The explanation for this effect is 
not completely apparent, but it is in line with the diminishing returns effect (Howard, 
Kopta, Krause, & Orlinsky, 1986). The diminishing returns effect is a change pattern 
frequently found to occur in psychotherapeutic treatment and entails rates of patient 
change leveling off after a particular point and further treatment not producing the same 
acceleration as seen earlier in treatment. Largest change was indeed found for the first 
module, yet, again, RT-ET and ET-RT did not differ with respect to these findings.   
The main limitation on the present study is the small sample size involved. It 
might be argued that we therefore had too little power to detect meaningful differences 
between RT-ET and ET-RT. Replication is certainly required. However, the study was 
carefully conducted, integrity of treatment was high, and the treatment modules were 
carefully selected, conducted, and supervised. Furthermore, both treatments produced 
better results than WL along on all of the outcome measures. We have no indication to 
believe that a larger patient sample would have yielded completely different results. In a 
replication study, it would be interesting, however, to include a follow-up measure to 
investigate possible differences between the two treatments several months following 
the last treatment session. 
The attrition rate of 24% in the present study from T1 (i.e., the moment of 
allocation) to T3 (i.e., post-treatment) may seem quite high but is commonly reported 
for patients with PDA (see, for instance, Barlow, Gorman, Shear, & Woods, 2000; 
Keijsers, Kampman, & Hoogduin, 2001). Approximately 50% of the dropouts in the 
present study were patients who had been assigned to WL. Most of these patients 
reported an unwillingness to await formal treatment any longer or a loss of interest in 
study participation. In the treatment conditions, the dropout rates from the first session 
(i.e. patients had experienced at least one session of the allocated treatment) to T3 were 
not equally distributed. More patients dropped out from ET-RT (6) than from RT-ET 
(2). Speculation as to why RT-ET may might be easier for the patient to continue than 
ET-RT is tentative, due to the small number of patients involved and because three out 
of the six patients who dropped out of ET-RT stated that their dropout was due to the 
fact that they had no symptoms left.  
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Although the present study is small-scale and the present findings must therefore 
be considered preliminary, the study is innovative in that it is the first to investigate the 
implications of the phase model via the design of the treatments (in line with, or 
deviated from, the phase model) and careful control of the treatment provided. The 
treatment effects were evaluated using the sophisticated standards for randomized 
clinical trials. The brief treatments were designed along the lines of treatment-analogous 
laboratory manipulations, which means that the methodological sophistication of 
laboratory experiments was combined with the ecological validity of real treatment with 
real patients. One might nevertheless suggest that the design and use of the brief 
treatments had little ecological validity but, in our opinion, such a treatment-analogous 
laboratory design was necessary to avoid the many problems associated with previous 
studies of the phase model. 
With the use of patients with PDA (i.e., a specific patient population), we were 
able to investigate symptom reduction specifically and validly as opposed to the 
previous studies of the phase model that used general symptom checklists. The present 
approach methodologically enlarged the a priori chances of detecting distinct effects of 
remoralization and symptom reduction. However, the findings cannot, as a result of the 
homogeneous patient population, be generalized to other patient populations such as 
patients with more chronic than acute syndromes like schizophrenia, because in such 
cases symptom reduction is less likely to occur than remoralization (Shrivastava, 
Johnston, Shah, & Bureau, 2010; Strauss, 1994).  
The studies discussed in the Introduction (Barkham et al., 1996; Callahan et al., 
2006, Hilsenroth, 2001; Howard et al., 1993; Holloway, 2004, Joyce et al., 2002; Kopta 
et al., 1994; Lutz et al., 2001) did not provide a conclusive answer to the question of 
whether the basic assumptions of temporal relation and conditional relation for the first 
two phases of the phase model are empirically valid. The lack of conclusive evidence of 
these studies could be attributable to methodological problems. However, in the present 
study with its innovative design and careful methodology, we also did not find evidence 
for an important treatment implication of the phase model, namely that a treatment first 
focussed on the first phase of the model (remoralization) should elicit more change than 
a treatment immediately focused on the second phase (symptom reduction). Frank 
(1974) and Howard et al. (1993) were right in their assumption that successful 
psychotherapy produces multiple effects: symptom reduction, on the one hand, and 
remoralization, on the other hand. However, in line with the results of previous studies, 
no additional proof in the direction of the phase model has been found. 
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Background 
 
There is a shortcoming in current outcome research of psychotherapy for patients in 
mental health care. As described in Chapter 1, the main question for the current research 
generation is whether a specific treatment effectively reduces the symptoms of a 
specific disorder. Although highly important, symptom reduction does not seem the 
only beneficial effect of treatments judged to be effective. However, other beneficial 
effects of psychotherapy have hardly been investigated in current psychotherapy 
outcome research. That is, the extent to which patients experience for example positive 
changes in their subjective sense of well-being, a better quality of social relationships, 
an increased sense of control, and reduced hopelessness has been neglected. Such a one-
sided emphasis on symptom reduction as the only important measure of 
psychotherapeutic outcome, moreover, has become so pervasive in outcome research 
today that a treatment is now referred to as “effective” without stipulation that 
“effective” means “effective with respect to symptom reduction.”  
In response to this one-sided focus on symptom reduction, there is a call to adopt 
a broader perspective on the measurement of effects in psychotherapy outcome research 
today. Remoralization is a promising supplementary outcome measure to broaden the 
scope of research on the beneficial effects of psychotherapy. In addition to symptom 
reduction, that is, remoralization can be expected to occur as a result of successful 
psychotherapy. Remoralization describes a valuable positive change that is independent 
of a specific therapeutic tradition. When patients remoralize, they regain hope and 
perspective; they learn to trust that a solution to their problems will become available. 
The state of demoralization — which is a state of isolation and despair (Frank, 1974) — 
decreases during remoralization.  
Frank stated that people who enter into psychotherapeutic treatment not only 
suffer from a specific mental disorder (i.e., experience symptomatic burden) but 
typically feel demoralized as well. Frank thus assumed that effective treatment should 
realize both: remoralization and symptom reduction. In assuming this, Frank indirectly 
suggested that remoralization and symptom reduction may constitute separate processes 
during the course of treatment. In the renowned phase model of psychotherapy outcome 
(phase model; Howard, Lueger, Malin, & Martinovich, 1993), remoralization and 
symptom reduction are also described as two successive phases during the course of 
psychotherapeutic treatment. 
Remoralization can theoretically be seen to make a valuable contribution to 
outcome research by broadening the perspective with respect to the effectiveness of 
psychotherapy, but the actual surplus value of remoralization remains unclear due to a 
lack of research on remoralization within the context of outcome research. Whether or 
not remoralization can be adequately measured, and whether or not measures of 
remoralization are sufficiently sensitive to changes as a result of psychotherapy, has 
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been unclear. Further, whether or not the measurement of remoralization can increase 
our understanding of the beneficial effects of psychotherapies has been unclear. Can 
new insights into the effects of psychotherapy be gained with the measurement of 
remoralization? Is the information provided by the measurement of remoralization 
supplementary, contradictory, or redundant to that provided by the measurement of 
symptom reduction? It is possible, for example, that the measurement of remoralization 
fails to provide greater insight into our current understanding of the effects of 
psychotherapy when measured in terms of symptom reduction, because it cannot be 
measured adequately or it cannot sufficiently de differentiated from symptom levels. 
The main question in the present dissertation was therefore as follows: Is remoralization 
a valuable outcome measure supplementary to the measurement of symptom reduction 
in psychotherapy outcome research?  
In this closing chapter, a summary of the findings of the empirical studies will 
first be presented. Thereafter, conclusions, and general limitations and considerations 
with regard to the results of these studies will be discussed. Finally, the implications of 
the findings will be discussed in relation to the background for this dissertation.   
 
 
The empirical studies: Chapters 2, 3, 4 and 5 
Chapter 2 
The search for an appropriate measurement instrument to assess remoralization of 
mental health care patients was critical as a suitable instrument was not available at the 
start of this research. Therefore, the Remoralization Scale (RS) was developed and 
tested for adequate psychometric properties in the five studies reported on in Chapter 2. 
In the first study, six instruments that measured concepts associated according to the 
literature with remoralization were selected: self-esteem, personal empowerment, 
feelings of competence, optimism, sense of inner control, and hope. A pool of 69 items 
was derived from these instruments. The items were completed by 299 outpatients. 
Exploratory factor analyses were conducted, and the pool of items was reduced to 16 
items constituting an initial scale with a unidimensional factor structure. 
In the second study, the unidimensionality and scalar invariance of the RS was 
tested in a sample of 199 outpatients and 192 non-patients. It was argued that the RS 
should measure the same construct in the same way for both patients and non-patients. 
A multi-group confirmatory factor analysis was conducted. To make the RS as short 
and easy to complete as possible, 4 items with low factor loadings were removed. The 
definitive version of the RS with a total of 12 items was the result. Factor analysis 
further confirmed the unidimensionality and scalar invariance of the final RS and 
showed the patients and non-patients to understand the items of the RS in a similar 
manner. The RS thus measured the same concept for patients and non-patients.  
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In the third study, the test-retest reliability and internal consistency of the RS 
were tested using a sample of 124 students. The test-retest reliability of the RS across a 
period of one week was found to be good (r = .89). The internal consistency of the RS 
was also found to be good (α = .87). The Cronbach’s alphas for the patient sample (α = 
.91) in Study 2 and the non-patient sample (α = .91) in Study 2 were comparable to that 
for the student sample. The internal consistency of the RS was thus judged to be high 
and similar across different samples. Furthermore, the removal of the four items, as 
described in Study 2, had only a negligible effect upon the internal consistency of the 
RS as the Cronbach’s alpha for the initial 16-item version of the RS was .92.  
In the fourth study, the validity of the RS was determined. First, the RS was 
shown to differentiate between patients and non-patients (see Study 2) as non-patients 
were found to be significantly and considerably more remoralized than patients (Effect 
Sizes [ES] = 1.87). The construct validity of the RS was next investigated by examining 
the correlations of the RS scores with scores on other relevant measures for mental 
health care patients. The RS scores showed high negative correlations with 
Demoralization Scale scores (r = .72; Kissane, Wein, Love, Lee, Kee, & Clarke, 2004) 
and high negative correlations with symptoms of anxiety (r = .52) and level of 
depression (r = .50) measured using the General Health Questionnaire (Goldberg, 
1972). Moderate negative correlations were also found for the RS scores with somatic 
symptoms (r = .36) and social dysfunction (r = .37) also measured by the General 
Health Questionnaire. It could thus be concluded that the RS shows satisfactory 
construct validity.  
In the fifth and final study reported on in Chapter 2, the sensitivity of the RS to 
therapeutic change was examined in a population of 24 patients suffering from panic 
disorder with agoraphobia (PDA). The patients were given an empirically supported 
treatment for their symptoms (either cognitive behavior therapy or a drug treatment 
using a selective serotonin reuptake inhibitor). The patients were followed across a 
periods of six months and significantly improved with respect to not only panic 
symptoms (ES = 1.21) as measured by the Mobility Inventory Avoidance when Alone 
(Chambless, Caputo, Jasin, Gracely, & Williams, 1985) but also remoralization (ES = 
1.51) as measured by the RS. The RS was thus shown to be sensitive to therapeutic 
change.  
In sum, the results of five empirical studies showed the self-report RS to have 
high internal consistency, excellent test-retest reliability, good construct validity, good 
discriminative validity, and clear sensitivity to therapeutic change. With only 12 items 
and a unidimensional factor structure, the RS is brief and easy to administer and 
interpret. 
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Chapter 3 
In the study reported on in Chapter 3, the question of whether the measurement of 
remoralization provides added value was taken a step further. In the literature, 
remoralization and symptom reduction are typically described as two distinguishable 
processes by de Figueiredo (2007), Frank (1974), and Howard et al. (1993). However, 
the relationship (i.e., correlation) between remoralization and symptom reduction were 
not directly investigated by the aforementioned authors.  
Various studies have been conducted to test the basic assumptions underlying 
the phase model of Howard et al. (Barkham, Rees, Stiles, Shapiro, Hardy, & Reynolds, 
1996; Callahan, Swift, & Hynan, 2006; Hilsenroth, Ackerman, & Blagys, 2001; 
Holloway, 2004; Joyce, Ogrodniczuk, Piper, & McCallum, 2002; Kopta, Howard, 
Lowry, & Beutler, 1994; Lutz, Lowry, Kopta, Einstein, & Howard, 2001; Martinovich, 
1998). But unequivocal evidence to confirm the occurrence of the two phases has yet to 
be provided. Remoralization has yet to be clearly distinguished from symptom 
reduction. However, the ambiguity of these earlier findings may stem from 
methodological shortcomings of the studies: the use of unspecified patient samples, 
unspecified treatments or treatments aimed at a variety of problems and syndromes, and 
general symptom checklists that are thus not suited to separate remoralization from 
symptom reduction. It is thus unclear whether remoralization and symptom reduction 
overlap considerably or are, indeed, two distinct but nevertheless, maybe somewhat 
related, measures of psychotherapy outcome.  
In a preliminary study, 24 outpatients with PDA were given an indicated, 
manual-based empirically supported treatment. The sample was the same as in the fifth 
study reported on in Chapter 2. Changes in specific symptoms of agoraphobic 
avoidance (Mobility Inventory Avoidance when Alone; Chambless et al., 1985) and 
agoraphobic cognitions (Agoraphobic Cognitions Questionnaire; Chambless, Caputo, 
Bright, & Gallager, 1984), and remoralization (RS) were measured every four weeks 
from pre- to post-assessment across a period of 28 weeks in addition to changes in 
health-related Quality of Life (QoL) measured using the RAND-36 (van der Zee & 
Sanderman, 1994) at pre- and post-assessment.  
As expected, the empirically supported treatment proved effective for symptom 
reduction (agoraphobic avoidance ES = 1.21; agoraphobic cognitions ES = 1.19); the 
change patterns were linear. The empirically supported treatment also proved effective 
for remoralization with also a linear pattern of change. The patients consistently were 
more remoralized in a subsequent interval than in the interval before for every four-
week interval (ES = 1.45). Remoralization was thus sensitive to treatment change when 
administered on several occasions during the course of treatment. The slopes for 
agoraphobic avoidance, agoraphobic cognitions, and remoralization correlated highly in 
the latent growth model analyses (r = .50 to .55), which show similar patterns of 
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change over time. Despite the use of a homogeneous group of patients suffering from a 
particular syndrome and the use of a specific treatment aimed at the alleviation of the 
symptoms of that particular disorder, the course of remoralization showed a similar 
pattern of change as the course of symptom reduction. The symptoms of patients with 
PDA thus change in a similar manner and at a similar pace as their remoralization and 
vice versa when given an empirically supported form of treatment. 
To determine if the measurement of remoralization possibly had some unique 
value that went unaddressed by the measures of symptom reduction, the correlations of 
the remoralization scores for the 24 outpatients with their health-related QoL scores 
were calculated. The slope for remoralization correlated with positive changes on a 
number of aspects of health-related quality of life, namely general health perception, 
mental health, bodily pain, and role limitations due to emotional problems; the slope of 
symptom reduction did not. In other words, when patients experience remoralization 
during the course of treatment, they are also more likely to report better overall feelings 
of health, fewer limitations in the domains of both work and daily life activities, less 
bodily pain, and a better general health status. Remoralization showed a high correlation 
with symptom reduction but a unique relationship to many aspects of an improved 
health-related QoL.  
Using a specific patient sample, a well-indicated empirically supported 
treatment, and specific measures of remoralization and symptom reduction to increase 
the a priori chances of finding different patterns of change for remoralization versus 
symptom reduction, significantly different patterns of change, nevertheless, could not be 
detected. This finding is in line with the results of previous studies that tested the phase 
model (Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; Howard et al., 
1993; Joyce et al., 2002; Kopta et al., 1994; Lutz et al., 2001; Martinovich, 1998). 
Hence, it is possible to assume that the offered treatments simultaneously prompt both 
remoralization and symptom reduction. To help unravel the relations between 
remoralization and symptom reduction, an experimental study in which the effects of a 
treatment focused solely on remoralization and a treatment focused solely on the 
symptoms of a specific disorder are compared was next deemed necessary. 
Chapter 4 
In Chapter 4, the effects of a treatment focused solely on remoralization versus a 
treatment focused solely on the symptoms of a specific disorder were compared. 
Separate forms of treatment and the accompanying experimental research design were 
adopted in order to maximize the chances of being able to distinguish remoralization 
and symptom reduction. If remoralization and symptom reduction can be distinguished, 
as Frank (1973) and Howard et al. suggest in the phase model (1993), then treatment 
aimed specifically at remoralization should not lead to clear symptom reduction and, 
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conversely, treatment aimed specifically at symptom reduction should not lead to clear 
remoralization. 
A total of 78 patients suffering from PDA were randomly assigned to a 4-week 
remoralization treatment (RT) with a strict focus on remoralization, a 4-week exposure 
treatment (ET) with a strict focus on symptoms, or a 4-week waiting list (WL). With the 
use of brief and strictly manualized treatments, a research design that resembles the 
design of laboratory experiments was thus attained for a naturalistic setting and thereby 
the methodological sophistication of a laboratory experiment combined with the 
ecological validity of the real treatment of real patients. Assessment at pre- and post-
treatment (i.e., assessment after the fourth session) were undertaken. Remoralization 
was measured using both the Subjective Well-being Scale (SWS; Howard et al., 1993) 
and the RS; symptoms of PDA were measured using the Panic-Agoraphobia Scale 
(Bandalow, 1995). Significant improvement was found for the intended effects of the 
treatments compared to WL: RT produced significant remoralization (ES = 0.70 – 0.74) 
and ET produced significant symptom reduction (ES = 0.72). In addition, however, 
unintended effects of the specific treatment conditions were found when compared to 
WL as well: RT also produced significant symptom reduction (ES = 0.55) and ET 
produced significant remoralization as well (ES = 0.47 – 0.76).  
In a highly controlled, experimental study using two — very different — brief 
treatments with 100 % treatment integrity, we were still unable to unravel the relations 
between remoralization and symptom reduction. It is thus unlikely, for at least patients 
suffering from PDA, that remoralization and symptom reduction can be distinguished 
empirically. This difficulty may explain why earlier studies that tested the phase model 
have not been able to confirm the assumptions underlying the phase model. 
Chapter 5 
In the phase model (Howard et al., 1993), psychotherapy is expected to progress in a 
stepwise manner with each phase of psychotherapy depending upon a previous phase 
and each phase thus constituting a different domain of psychotherapeutic change. The 
first phase in the model draws upon the demoralization theory of Frank and Frank 
(1991) and is referred to as the remoralization phase. The second phase addresses the 
symptoms of the patient and is referred to as the remediation phase. In the phase model, 
a customary sequence is assumed, namely: remoralization followed by symptom 
reduction. In addition, significant improvement during one phase is assumed to be a 
necessary condition for significant improvement in the next phase. That is, without 
improvement during one phase, significant improvement during the next phase cannot 
be expected. While several studies have examined the assumptions underlying the phase 
model, none have addressed the question whether a treatment designed in line with the 
phase model is more effective than a treatment that deviates form the phase model.  
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In Chapter 5, a study undertaken to answer this question is reported. The patients 
from the study described in Chapter 4 were followed further using the same measures 
administered at post-assessment. After the fourth session, the patients in the two 
treatment conditions (i.e., RT and ET) were now given the opposite treatment. In such a 
manner, two treatment conditions of eight sessions each were obtained: either four 
sessions of RT followed by four sessions of ET (RT-ET) or four sessions of ET 
followed by four sessions of RT (ET-RT). The patients in WL were also followed for an 
additional four weeks. The three research conditions, RT-ET, ET-RT and WL, were 
compared with respect to change on remoralization and symptom reduction (pre- and 
post-treatment which was after session 8). We expected to reveal better outcomes for 
treatment in line with the sequence proposed by the phase model. That is, RT-ET was 
expected to produce better treatment outcomes than ET-RT because RT-ET is in line 
with the sequence of change proposed by the phase model. Patients should first receive 
treatment aimed at remoralization as this provides hope and perspective, which are 
needed for treatment aimed at the specific symptoms of a disorder (i.e., symptoms of 
PDA in the present case). ET-RT was expected to be less efficacious because, in the 
phase model, addressing symptoms immediately does not leave room for attention on 
remoralization, which is assumed to be needed for effective treatment to start with. 
A total of 72 patients with PDA completed the study described in Chapter 5. 
Compared to WL, significant improvement on remoralization was found for both RT-
ET (ES = 0.52 – 0.88) and ET-RT (ES = 0.43 – 0.61). Compared to WL, significant 
symptom reduction was similarly found for both RT-ET (ES = 0.65) and for ET-RT (ES 
= 0.87). Proof for RT-ET being more effective than ET-RT could not be found, thus, for 
either measure of remoralization or symptom reduction. Treatment that immediately 
addressed the patient’s symptoms and then addressed remoralization was just as 
effective as treatment that first devoted attention to the patient’s state of hopelessness 
and thereby provided hope and perspective prior to addressing the patient’s specific 
symptoms. In the present study, treatment that was designed in line with the phase 
model was not found to be more effective than treatment that deviated from the phase 
model. 
 
 
Summary of the main findings of the empirical studies 
 
1. Remoralization is appropriately measured by the newly developed RS. This 12-
item self-rating instrument is psychometrically sound, easy to administer, and 
easy to interpret when used in psychotherapy outcome research with mental 
health care patients.  
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2. Remoralization is sensitive to therapeutic change in patients suffering from 
PDA. This is the case for all studied treatments (panic control treatment, medi-
cation treatment using SSRI, RT, ET, RT-ET, and RT-ET).  
3. Remoralization and symptom reduction follow the same change pattern over 
time.  
4. Remoralization is associated with beneficial changes in health related QoL while 
symptom reduction is not. 
5. Treatment effects for remoralization and symptom reduction cannot be dis-
tinguished from each other: Treatment strictly focused on only one of the mea-
sures (i.e., either remoralization or symptom reduction) proved effective for both 
measures.  
6. A treatment programmed in line with the phase model of Howard et al. (1993) is 
no more effective than a treatment that deviates from the phase model. Both 
treatments effectively produce both remoralization and symptom reduction.  
 
 
General limitations and considerations 
 
In this section, general limitations and considerations with regard to the reported studies 
are presented. The information provided is in addition to the discussions in each of the 
previous chapters and thus of a more general nature.  
In all of the treatment studies (Chapter 2: study 5, Chapters 3, 4, and 5), the 
patient samples were rather small. Replication with larger sample sizes is therefore 
required. The experimental study in Chapter 5, in which the effects of two treatments 
(i.e. RT-ET and ET-RT) — that turned out to be both effective — were directly 
compared, certainly requires replication with a larger sample because proof of non-
existence of different effects between two effective treatments requires a larger sample 
than we had. However, we have no indication that a larger patient sample would yield 
completely different results; there is strong evidence, that the implication of the phase 
model, that a treatment needs first to be focused on a patients’ remoralization, does not 
hold. 
For the development of the RS, different patient samples were used. In the 
treatment studies, however, only patients with PDA were included. The present findings 
therefore cannot, strictly speaking, be generalized to other groups of patients. The 
reason for concentrating on this specific group of patients in the treatment studies was 
methodological. In previous studies that tested the phase model (Callahan et al., 2006; 
Hilsenroth et al., 2001; Holloway, 2004; Howard et al., 1993; Joyce et al., 2002; Kopta 
et al., 1994; Lutz et al., 2001; Martinovich, 1998), general symptom checklists were 
administered to measure the level of symptoms. These instruments are known to 
measure mostly general distress while distress is considered an important part of the 
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state of being demoralized (de Figueiredo & Frank, 1982). General symptom checklists 
are thus not suited to distinguish remoralization from symptom reduction. It was 
therefore decided in our project to include a patient group that has been not only well-
researched and well-described in the literature but also has well-documented and 
suitable measurement instruments available to assess its specific symptoms. This was 
the case for patients with PDA. This group was also attractive because a specific, 
empirically supported treatment was available for patients with PDA as well. According 
to the literature, the group of patients with PDA is, moreover, one of best responding to 
psychological treatments (Oei, Llamas, & Devilly, 1999; van Balkom, et al., 1997). We 
have no particular reason to believe that the present results would not hold for other 
patient groups — that is, patient groups that are known to respond well to empirically 
supported treatment and for which specific symptom measurement instruments are 
available. Future studies should, of course, nevertheless be conducted to document this. 
However, it is not inconceivable that different change patterns for remoralization 
and symptom reduction can be detected for highly different groups of patients. For 
patient populations with such chronic conditions as schizophrenia or somatization 
disorder, different change patterns can perhaps be expected because symptom reduction 
is much less likely to occur than remoralization in such cases (Shrivastava, Johnston, 
M., Shah, & Bureau, 2010; Strauss, 1994). Further study of remoralization in chronic 
patient samples is thus necessary to attain a full understanding of remoralization.  
One might raise objections to the fact that the sample reported on in Study 5 of 
Chapter 2, was the same sample as in Chapter 3. We belief, however, that this causes no 
problems since the aim of the studies was very different and in Study 5 of Chapter 2 
only pre and post assessments were used. In addition to the other studies of Chapter 2 
on the development, reliability and validity of the RS, the goal of this study was only to 
globally determine the RS' sensitivity to change. In Chapter 3, on the other hand, all 
eight measure points were used to compare patterns of change across various points in 
time between remoralization and symptom reduction.  
Given that the purpose of the studies in Chapters 4 and 5 was to elaborate upon 
the phase model, the SWS of Howard et al. was also included as a measure of 
remoralization. In fact, the SWS was used as the primary measure of remoralization and 
the RS as a secondary measure due to missing RS data. The results of both studies 
showed the SWS and RS scores to be comparable. For the research questions posed in 
Chapters 4 and 5 the detected small differences were not of interest. In retrospect, 
however, these findings raise the question of whether the SWS and the RS are equally 
well-suited to study the course of remoralization during psychotherapy. We could not 
know a priori that the SWS would turn out to be quite appropriate in these studies. 
Knowing what we do now, however, we still consider the RS a better alternative for the 
measurement of remoralization than the SWS. First, the RS has been clearly tested and 
documented in the five studies presented in Chapter 2 using several samples that include 
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a wide variety of mental health care patients and also non-patients. Second, the RS is 
large enough to have good reliability and validity but small enough to be easily 
administered on repeated occasions for purposes of outcome research. The SWS, in 
contrast, is very brief with only three items in the version used here; this means that the 
reliability and content validity of the scale can easily drop below acceptable values, 
which is not the case for the RS. Third, various versions of the SWS have been used. 
This means that an agreed-upon version of the SWS does not exist, and it is not clear 
which version should be preferred (i.e., the two-item version of Howard et al., 1993; the 
three-item version of Grissom, Lyons, & Lutz, 2002; the four-item version of Callahan 
et al., 2006). Fourth, according to de Figueiredo and Frank (1982), demoralization 
involves two dimensions: subjective incompetence and distress. However, all three 
versions of the SWS lack items to assess subjective incompetence, which means that the 
SWS does not encompass Frank’s broader definition of demoralization. The RS, in 
contrast, does. 
In the experimental studies presented in Chapters 4 and 5, we followed patients 
undergoing treatment across a relatively short period of time (i.e., four and eight 
sessions). On the basis of the phase model, it was expected that remoralization and 
symptom reduction would be distinguishable within this period of time (i.e., in response 
to the first few sessions of treatment). It is, nevertheless, theoretically possible that 
remoralization and symptom reduction only become distinguishable later on in 
treatment. The results of the naturalistic study presented in Chapter 3, on the other hand, 
show this to be unlikely as the change patterns for remoralization and symptom 
reduction correlated highly across the longer period of 28 weeks as well. It is not likely 
that we have missed the opportunity to clearly separate remoralization from symptom 
reduction due to the short treatments in our experimental studies. 
 
 
Implications of the findings 
 
In discussing the implications of the results of the research reported here for the phase 
model and the main research question of this dissertation, the limitations and 
considerations pointed out above should be taken into account. The implications for the 
phase model of Howard and colleagues (1993) will first be discussed. Thereafter, the 
implications for the main research question will be discussed.  
The phase model was judged to be attractive and theoretically valuable for 
clinicians given its simplicity, transparency, and detailed description of the phases of 
psychotherapy change. Clinicians report recognition of the phases of change for all 
kinds of patients from clinical practice (Joyce et al., 2002). As described in Chapters 4 
and 5, however, empirical tests of the phase model in the past (Barkham et al., 1996; 
Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; Howard et al., 1993; 
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Joyce et al., 2002; Kopta et al., 1994; Lutz et al., 2001; Martinovich, 1998) suffer from 
a number of methodological drawbacks, and the results are ambiguous at best, and 
thereby hinder confirmation or disconfirmation of the basic assumptions underlying the 
phase model. According to the phase model, the first phase of change is remoralization 
and the second phase is symptom reduction. In the studies described in Chapters 3 and 
4, however, remoralization could not be distinguished from symptom reduction. Instead, 
both co-occur. This co-occurrence of remoralization and symptom reduction may 
additionally explain the absence of confirmation for the assumptions underlying the 
phase model by the previous studies. That is, it is not possible to show that change in 
the first phase of treatment precedes change in the second phase or that change in the 
first phase is necessary for change in the second phase to occur as the effects for 
remoralization (i.e., phase one) and symptom reduction (i.e., phase two) are 
indistinguishable. In combination with the fact that we could not find evidence in 
Chapter 5 that a treatment sequence that was in line with the phase model (i.e., RT 
followed by ET) was more effective than a treatment sequence that deviated from the 
model (i.e., ET followed by RT), these findings seriously question the appropriateness 
of the outline of psychotherapeutic change that is provided by the phase model.  
The main research question in this dissertation was: Is remoralization a valuable 
outcome measure supplementary to the measurement of symptom reduction in 
psychotherapy outcome research? There are several answers to offer. We start with 
several practical issues and then, finally, theoretically address the relation between 
symptom reduction and remoralization.  
The research of this dissertation resulted in a proper and useful instrument to 
measure remoralization. As expected, remoralization was found to be a concept that is 
sensitive to psychological changes and suitable for repeated assessment during the 
course of treatment. The present research has thus contributed to our knowledge of 
remoralization as it has shown the measurement of remoralization to be clearly possible 
and bona fide treatments to produce satisfactory increases in remoralization compared 
to a waiting list. This is in line with expectations derived from the theory of Jerome 
Frank in which it is stated that remoralization is a crucial aspect of effective treatment 
(see, for instance, Frank & Frank, 1991). The inclusion of remoralization as an outcome 
measure in psychotherapy outcome research thus appears to be valuable and 
meaningful.  
The inclusion of remoralization is also likely to broaden the perspective on 
outcome measures in psychotherapy research and, by doing so, it might contribute to the 
improvement of the overall acceptance of research outcome as the criticism that the 
research only reflects the amount of symptom reduction will no longer hold. Positive 
consequences for the implementation of research findings into actual clinical practice 
may also be a result. In light of the broader perspective taken on treatment outcome, 
therapists may feel that their practices are better reflected in research results.  
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From the perspective of patients, the addition of remoralization to psychotherapy 
outcome measurement may also provide a more complete picture as only a small 
minority of patients mentioned symptom reduction as the only or most important goal of 
treatment (Grosse Holtforth & Grawe, 2002). For those patients groups that are known 
to be difficult to cure from the perspective of symptom reduction and thus designated as 
untreatable in the current research paradigm, the measurement of remoralization may 
result in the idea that these patients groups are treatable.  
 Now that we know that the measurement of remoralization is perfectly possible 
and that bona fide treatments can increase remoralization, we can now consider the 
relation between remoralization and symptom reduction. The present results show the 
two measures to be difficult to distinguish. Scores on the measures co-occurred and co-
varied in the present studies. This co-variance could be caused by the (methodological) 
decisions we have made such as the patient samples we studied or the duration of the 
treatments (see Limitations and considerations), but in the series of studies conducted 
here, we were not able to unravel the two. Akin to lightning and thunder, which co-
occur but are clearly different phenomena, remoralization and symptom reduction might 
then co-occur but are distinct psychological processes with very different content and 
significance. The only result that points in the direction of a distinction between 
remoralization and symptom reduction in the present research is that described in 
Chapter 3 where remoralization and symptom reduction clearly overlapped but only 
remoralization related to health-related QoL. The general functioning of the patient at 
work or during daily activities and experienced mental health correlated with 
remoralization but not with symptom reduction.  
Overall and until replication possibly proves otherwise, it is most 
straightforward to conclude that remoralization and symptom reduction cannot be 
distinguished from each other in psychotherapy outcome research. Remoralization does 
not appear to occur without symptom reduction and, conversely, symptom reduction 
does not take place without remoralization. A new perspective and regained hope 
appear to ease the negative impact of the symptoms of a mental disorder to at least a 
certain extent; conversely, reduced fear, less avoidance, and fewer panic attacks foster a 
more realistic perspective on the part of a patient and thereby hope. 
 Given that remoralization and symptom reduction have proved indistinguishable 
during the course of treatment in the studies of this dissertation, the question that should 
now be asked is what the value of remoralization measurement is, supplementary to 
symptom reduction measurement. Apparently, when symptom reduction is assessed in 
outcome research, change on remoralization can be predicted, as well. This suggests 
that remoralization need not be assessed in addition to symptom reduction. On the other 
hand, this line of reasoning permits the alternative conclusion as well: the measurement 
of remoralization makes the measurement of symptom reduction redundant. That is, the 
demonstration of remoralization is sufficient to indicate the effectiveness of a treatment 
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as symptom reduction measurement adds nothing to remoralization measurement — at 
least for a group of patients with PDA.  
The question can next be raised whether we would have been able to really 
measure a distinction between remoralization and symptom reduction on the basis of 
our measurements. In all of the studies reported on here, self-report instruments were 
used to measure both remoralization and symptom reduction. Patients rate their own 
level of remoralization and their own level of symptoms on the basis of their subjective 
perceptions. For the measurement of remoralization, there is no doubt that this method 
is most suitable. Remoralization is all about the person’s subjective perceptions, sense 
of self-worth, and perceived ability to meet goals. However, for the measurement of 
symptoms, the suitability of self-report instruments is open to debate. Actually, one can 
wonder whether patients are capable of carefully estimating the extent to which they 
suffer from a range of symptoms typical of a disorder. Further investigation of the 
relationship between remoralization and symptom reduction using alternative forms of 
symptom measurement, such as observer ratings, behavioral approach tests, or so-called 
implicit measures of symptoms, might very well show self-reports of symptomatology 
— which is by far the most frequently used measurement method in psychotherapy 
outcome research today — to produce less straightforward and clearly interpretable 
research results than is often assumed.  
Elaborating on the above, it is the question whether it really makes sense to try 
to distinguish between actual (i.e. identifiable, and countable) symptoms and the 
experience of being bothered and hampered by having symptoms, as being two separate 
notions. Such a distinction between factual symptoms and the experience of symptoms 
is in line with the medical model adopted in the current psychotherapy outcome 
research paradigm. Whether or not this distinction holds or is helpful for most mental 
disorders is very much the question. For a mental disorder such as a panic disorder, the 
assumption that actual symptoms can be separated from experienced constraints seems 
rather artificial. In stead, it seems obvious that many psychological problems are about 
recurrent unwanted feelings and thoughts, and that symptoms of the disorder are exactly 
what the patient experiences. Perhaps we were unable to distinguish remoralization 
from symptom reduction in this dissertation, precisely because, just as symptoms, 
remoralization is what the patient experiences.  
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Het meten van remoralisatie: een verbreding van hedendaags onderzoek naar de 
effecten van psychotherapie  
 
Achtergrond 
 
Het hedendaags onderzoek naar de effecten van psychotherapie bij patiënten in de 
geestelijke gezondheidszorg (GGZ) schiet tekort. De huidige onderzoeksgeneratie stelt 
zich voornamelijk de vraag in hoeverre een specifieke behandeling effectief is ten 
aanzien van het verminderen van symptomen die kenmerkend zijn voor de behandelde 
stoornis. Natuurlijk is symptoomreductie van groot belang, maar zoals in hoofdstuk 1 
van dit proefschrift is beargumenteerd, lijkt een effectieve behandeling meer te 
bewerkstelligen dan symptoomreductie alleen. In hedendaags effectonderzoek worden 
echter nauwelijks andere positieve behandeleffecten onderzocht. In hoeverre patiënten 
als gevolg van psychotherapie verbeteringen ervaren in hun subjectief welbevinden, in 
de kwaliteit van hun sociale relaties, in hun gevoel van controle of hoop, is zelden of 
nooit onderwerp van onderzoek. De eenzijdige focus op symptoomreductie is zo 
ingeburgerd in het bestaande effectonderzoek, dat een behandeling vaak wordt 
aangeduid als effectief, zonder vermelding dat ‘effectief’ hier feitelijk betekent 
‘effectief met betrekking tot symptoomreductie’.  
 Als reactie op deze eenzijdige focus op symptoomreductie pleit een toenemend 
aantal auteurs voor een verbreding van de meting van psychotherapie-effecten. 
‘Remoralisatie’ lijkt een veelbelovende, complementaire uitkomstmaat om 
effectenmetingen van psychotherapie te verbreden. Naar verwachting zal een goede 
therapie naast symptoomreductie ook leiden tot remoralisatie. Remoralisatie houdt in: 
het herwinnen van hoop en perspectief en het hervinden van vertrouwen in de 
oplosbaarheid van de ervaren problemen. Remoralisatie als positieve uitkomst wordt 
bovendien erkend in verschillende psychotherapeutische tradities. 
 Remoralisatie is afgeleid van het begrip demoralisatie. Jerome Frank stelde in 
1974 dat mensen die psychotherapeutische hulp zoeken niet alleen lijden aan een 
specifiek psychisch probleem (symptomatisch lijden), maar zich meestal ook 
gedemoraliseerd voelen. Demoralisatie beschreef hij als een toestand van isolatie en 
wanhoop. Het proces waarin deze toestand van demoralisatie wordt opgeheven wordt 
remoralisatie genoemd. Frank veronderstelde dat een effectieve behandeling zowel 
remoralisatie als symptoomreductie zou moeten bewerkstelligen. Frank ging er dus 
impliciet van uit dat remoralisatie en symptoomreductie twee verschillende processen 
zijn, die los van elkaar kunnen optreden gedurende de behandeling. Ook Howard en 
collega’s beschreven in het bekende phase model of psychotherapy outcome (kortweg 
‘fasemodel’; Howard, Lueger, Malin, & Martonovich, 1993) remoralisatie en 
symptoomreductie als twee opeenvolgende, dus verschillende, fases van psycho-
therapeutische behandeling. 
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 Vanuit een theoretisch perspectief zal de toevoeging van remoralisatiemeting 
een waardevolle bijdrage leveren aan kennis over effecten van psychotherapie. Daarmee 
wordt immers de beoordeling van de effectiviteit van psychotherapie verbreed. Maar de 
feitelijke meerwaarde van remoralisatie als uitkomstmaat blijft onduidelijk zolang 
effectonderzoek naar remoralisatie ontbreekt. Onduidelijk is nog in hoeverre 
remoralisatie adequaat kan worden gemeten en of metingen hiervan voldoende gevoelig 
zijn om veranderingen ten gevolge van psychotherapie vast te stellen. We weten niet in 
welke mate het zinnig is om remoralisatie te meten. Zo is het mogelijk dat het meten 
van remoralisatie geen toegevoegde waarde heeft naast het meten van 
symptoomreductie. Ook weten we niet of met het meten van remoralisatie nieuwe 
inzichten in de effecten van psychotherapie worden verkregen.  
De centrale vraag in het onderhavige proefschrift is daarom als volgt: Is 
remoralisatie in het onderzoek naar de effecten van psychotherapie een waardevolle 
aanvullende uitkomstmaat naast het meten van symptoomreductie? 
 Hieronder volgt een samenvatting van de studies die zijn beschreven in de vier 
empirische hoofdstukken van dit proefschrift. Daarna worden de conclusies, de 
algemene beperkingen en overwegingen met betrekking tot de resultaten van deze 
studies besproken. Ten slotte zal een aantal implicaties van de bevindingen worden 
geschetst.  
 
 
De empirische studies: hoofdstuk 2, 3, 4 en 5 
Hoofdstuk 2 
In de literatuur werd geen geschikt instrument aangetroffen voor het meten van 
remoralisatie. Daarom was het noodzakelijk om een meetinstrument te ontwikkelen ter 
bepaling van remoralisatie bij patiënten uit de GGZ. Op basis van deze constatering 
werd vervolgens de Remoralisatieschaal (RS) ontwikkeld en getest op adequate 
psychometrische eigenschappen. In hoofdstuk 2 werd dit in vijf studies beschreven. In 
de eerste werden zes instrumenten geselecteerd die concepten meten die volgens de 
literatuur geassocieerd zijn met remoralisatie: zelf-waardering, persoonlijke 
empowerment, gevoelens van competentie, optimisme, besef van innerlijke controle en 
ten slotte hoop. Deze zes instrumenten werden samengevoegd in een enquête bestaande 
uit 69 items. In totaal hebben 299 ambulante patiënten de enquête volledig ingevuld. 
Exploratieve factoranalyses werden uitgevoerd en het aantal items werd gereduceerd tot 
16. Deze 16 items vormden samen de initiële RS, die bestaat uit een unidimensionale 
factorstructuur.  
In de tweede studie werden de unidimensionaliteit en de schaalinvariantie van de 
RS getest in een steekproef met 199 ambulante patiënten en 192 zogenaamde ‘niet-
patiënten’ (een willekeurige steekproef uit de Nederlandse populatie). De 
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veronderstelling daarbij was dat de RS bij zowel patiënten als niet-patiënten, hetzelfde 
construct op dezelfde wijze zou moeten meten. Op de data werd vervolgens een multi-
groep confirmatorische factoranalyse uitgevoerd. Om de RS zo kort mogelijk te houden 
en ervoor te zorgen dat deze zo gemakkelijk mogelijk in te vullen was, werden vier 
items met lagere factorladingen verwijderd. Dit resulteerde in een lijst van 12 items: de 
definitieve RS. Een factoranalyse leverde verder bewijs voor zowel de 
unidimensionaliteit als de schaalinvariantie van de definitieve RS en toonde aan dat 
zowel patiënten als niet-patiënten de items van de RS op dezelfde wijze begrepen. De 
RS bleek dus bij patiënten en niet-patiënten hetzelfde concept te meten.  
 In de derde studie werd de test-hertestbetrouwbaarheid en interne consistentie 
van de RS getest in een steekproef met 124 studenten. De test-hertestbetrouwbaarheid 
over een periode van een week bleek goed (r = .89). De interne consistentie van de RS 
bleek eveneens goed (α = .87). Deze Cronbach’s alfa was vergelijkbaar met die van de 
patiëntensteekproef (α = .91) en de niet-patiëntensteekproef (α = .91) uit de tweede 
studie. De interne consistentie van de RS is dus hoog en vergelijkbaar in verschillende 
steekproeven. Voorts heeft het verwijderen van de vier items, zoals beschreven in de 
tweede studie, slechts een verwaarloosbaar effect gehad op de interne consistentie van 
de RS (de Cronbach’s alfa, voor de initiële 16-item versie was .92). 
 In de vierde studie stond de validiteit van de RS centraal. Eerst werd aangetoond 
dat de RS differentieerde tussen patiënten en niet-patiënten (uit de tweede studie), 
aangezien niet-patiënten significant meer geremoraliseerd waren dan patiënten (effect 
size [ES] = 1.87). De constructvaliditeit van de RS werd vervolgens onderzocht door de 
correlaties van de RS met andere relevante meetinstrumenten voor patiënten uit de GGZ 
te bekijken. De scores van de RS bleken hoog en negatief samen te hangen met die van 
de Demoralization Scale (r = .72; Kissane, Wein, Love, Lee, Kee, Clarke, 2004) 
evenals hoog en negatief met symptomen van angst (r = .52) en depressie (r = .50) 
gemeten met de General Health Questionnaire (Goldberd, 1972). De scores van de RS 
bleken daarnaast gematigd en negatief samen te hangen met somatische symptomen (r = 
.36) en sociaal disfunctioneren (r = .37), eveneens gemeten met de General Health 
Questionnaire. Op basis van deze bevindingen werd geconcludeerd dat de RS een 
toereikende constructvaliditeit bezit.  
 In de vijfde en laatste studie van hoofdstuk 2 werd de gevoeligheid voor 
therapeutische verandering van de RS onderzocht bij een populatie van 24 patiënten die 
leden aan paniekstoornis met agorafobie. De patiënten kregen een empirisch 
onderbouwde behandeling (empirically supported treatment) voor hun klachten 
(paniekmanagement of medicamenteuze behandeling met een selectieve serotonine 
heropnameremmer) en werden gedurende een periode van zes maanden gevolgd. De 
patiënten verbeterden significant wat panieksymptomen betreft (ES = 1.21) zoals 
gemeten met de Mobility Inventory Avoidance when Alone (Chambless, Caputo, Jasin, 
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Gracely, & Williams, 1985), en ook wat remoralisatie betreft (ES = 1.51) zoals geme-
ten met de RS. De RS bleek dus gevoelig voor therapeutische verandering. 
 Samenvattend laten de vijf studies van hoofdstuk 2 zien dat de RS een 
zelfrapportageinstrument is met een hoge interne consistentie, een excellente test-hertest 
betrouwbaarheid, een toereikende constructvaliditeit en een goede discriminatieve 
validiteit die duidelijk gevoelig is voor therapeutische verandering. Met slechts 12 items 
en een unidimensionale factorstructuur is de RS kort, gemakkelijk af te nemen en 
eenvoudig te interpreteren.  
 
Hoofdstuk 3 
In de studie die in hoofdstuk 3 is beschreven, werd de toegevoegde waarde van het 
meten van remoralisatie verder onderzocht. In de literatuur worden remoralisatie en 
symptoomreductie als twee te onderscheiden processen beschreven (Figueiredo, 2007; 
Frank, 1974; Howard et al., 1993), maar de relatie tussen remoralisatie en 
symptoomreductie is nooit eerder direct onderzocht.  
 In het verleden werden meerdere studies uitgevoerd om de basale aannames te 
onderzoeken die ten grondslag liggen aan het fasemodel (Barkham, Rees, Stiles, 
Shapiro, Hardy, & Reynolds, 1996; Callahan, Swift, & Hynan, 2006; Hilsenroth, 
Ackerman, & Blagys, 2001; Holloway, 2004; Joyce, Ogrodniczuk, Piper, & McCallum, 
2002; Kopta, Howard, Lowry, & Beutler, 1994; Lutz, Lowry, Kopta, Einstein, & 
Howard, 2001; Martinovich, 1998). Eenduidig bewijs voor het optreden van de twee 
fases werd echter niet eerder geleverd. Remoralisatie bleek vooralsnog niet duidelijk te 
onderscheiden van symptoomreductie. Het zou echter kunnen dat deze eerdere 
bevindingen werden veroorzaakt door methodologische tekortkomingen. Deze studies 
gebruikten namelijk ongespecificeerde patiëntensteekproeven, ongespecificeerde 
behandelingen of behandelingen die waren gericht op een grote variatie aan problemen 
en syndromen. Er werden ook algemene symptoominstrumenten gebruikt die bijgevolg 
niet geschikt waren voor het scheiden van remoralisatie en symptoomreductie. Het was 
met andere woorden onduidelijk of remoralisatie en symptoomreductie elkaar 
aanzienlijk overlapten of dat ze inderdaad twee te onderscheiden, zij het enigszins 
gerelateerde, uitkomstmaten van psychotherapie waren. 
In onze pilotstudie kregen 24 ambulante patiënten die leden aan paniekstoornis 
met agorafobie een geïndiceerde, geprotocolleerde, empirisch onderbouwde behan-
deling. Deze steekproef was dezelfde als die in de vijfde studie van hoofdstuk 2. Na de 
voormeting, werd, gedurende 28 weken, iedere vier weken de verandering van 
symptomen van agorafobische vermijding (Mobility Inventory Avoidance when Alone; 
Chambless et al., 1985), agorafobische cognities (Agoraphobic Cognitions 
Questionnaire; Chambless, Caputo, Bright, & Gallager, 1984) en van remoralisatie (RS) 
gemeten. Daarnaast werden bij de voormeting en tijdens de nameting (bij 28 weken) de 
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veranderingen gemeten in de gezondheidsgerelateerde kwaliteit van leven (RAND-36; 
van der Zee & Sanderman, 1994).  
Zoals verwacht was de empirisch onderbouwde behandeling effectief met 
betrekking tot symptoomreductie (agorafobische vermijding ES = 1.21 en agorafobische 
cognities ES = 1.19). Het patroon van verandering was lineair. Daarnaast bleek de 
empirisch onderbouwde behandeling ook effectief met betrekking tot remoralisatie (ES 
= 1.45). Ook hier was sprake van een lineair patroon: bij iedere nieuwe meting in een 
volgend tijdsinterval waren de patiënten consistent meer geremoraliseerd. Remoralisatie 
bleek dus gevoelig voor therapeutische verandering, gemeten op diverse momenten 
tijdens de behandeling. De helling (slope) voor agorafobische vermijding, voor 
agorafobische cognities en voor remoralisatie correleerden sterk in de latente 
groeimodelanalyses (r = .50 tot .55). Die uitkomst betekende dat er sprake was van 
vergelijkbare veranderingen gedurende de behandeling, op elk van deze drie 
instrumenten. Tijdens effectief bewezen behandeling veranderen de symptomen van 
patiënten lijdend aan paniekstoornis met agorafobie dus op vergelijkbare wijze en in een 
vergelijkbaar tempo als remoralisatie en visa versa. 
Om te bepalen of het meten van remoralisatie een (gedeeltelijk) unieke 
toegevoegde waarde had ten opzichte van symptoomreductie, werden remoralisatie en 
symptoomreductie gecorreleerd met de verschillende aspecten van 
gezondheidgerelateerde kwaliteit van leven. De helling van remoralisatie correleerde 
met positieve veranderingen op een aantal aspecten hiervan, namelijk algemene 
gezondheidsbeleving, psychische gezondheid, lichamelijke pijn en rolbeperking als 
gevolg van emotionele problemen. De helling van symptoomreductie correleerde met 
geen van de aspecten van gezondheidgerelateerde kwaliteit van leven. Met andere 
woorden, wanneer patiënten remoralisatie ervaren gedurende de behandeling hebben zij 
ook meer kans om een betere psychische gezondheid te ervaren, met minder 
beperkingen in het domein van werk en dagelijkse activiteiten, minder lichamelijke pijn 
en een betere algemene gezondheid.  
De conclusie van de studie die is beschreven in hoofdstuk 3 is dat remoralisatie 
correleerde met symptoomreductie en eveneens een unieke relatie had met diverse 
aspecten van gezondheidsgerelateerde kwaliteit van leven. Hoewel in de studie sterk 
was ingezet op een grote a priori kans op het vinden van verschillende patronen van 
verandering betreffende remoralisatie en symptoomreductie door het gebruik van een 
specifieke patiëntenpopulatie, een goed geïndiceerde, empirisch onderbouwde 
behandeling en specifieke meetinstrumenten voor remoralisatie en symptoomreductie, 
konden significant verschillende patronen van verandering niet gevonden worden. Deze 
bevinding komt overeen met de bevindingen van eerdere studies naar het fasemodel 
(Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; Howard et al., 1993; 
Joyce et al., 2002; Kopta et al., 1994; Lutz et al., 2001; Martinovich, 1998). Het is 
mogelijk dat de aangeboden behandelingen zowel remoralisatie als symptoomreductie 
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bewerkstelligden. Om de relatie tussen remoralisatie en symptoomreductie 
daadwerkelijk te ontrafelen is een experimentele studie vereist waarin de effecten van 
een behandeling die alleen gericht is op remoralisatie worden vergeleken met de 
effecten van een behandeling die alleen gericht is op symptoomreductie.  
 
Hoofdstuk 4 
In hoofdstuk 4 werden de effecten van een behandeling die alleen gericht is op 
remoralisatie vergeleken met die van een behandeling die alleen gericht is op de 
vermindering van symptomen van een specifieke stoornis. Twee duidelijk verschillende 
vormen van behandeling en een experimenteel onderzoeksdesign werden toegepast met 
als doel de kansen te vergroten om remoralisatie en symptoomreductie van elkaar te 
onderscheiden. Als remoralisatie en symptoomreductie van elkaar te onderscheiden zijn, 
zoals Frank (1973) en Howard en collega’s in het fasemodel (1993) suggereerden, zou 
een behandeling specifiek gericht op remoralisatie niet tot duidelijke symptoomreductie 
moeten leiden. Omgekeerd zou een behandeling specifiek gericht op symptoomreductie 
niet tot duidelijke remoralisatie moeten leiden.  
 Achtenzeventig patiënten die leden aan een paniekstoornis met agorafobie 
werden willekeurig toegewezen aan óf een vier weken durende remoralisatietherapie 
(RT) met een strikte focus op remoralisatie, óf een vier weken durende exposuretherapie 
(ET) met een strikte focus op symptoomreductie, óf aan een wachtlijst (WL) van vier 
weken. Met het gebruik van korte en strak geprotocolleerde behandelingen werd in een 
naturalistische behandelsetting een onderzoeksdesign verkregen dat overeenkomsten 
vertoonde met het design van laboratoriumexperimenten. Hiermee werd de 
methodologische hoogwaardigheid van laboratoriumexperimenten gecombineerd met de 
ecologische validiteit van een naturalistische studie met een echte behandeling voor 
echte patiënten. Metingen werden vóór en na behandeling (na de vierde sessie) verricht. 
Remoralisatie werd gemeten door gebruik te maken van zowel de Subjective Well-
being Scale (SWS; Howard et al., 1993) als de RS. Symptomen werden gemeten met de 
Panic and Agoraphobia Scale (Bandalow, 1995). Vergeleken met de WL werden 
verbeteringen gevonden ten aanzien van de beoogde effecten van de behandelingen: RT 
resulteerde in significante remoralisatie (ES = 0.70 – 0.74) en ET resulteerde in 
significante symptoomreductie (ES = 0.72). Daarnaast werden er ook verbeteringen 
gevonden in de niet-beoogde effecten van de behandelingen vergeleken met de WL: RT 
resulteerde in significante symptoomreductie (ES = 0.55) en ET resulteerde in 
significante remoralisatie (ES = 0.47 – 0.76). 
 Ondanks deze gecontroleerde, experimentele studie die gebruikmaakte van twee 
sterk verschillende, korte behandelingen met een 100 % correcte behandelintegriteit, 
waren we nog steeds niet in staat om de relatie tussen remoralisatie en 
symptoomreductie te ontrafelen. Het lijkt derhalve onwaarschijnlijk, ten minste voor 
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patiënten die lijden aan paniekstoornis met agorafobie, dat remoralisatie en 
symptoomreductie empirisch van elkaar kunnen worden onderscheiden. Dit zou kunnen 
verklaren waarom eerdere studies naar het fasemodel niet in staat waren om de 
aannames van het fasemodel te bewijzen. 
 
Hoofdstuk 5 
Volgens het fasemodel (Howard et al., 1993) verloopt psychotherapie in een stapsgewijs 
patroon. Elke fase is afhankelijk van de vorige fase en elke fase kent een ander domein 
van verandering. De eerste fase van dit model is gebaseerd op de demoralisatietheorie 
van Frank en Frank (1991) en wordt aangeduid als de remoralisatiefase. De tweede fase 
richt zich op de vermindering van symptomen en wordt aangeduid als de 
remediatiefase. In het fasemodel wordt een vaste volgorde van de fases verondersteld, 
namelijk remoralisatiefase gevolgd door remediatiefase. Daarnaast wordt verondersteld 
dat duidelijke verbetering gedurende de ene fase een noodzakelijke voorwaarde is voor 
verbetering in de volgende fase. Dit houdt in dat zonder significante verbetering in 
remoralisatie onmogelijk een significante verbetering in symptoomreductie kan 
optreden.  
Hoewel meerdere studies de aannames die ten grondslag liggen aan het 
fasemodel hebben onderzocht, heeft geen van die studies de vraag aan de orde gesteld 
of een behandeling die ontworpen is overeenkomstig de veronderstellingen van het 
fasemodel, effectiever is dan een behandeling die afwijkt van deze veronderstellingen. 
In dit vijfde hoofdstuk wordt een studie beschreven die deze vraag wél aan de orde stelt. 
De patiënten die zijn beschreven in hoofdstuk 4 werden vier weken langer gevolgd, 
waarbij dezelfde meetinstrumenten werden gebruikt. Na de vier in hoofdstuk 4 
genoemde sessies, kregen de patiënten in de twee behandelcondities (RT en ET) nog 
vier sessies van de tegenovergestelde behandeling. Hierdoor werden twee 
behandelcondities verkregen die bestonden uit acht sessies: óf vier RT-sessies gevolgd 
door vier ET-sessies (RT-ET), óf vier ET-sessies gevolgd door vier RT-sessies (ET-
RT). De patiënten in WL werden ook gedurende vier extra weken gevolgd. De effecten 
van de drie onderzoekscondities, RT-ET, ET-RT en WL werden met elkaar vergeleken 
ten aanzien van verandering in remoralisatie en symptoomreductie (voormeting en 
nameting na sessie 8). We verwachtten dat RT-ET tot betere uitkomsten zou leiden dan 
ET-RT, omdat RT-ET overeenkomt met de volgorde van verandering zoals in het 
fasemodel wordt verondersteld. Van ET-RT werd verwacht dat deze tot minder goede 
uitkomsten zou leiden. Het direct aan de orde stellen van de symptomen zou immers 
geen ruimte laten aan de remoralisatie die nodig is om een effectieve behandeling van 
symptomen mogelijk te maken. 
 Tweeënzeventig patiënten met een paniekstoornis met agorafobie voltooiden de 
studie zoals beschreven in hoofdstuk 5. Vergeleken met de WL werd er significante 
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verbetering gevonden op remoralisatie bij zowel RT-ET (ES = 0.52 – 0.88) als bij ET-
RT (ES = 0.43 – 0.61). Vergeleken met de WL werd er tevens significante verbetering 
gevonden in symptoomreductie voor zowel RT-ET (ES = 0.65) als voor ET-RT (ES = 
0.87). Bewijs dat RT-ET effectiever was dan ET-RT kon bij geen van de uitkomstmaten 
worden vastgesteld. Een behandeling die onmiddellijk startte met de aanpak van de 
symptomen en daarna overging op remoralisatie bleek dus even effectief als een 
behandeling die als eerste gericht was op remoralisatie en daarna pas op de aanpak van 
de symptomen. Concluderend kan gesteld worden dat in de huidige studie een 
behandeling die ontworpen was overeenkomstig de veronderstellingen van het 
fasemodel niet effectiever was dan een behandeling die afweek van deze 
veronderstellingen.  
 
 
Samenvatting van de centrale bevindingen van de empirische studies 
 
1. Remoralisatie wordt adequaat gemeten met de nieuw ontwikkelde RS. Dit 12-
item zelfrapportageinstrument heeft goede psychometrische eigenschappen, is 
gemakkelijk af te nemen en eenvoudig te interpreteren wanneer het wordt 
gebruikt in onderzoek naar de effecten van psychotherapie met patiënten uit de 
GGZ.  
2. Remoralisatie is gevoelig voor therapeutische verandering bij patiënten die 
lijden aan paniekstoornis met agorafobie. Dit is het geval voor alle in onze 
studies bestudeerde behandelingen (paniekmanagement, medicamenteuze behan-
deling met SSRI’s, RT, ET, RT-ET en ET-RT).  
3. Gedurende de bestudeerde behandelingen volgen remoralisatie en symptoom-
reductie eenzelfde patroon van verandering. 
4. Remoralisatie is gerelateerd aan veranderingen in gezondheidsgerelateerde 
kwaliteit van leven, terwijl dat voor symptoomreductie niet het geval is.  
5. Behandeleffecten voor remoralisatie en symptoomreductie zijn niet te 
onderscheiden van elkaar: behandeling specifiek gericht op slechts één van de 
effecten (óf remoralisatie óf symptoomreductie) is aantoonbaar effectief op 
beide. 
6. Een behandeling overeenkomstig het fasemodel van Howard en collega’s (1993) 
is niet effectiever dan een behandeling die afwijkt van dat model. Beide 
behandelingen zijn effectief in het bewerkstelligen van remoralisatie en 
symptoomreductie. 
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Algemene beperkingen en overwegingen 
 
Hieronder worden beperkingen en overwegingen met betrekking tot de gerapporteerde 
studies besproken. De informatie die wordt gegeven moet als aanvulling worden gezien 
op de discussies zoals die zijn beschreven in de eerdere hoofdstukken en is van meer 
algemene aard. 
 In alle behandelstudies (vijfde studie van hoofdstuk 2, hoofdstuk 3, 4 en 5) 
waren de steekproeven tamelijk klein. Replicatie met grotere aantallen patiënten is 
daarom nodig. Dit geldt in het bijzonder voor de in hoofdstuk 5 beschreven 
experimentele studie, waarin de effecten van twee behandelingen (RT-ET en RT-ET, 
die beiden effectief bleken) direct werden vergeleken. Het vereist een grotere steekproef 
dan de onze om te bewijzen dat er een verschil in resultaat is tussen twee effectieve 
behandelingen.  Er waren echter binnen onze bevindingen beslist geen aanwijzingen dat 
een grotere steekproef tot totaal andere resultaten zou hebben geleid. Er is sterk bewijs 
dat de veronderstelling van het fasemodel, namelijk dat een behandeling eerst gericht 
moet zijn op iemands remoralisatie, geen stand houdt.  
 Voor de ontwikkeling van de RS werden verschillende patiëntensteekproeven 
gebruikt. In onze behandelstudies werden echter alleen patiënten met paniekstoornis 
met agorafobie geïncludeerd. De resultaten uit die studies kunnen strikt genomen dus 
niet gegeneraliseerd worden; ze gelden mogelijk niet voor andere patiëntengroepen. De 
reden waarom we ons in de behandelstudies concentreerden op patiënten met 
paniekstoornis met agorafobie was een methodologische. In de eerdere studies die het 
fasemodel testten (Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; 
Howard et al., 1993; Joyce et al., 2002; Kopta et al., 1994; Lutz et al., 2001; 
Martinovich, 1998) werd gebruikgemaakt van algemene symptoominstrumenten. Het is 
bekend dat deze instrumenten algemeen psychisch lijden (distress) meten, terwijl dat 
juist een belangrijk aspect van de toestand van demoralisatie is (de Figueiredo & Frank, 
1982). Algemene symptoominstrumenten zijn daarom ongeschikt om remoralisatie en 
symptoomreductie van elkaar te onderscheiden. Daarom besloten wij in het huidige 
onderzoeksproject een patiëntengroep te selecteren die niet alleen goed onderzocht en 
goed beschreven is in de literatuur, maar waarvoor ook goed gedocumenteerde en 
passende meetinstrumenten beschikbaar zijn om de specifieke symptomen te meten. Dit 
was het geval bij patiënten lijdend aan paniekstoornis met agorafobie. Deze 
patiëntengroep was ook aantrekkelijk omdat daarover specifieke en empirisch 
onderbouwde behandelingen beschikbaar zijn. We hebben echter geen duidelijke reden 
om aan te nemen dat de bevindingen uit onze behandelstudies niet zouden gelden voor 
andere patiëntengroepen voor wie ook empirisch onderbouwde behandelingen en 
specifieke symptoominstrumenten beschikbaar zijn. Toekomstig onderzoek zal moeten 
worden uitgevoerd om hier meer duidelijkheid over te verschaffen.  
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Voor heel andere patiëntengroepen is het echter niet ondenkbaar dat 
remoralisatie een ander patroon van verandering laat zien dan symptoomreductie. Bij 
patiëntengroepen met chronische aandoeningen, zoals schizofrenie of somatisatie-
stoornis, zou verwacht kunnen worden dat er geen verandering optreedt in symptoom-
reductie, terwijl er wel verandering in remoralisatie optreedt (Shrivastava, Johnston, M., 
Shah, & Bureau, 2010; Strauss, 1994). Verder onderzoek naar remoralisatie bij 
chronische patiëntengroepen is noodzakelijk om een volledig inzicht in remoralisatie te 
krijgen. 
 Men kan bezwaren hebben tegen het feit dat de steekproef waarover werd 
gerapporteerd in studie 5 van hoofdstuk 2 dezelfde is als in hoofdstuk 3. Wij zijn echter 
van mening dat dit geen probleem oplevert aangezien de doelstelling van de studies 
verschillend is en in studie 5 van hoofdstuk 2 alleen de voor- en nametingen zijn 
gebruikt. Het doel was om, in aanvulling op de andere studies van hoofdstuk 2 naar de 
ontwikkeling, betrouwbaarheid en validiteit van de RS, globaal de gevoeligheid voor 
verandering van de RS te meten. In hoofdstuk 3 daarentegen zijn alle acht metingen 
gebruikt om de patronen van verandering gedurende meerdere meetmomenten van 
remoralisatie en symptoomreductie te vergelijken.  
De studies zoals beschreven in hoofdstuk 4 en 5 bouwden voort op het 
fasemodel. Daarom werd de SWS van Howard en collega’s toegevoegd aan de RS als 
maat voor remoralisatie. In feite werd de SWS zelfs als primaire en de RS als 
secundaire remoralisatiemaat gebruikt omdat er gegevens van de RS verloren waren 
gegaan. De resultaten van beide studies toonden aan dat de SWS-scores en RS-scores 
vergelijkbaar waren. Achteraf roepen deze bevindingen de vraag op of de SWS en de 
RS niet even geschikt zijn om de verandering van remoralisatie tijdens psychotherapie 
te onderzoeken. Van tevoren konden wij niet weten dat de SWS redelijk geschikt zou 
zijn voor de beantwoording van onze onderzoeksvragen in deze twee studies. Met de 
wetenschap van nu beschouwen we de RS echter nog steeds als een beter alternatief 
voor het meten van remoralisatie dan de SWS. Ten eerste is de RS goed onderzocht en 
gedocumenteerd in de vijf studies die zijn beschreven in hoofdstuk 2, waarbij 
verschillende steekproeven werden gebruikt die een verscheidenheid aan patiënten uit 
de GGZ betroffen alsmede niet-patiënten. Ten tweede is de RS met 12 items van 
voldoende lengte om over een goede betrouwbaarheid en validiteit te beschikken en 
tegelijkertijd kort genoeg om gemakkelijk te worden afgenomen bij herhaalde metingen 
in effectonderzoek. De SWS daarentegen is zeer kort met slechts drie items in de versie 
die hier gebruikt is. Dit betekent dat de betrouwbaarheid en constructvaliditeit 
gemakkelijk te laag kunnen worden. Ten derde zijn er verschillende versies van de SWS 
in omloop (de 2-itemversie van Howard et al., 1993; de 3-itemversie van Grissom, 
Lyons, & Lutz, 2002 en de 4-itemversie van Callahan et al., 2006). Er is dus geen 
eenduidige versie en het is niet duidelijk of er een voorkeur bestaat voor één van deze 
versies. Ten vierde bestaat demoralisatie volgens de Figueiredo en Frank (1982) uit 
Samenvatting en Algemene Discussie 
 117
twee dimensies: subjectieve incompetentie en psychisch lijden. De drie versies van de 
SWS bevatten echter geen items over subjectieve incompetentie, wat impliceert dat de 
SWS niet de bredere definitie van demoralisatie van Frank omvat, in tegenstelling tot de 
RS die wél uitgaat van de bredere definitie.  
 In de experimentele studies die in hoofdstuk 4 en 5 worden besproken volgden 
we patiënten die gedurende relatief korte tijd een behandeling ondergingen (namelijk 
vier en acht sessies). Op basis van het fasemodel zouden we mogen verwachten dat 
remoralisatie en symptoomreductie gedurende deze periode (namelijk als reactie op de 
eerste paar sessies van de behandeling) van elkaar te onderscheiden zouden zijn. Het is 
evenwel theoretisch mogelijk dat remoralisatie en symptoomreductie pas later in de 
behandeling van elkaar te onderscheiden zijn. De resultaten van de naturalistische studie 
in hoofdstuk 3 laten aan de andere kant zien dat dit onwaarschijnlijk is, aangezien het 
patroon van verandering ten aanzien van remoralisatie en symptoomreductie ook hoog 
correleerde gedurende de langere periode van 28 weken. Het lijkt dus onwaarschijnlijk 
dat wij, als gevolg van de korte duur van de behandelingen in onze experimentele 
studies, de mogelijkheid om een duidelijk onderscheid te vinden tussen remoralisatie en 
symptoomreductie hebben gemist.  
 
 
Implicaties van de bevindingen 
 
Bij de bespreking van de implicaties van de bevindingen van onze studies moeten de 
beperkingen en overwegingen die hierboven zijn beschreven in aanmerking  worden 
genomen. Allereerst zullen de implicaties voor het fasemodel van Howard en collega’s 
(1993) worden besproken. Daarna komen de implicaties voor de centrale onderzoeks-
vraag aan bod. 
 Clinici vinden het fasemodel aantrekkelijk en theoretisch waardevol vanwege 
zijn eenvoud, transparantie en gedetailleerde beschrijving van de fases voor allerlei 
soorten patiënten in de klinische praktijk (Joyce et al., 2002). Zoals beschreven in 
hoofdstuk 4 en 5 hadden de eerdere studies naar het fasemodel (Barkham et al., 1996; 
Callahan et al., 2006; Hilsenroth et al., 2001; Holloway, 2004; Howard et al., 1993; 
Joyce et al., 2002; Kopta et al., 1994; Lutz et al., 2001; Martinovich, 1998) te lijden 
onder een aantal methodologische tekortkomingen en zijn de bevindingen op zijn best 
ambigu, waardoor bevestiging of weerlegging van de basale assumpties van het model 
wordt bemoeilijkt. Volgens het fasemodel vormt remoralisatie de eerste fase van 
verandering en symptoomreductie de tweede. In de studies beschreven in hoofdstuk 3 
en 4 kon remoralisatie echter niet worden onderscheiden van symptoomreductie. Beide 
traden gelijktijdig op. Dit kan een aanvullende verklaring zijn voor het feit dat eerdere 
studies de assumpties waarop het fasemodel is gebaseerd niet konden bevestigen. Het is 
namelijk niet mogelijk om aan te tonen dat verandering in de ene fase vooraf gaat aan 
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verandering in de volgende fase, of dat verandering in de eerdere fase noodzakelijk is 
om verandering in de volgende fase te laten optreden, indien de effecten voor 
remoralisatie (fase 1) en symptoomreductie (fase 2) niet van elkaar te onderscheiden 
zijn. Omdat we bovendien in hoofdstuk 5 niet konden bewijzen dat een 
behandelvolgorde overeenkomstig het fasemodel (RT gevolgd door ET) effectiever was 
dan een omgekeerde behandelvolgorde (ET gevolgd door RT), kunnen er dus serieuze 
vragen gesteld worden over de juistheid van de beschrijving van de 
psychotherapeutische verandering zoals die wordt geschetst in het fasemodel.  
De hoofdvraag van dit proefschrift was: Is remoralisatie in het onderzoek naar 
de effecten van psychotherapie een waardevolle aanvullende uitkomstmaat naast het 
meten van symptoomreductie? Er zijn meerdere antwoorden te geven. We beginnen met 
een aantal praktische kwesties, waarna we ten slotte de relatie tussen remoralisatie en 
symptoomreductie theoretisch aan de orde stellen. 
 Het onderzoek van dit proefschrift resulteerde in een geschikt en bruikbaar 
instrument om remoralisatie te meten. Zoals we verwachtten bleek remoralisatie een 
concept dat gevoelig is voor psychologische verandering en geschikt voor herhaalde 
metingen gedurende het verloop van de behandeling. Het huidige onderzoek heeft 
daarom bijgedragen aan de kennis over remoralisatie. Het onderzoek heeft aangetoond 
dat de meting ervan goed mogelijk is en dat de geboden behandelingen voldoende 
verandering bewerkstelligen in relatie tot een wachtlijst. Dit is in overeenstemming met 
de verwachtingen op basis van de theorie van Jerome Frank waarin wordt verondersteld 
dat remoralisatie een cruciaal aspect is van een effectieve behandeling (zie bijvoorbeeld 
Frank & Frank, 1991). Het lijkt daarom waardevol en belangrijk remoralisatie als 
uitkomstmaat in onderzoek naar de effecten van psychotherapie op te nemen. 
 Het opnemen van remoralisatie zal vermoedelijk het perspectief op 
uitkomstmaten in onderzoek naar de effecten van psychotherapie verbreden. Dit zou tot 
een toename van algehele acceptatie van de resultaten van dergelijk onderzoek kunnen 
leiden. Kritiek dat dergelijke resultaten alleen maar symptoomreductie betreffen, is dan 
immers niet langer houdbaar. Opnemen van remoralisatie als uitkomstmaat kan 
positieve consequenties hebben voor de implementatie van onderzoeksresultaten in de 
klinische praktijk. Therapeuten zullen waarschijnlijk vinden dat, door het bredere 
perspectief op behandeleffecten, hun praktijk beter wordt gereflecteerd in de 
onderzoeksresultaten.   
 Vanuit het perspectief van patiënten kan het opnemen van remoralisatie als 
uitkomstmaat ook zorgen voor een completer beeld, omdat slechts een klein deel van de 
patiënten symptoomreductie als enige of meest belangrijke doel van behandeling noemt 
(Grosse Holtforth & Grawe, 2002). Voor patiëntengroepen die bekend staan als moeilijk 
te genezen in termen van symptoomreductie en daardoor het stempel onbehandelbaar 
krijgen in de huidige onderzoeksgeneratie, kan het meten van remoralisatie resulteren in 
het besef dat zij wel degelijk behandelbaar zijn.  
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 Nu we weten dat het meten van remoralisatie goed mogelijk is en dat 
betrouwbare behandelingen remoralisatie bewerkstelligen, kunnen we de relatie tussen 
remoralisatie en symptoomreductie nader bekijken. De huidige resultaten laten zien dat 
de twee maten moeilijk te onderscheiden zijn. De verandering op beide uitkomstmaten 
traden samen op en covarieerden in de huidige studies. Deze covariantie zou kunnen 
worden veroorzaakt door de (methodologische) keuzes die we hebben gemaakt, zoals de 
patiëntenpopulatie die we onderzochten of de duur van de behandelingen (zie Algemene 
beperkingen en overwegingen). In de serie van studies die hier werden uitgevoerd 
waren wij echter niet in staat die relatie te ontrafelen. Zoals bliksem en donder samen 
optreden, maar ook twee duidelijk te onderscheiden fenomenen zijn, zouden 
remoralisatie en symptoomreductie ook samen kunnen optreden en toch twee te 
onderscheiden psychologische processen met verschillende inhoud en betekenis kunnen 
zijn. Het enige resultaat dat in de richting van onderscheid tussen remoralisatie en 
symptoomreductie wijst, is beschreven in hoofdstuk 3. Hierin overlapten remoralisatie 
en symptoomreductie weliswaar sterk, maar was alleen remoralisatie gerelateerd aan 
gezondheidsgerelateerde kwaliteit van leven. Het algemeen functioneren van de patiënt, 
op het werk en gedurende zijn dagelijkse activiteiten en de door hem ervaren psychische 
gezondheid, correleerden wél met remoralisatie, maar niet met symptoomreductie.  
 Over het geheel genomen, tenzij door replicatie mogelijk het tegendeel wordt 
bewezen, is de meest voor de hand liggende conclusie dat remoralisatie en 
symptoomreductie niet van elkaar te onderscheiden uitkomstmaten van psychotherapie 
zijn. Remoralisatie lijkt niet op te treden zonder symptoomreductie en andersom lijkt 
symptoomreductie niet op te treden zonder remoralisatie. Dit betekent dat nieuw 
perspectief en herwonnen hoop de negatieve impact van de symptomen van een 
psychische stoornis verlichten. Omgekeerd geven verminderde angst, minder 
vermijdingsgedrag en minder paniekaanvallen, perspectief aan patiënten en daarmee 
herwonnen hoop.  
 Nu in het verloop van de studies voor dit proefschrift steeds duidelijker lijkt te 
zijn geworden dat remoralisatie en symptoomreductie niet van elkaar te onderscheiden 
zijn, is de vraag die op dit moment gesteld moet worden wat de waarde van het meten 
van remoralisatie is in aanvulling op het meten van symptoomreductie. Wanneer 
symptoomreductie wordt gemeten kan blijkbaar ook de verandering in remoralisatie 
worden voorspeld. Dit suggereert dat wanneer symptoomreductie wordt bepaald, 
remoralisatie niet bepaald hoeft te worden. Aan de andere kant staat deze wijze van 
redeneren tevens een andere conclusie toe, namelijk dat het meten van remoralisatie het 
meten van symptoomreductie overbodig maakt. Het aantonen van remoralisatie is 
immers voldoende om de effectiviteit van een behandeling te bepalen, aangezien het 
meten van symptoomreductie niets toevoegt aan het meten van remoralisatie. Dit geldt 
in elk geval voor de groep patiënten met paniekstoornis en agorafobie.  
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 De vraag dient zich vervolgens aan of we met de gebruikte meetmethoden 
überhaupt wel in staat zouden zijn geweest om een onderscheid te meten tussen 
remoralisatie en symptoomreductie. In alle studies die hier zijn beschreven werden 
zelfrapportageinstrumenten gebruikt om zowel remoralisatie als symptoomreductie te 
meten. Patiënten waarderen hun eigen niveau van remoralisatie en hun niveau van 
symptomen op basis van eigen, subjectieve, waarnemingen. Voor het meten van 
remoralisatie bestaat er geen twijfel over dat deze methode de meest juiste is. 
Remoralisatie gaat namelijk over iemands subjectieve waarnemingen, gevoel van 
zelfwaarde en waargenomen vermogen om doelen te bereiken. Echter, voor het meten 
van symptomen is de juistheid van zelfrapportage discutabel. Men kan zich namelijk 
afvragen of patiënten wel in staat zijn om een zorgvuldige inschatting te maken van de 
mate waarin zij lijden aan een scala van symptomen behorende bij een bepaalde 
stoornis. Er zijn alternatieve vormen van symptoommeting zoals observatie-
instrumenten, gedragsmaten of zogenaamde impliciete symptoommaten. Het is zeer 
goed mogelijk dat nader onderzoek naar de relatie tussen remoralisatie en dergelijke 
alternatieve symptoommaten uitwijst dat zelfrapportage van symptomatologie  veruit 
de meest gebruikte meetmethode in hedendaags onderzoek naar de effecten van 
psychotherapie  tot minder vanzelfsprekende en minder duidelijk te interpreteren 
onderzoeksresultaten leidt dan meestal wordt aangenomen. 
 Voortbouwend op het bovenstaande kunnen we stellen dat er blijkbaar een 
verschil gemaakt wordt tussen daadwerkelijke (identificeerbare en meetbare) 
symptomen en de beleving van de beperkingen van symptomen als twee van elkaar te 
onderscheiden fenomenen. Een dergelijk onderscheid tussen de feitelijke symptomen en 
de beleving van symptomen is in overeenstemming met het medische model dat is 
omarmd door de huidige generatie onderzoekers op het gebied van de psychotherapie. 
Bij een somatische aandoening zou een verhoogde lichaamstemperatuur een voorbeeld 
zijn van een feitelijk symptoom en koude rillingen de daarbij behorende beleving van 
het symptoom. In hoeverre dit onderscheid houdbaar of behulpzaam is voor de meeste 
psychiatrische stoornissen is echter zeer de vraag. Voor een psychiatrische stoornis, 
zoals paniekstoornis met agorafobie, lijkt de aanname van een onderscheid tussen de 
feitelijke symptomen en de beleefde klachten kunstmatig. Het is namelijk overduidelijk 
dat veel psychiatrische problemen juist gaan over ongewenste gevoelens en gedachten 
en dat de symptomen van de stoornis juist bestaan uit wat de patiënt beleeft. Misschien 
is dit dus de uiteindelijke reden waarom wij in dit proefschrift niet in staat bleken om 
remoralisatie en symptoomreductie van elkaar te onderscheiden, omdat namelijk 
remoralisatie, evenals symptoomreductie, juist datgene is wat een patiënt beleeft. 
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Remoralization Scale – English Version 
 
Instruction: This questionnaire concerns your self-perceptions. Please indicate the extent 
to which you agree with the following statements by marking the appropriate box. 
Indicate how you feel at this point in time. Do not think too long before answering; your 
initial reaction is usually the best. There are no wrong answers.  
If you feel that the answer you would like to give is not one of the options, please 
choose that statement which is closest to your answer. Mark only one box per question.  
 
1. I am in control of my life. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
2. I am usually confident about the decisions I make. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
3. I feel relaxed. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
4. On the whole, I am satisfied with myself. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
5. I enjoy life. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
6. Right now, I see myself as being pretty successful.  
  totally disagree   disagree a lot   agree a lot   totally agree 
 
7. I take a positive attitude toward myself.  
  totally disagree   disagree a lot   agree a lot   totally agree 
 
8. At this point in time, I am meeting the goals I set for myself. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
9. I feel that I am a person of worth, at least on an equal plane with others. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
10. I am generally optimistic about the future. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
11. I can think of many ways to reach my current goals. 
  totally disagree   disagree a lot   agree a lot   totally agree 
 
12. I have self-confidence. 
  totally disagree   disagree a lot   agree a lot   totally agree 
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Remoralisatieschaal – Nederlandse Versie 
 
Deze vragenlijst gaat over uw zelfbeleving. Wilt u telkens aangeven in welke mate u het 
eens bent met de uitspraak, door het hokje van uw keuze aan te kruisen. Geef aan hoe u 
er op dit moment over denkt. Denk niet te lang na over uw antwoord; uw eerste reactie 
is meestal de beste. Er bestaan geen foute antwoorden.  
Wanneer u de indruk heeft dat uw antwoord niet bij de antwoordcategorieën staat, kies 
dan het hokje dat uw antwoord het best benadert. Kruis per vraag slechts één hokje aan.  
 
1. Ik heb de regie over mijn leven. 
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
2. Ik heb meestal vertrouwen in de beslissingen die ik neem.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
3. Ik voel me ontspannen.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
4. Over het geheel genomen ben ik tevreden met mezelf. 
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
5. Ik heb zin in het leven.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
6. Op dit moment vind ik mezelf redelijk succesvol.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
7. Ik sta positief tegenover mijzelf. 
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
8. Op het ogenblik lukt het me de dingen te realiseren die ik mezelf tot doel heb gesteld. 
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
9. In vergelijking met anderen vind ik mijzelf even waardevol.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
10. Ik ben in het algemeen optimistisch over de toekomst.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
11. Ik kan momenteel tal van manieren bedenken om mijn doelen te bereiken. 
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
 
12. Ik heb zelfvertrouwen.  
  helemaal mee oneens   grotendeels mee oneens   grotendeels mee eens   helemaal mee eens 
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 Nicole (jij maakte je op meerdere terreinen onmisbaar), Ruth, Josh, Anneke, Iris, 
Lieke, Sanne, Anke, Lieke, Marieke, Spence en Lars: dank jullie wel voor je inspanning 
en enthousiasme bij het leren en het uitvoeren van de onderzoeksbehandelingen. Paul 
Rijnders, dank je wel voor het bewerken van het kortdurend behandelmodel tot de hier 
gebruikte remoralisatietherapie en voor het tot driemaal toe trainen van de nieuwe stu-
denttherapeuten. Hedwig, jou wil ik bedanken voor de supervisies van de remoralisatie-
therapie. Mirjam en Ger, fijn dat de studenttherapeuten tijdens de supervisies konden 
profiteren van jullie jarenlange ervaring met exposuretherapie. 
 Ik heb veel hulp gekregen voor het berekenen van de resultaten en het correct en 
mooi opschrijven hiervan. Graag noem ik hier Lee Ann Weeks voor het corrigeren van 
de Engelse teksten, William van der Veld, Rinske de Graaff Stoffers en Theo van der 
Weegen voor de statistische hulp. Raoul Postel, bedankt voor het mooie ontwerp van de 
omslag.  
 Portiers van ‘het Spinoza’ Cor en Ron, bedankt voor de gezellige entree en de 
praatjes bij het ophalen van de post. Medewerkers van de sectie klinische psychologie, 
wat fijn dat jullie mij al die jaren hebben geadopteerd! Het was prettig dat ik zomaar een 
kamer kreeg en dat jullie me onderdeel van de sectie lieten voelen. Hiervoor met name 
ook dank aan Eni. In al die jaren zijn er natuurlijk veel medewerkers en vooral junioren 
geweest met wie ik gezellig heb geluncht, zoals met Gero, Laura, Julie, Joyce, 
Machteld, Leontien, Monique, Cilia, Linda, Floor en Anke. Het is onmogelijk om hier 
iedereen te noemen, maar toch: allemaal bedankt! Maria en Wies, bedankt voor jullie 
interesse en gezelligheid. 
 De maandelijkse vrijdagmiddagen met het Manipel, later NijCARE waren ont-
zettend inspirerend. Het bespreken van mijn en andermans onderzoek heeft me steeds 
geprikkeld en scherp gehouden. En wat was het ondertussen ook leuk!  
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 Een woord van dank aan De Gelderse Roos, mijn werkgever vanaf 2006, is hier 
op zijn plaats. Fysiek zat ik in Nijmegen, maar ik voelde me ook thuis op mijn officiële 
onderzoeksplek Grip (thans ProCES) in Wolfheze. De promovendi-bijeenkomsten 
waren voor mij een waardevolle gelegenheid om teksten voor te leggen. Alle 
promovendi van Grip, dank jullie wel. Giel, Bea en Annet, jullie werden vaak 
gesommeerd om vooral de promovendi aan het woord te laten. Ik ben blij dat jullie je af 
en toe niet in konden houden: jullie inbreng was waardevol, ik heb veel van jullie 
geleerd. Gerrit, Bauke en ik, we hebben alle drie de ZonMW-OOG subsidie 
binnengehaald en zijn alle drie net klaar met ons promotieonderzoek. Ik vond het leuk 
om dit traject samen met jullie te bewandelen en zal het contact met jullie missen. 
Bauke, geen lange gesprekken meer totdat de portier van Soeterbeeck gaat slapen. De 
‘buitenklas’ van het ACSW heeft mij sowieso altijd energie en onderzoekszin gegeven.  
Caroline, Hanneke, Ger, Huub, Alphons en Miranda, het was heel fijn om een 
aantal jaar onderdeel van jullie team uit te maken. Het voelt als thuiskomen nu ik weer 
bij jullie werk. Het SPON ken ik al van voor de GZ-opleiding en het leek mij altijd al 
een enthousiaste werkkring. Monic, Jan, Hella en de anderen: leuk dat ik daar nu deel 
van uit mag maken.  
 
Giel en Ger, wat hebben we véél GGW’s gehad. Dat waren zeker geen kabbelende 
besprekingen. We hebben gestreden en het elkaar niet makkelijk gemaakt (soms vooral 
jullie mij niet). Maar het was ook leuk, inspirerend, behulpzaam en het meest leerzame 
van alles wat ik in dit hele traject heb meegemaakt. Jullie hebben ontzettend veel in dit 
project, en dus in mij, geïnvesteerd. Giel, jouw scherpte en bezieling waren als 
stuwende kracht essentieel om het onderzoek naar grotere hoogten te brengen. Ger, als 
ik jouw kennis van (experimentele) behandelstudies, van angststoornissen, jouw 
nauwlettendheid en geduld bij het redigeren toch niet had gehad… hoe had het dan 
gemoeten?! Dank je wel Giel en Ger. Ik kan me geen beter begeleidingsduo voorstellen. 
Jullie vulden elkaar zo mooi aan. Ik vraag me af hoe het straks, zonder onze regelmatige 
GGW’s, zal zijn. Hopelijk zetten we de traditie van af en toe een borrel of dinertje 
voort. Giel, jij blijft mijn baas en daar ben ik blij om.  
 
Nu richt ik mij tot de mensen die minder direct, maar wel persoonlijk, bij mijn onder-
zoek betrokken zijn geweest. Els, tante en coach, jij liet me inzien dat niemand anders 
dan ikzelf het mij oplegde dit promotieonderzoek af te ronden. Dank je wel hiervoor. Jij 
en Peter, bedankt voor jullie liefdevolle interesse en dat jullie zo gek zijn op Jules!  
En dan Nienke. Niemand was méér dan jij op de hoogte van mijn 
onderzoek(sperikelen), onder andere door de talloze fietsritten naar het werk. Het was 
fijn om dit met je te delen en ik vind het een heel plezierig idee dat jij straks in de aula 
achter me staat. En ik weet dat dat niet alleen letterlijk is. Ik wil je hier graag bedanken 
voor je vriendschap. We zetten dit allemaal voort! Eveline en ook Michiel, ik ben blij 
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met het feit dat onze vriendschap in de afgelopen jaren steeds hechter is geworden. We 
delen zoveel ervaringen omdat we in dezelfde levensfase zitten. Wat is het fijn dat we 
nu ook dezelfde woonplaats delen! Eveline, dat jij ook mijn paranimf bent past helemaal 
bij deze ontwikkeling. Dank je wel.  
Lisabeth en Maartje, we zaten in hetzelfde schuitje: promotieonderzoek en de 
GZ-opleiding tegelijkertijd. We hebben heerlijk samen lopen klagen en roddelen. Jullie 
kozen moedig een andere weg voor jullie onderzoek, maar onze vriendschap is 
gebleven. Samen met die andere oud-gripper Hedwig hebben we onze regelmatige 
etentjes. Dank jullie wel, alle drie, voor die gezelligheid. Irma en Marieke, vriendinnen 
vanaf de studietijd, bedankt. Vriendschappen maken alles lichter! 
 Graag richt ik ook een woord van dank aan mijn schoonfamilie. Jullie hebben je, 
ieder op zijn of haar eigen wijze, betrokken gevoeld bij mijn onderzoek en werk-
zaamheden. Dank aan jullie allemaal. 
Lieve Irene, ik ben blij dat jij mijn zus bent! Niemand die mij en mijn 
achtergrond zo goed kent als jij. Samen hebben we plezier en we vinden steun bij 
elkaar. Ik geniet altijd van jouw aanwezigheid en voel me zo heerlijk thuis bij jou en 
ook bij mijn lieve zwager Jaron. Dank je wel voor dit alles.  
 Nu ik alle mensen die me na staan de revue laat passeren zie ik hoeveel warmte 
en betrokkenheid mij omringt. Papa en Mama, jullie waren de allereerste die mij 
hiermee omringden en jullie zijn hier nooit mee gestopt. Ik ben jullie zó dankbaar, om 
dat te uiten schieten woorden te kort. Mama, als het even minder gaat hoef ik jou dat 
nooit te zeggen. Met jouw voelsprieten heb je het soms al eerder door dan ikzelf. Dank 
je voor al je steun en liefde. Alex, jij bent als een vader, zo betrokken, lief, en geduldig. 
Ik prijs mezelf gelukkig dat jij in mijn leven bent gekomen. Papa, jouw interesse en 
geloof in mijn kunnen zijn voor mij als een rots in de branding. Dank je wel voor jouw 
liefde en vertrouwen. Elisabeth, jij ook bedankt voor je betrokkenheid. Jullie kregen 
samen vijf jaar geleden Cara en Macha. Lieve zusjes, jullie zijn schatten en kleine 
doerakken. 
 
Nu wil ik hier met liefde de twee belangrijkste mannen in mijn leven noemen.  
Lieve Jules, jij bent de enige in deze hele rij die niet heeft gezorgd dat het 
onderzoek mogelijk was of dat het makkelijker was. Maar jij hebt met je heerlijke, 
zonnige, enthousiaste aard zoveel lichtheid in mijn bestaan gebracht dat ik je daarvoor 
op deze plek zielsgraag wil bedanken. Jij zorgt voor heel veel kleur! 
Lieve Joris, nu jij nog, jij maakte het onderzoek zeker makkelijker, zoals jij 
zovéél makkelijker maakt in mijn leven. Ik wil je bedanken voor het zijn van mijn huis 
en mijn thuis, en ook voor ons mooie gezin en voor het plezier wat wij samen steeds 
weer hebben. Jij bent goud waard! 
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Wiede Vissers werd geboren op 19 augustus 1979 in Eindhoven. Zij behaalde in 1998 
haar VWO-diploma, waarna zij de studie psychologie aan de Katholieke Universiteit 
Nijmegen (thans Radboud Universiteit) begon. Zij koos voor de afstudeerrichting 
klinische psychologie. Na haar afstuderen in 2002 startte zij met haar promotie-
onderzoek naar remoralisatie bij het Academisch Centrum Sociale Wetenschappen 
(ACSW) van dezelfde universiteit. Daarnaast werkte zij tevens als psycholoog op het 
Ambulatorium Volwassenen van het ACSW. Eind 2005 verwierf zij de ZonMW OOG-
subsidie. Vanaf 2006 was zij als wetenschappelijk medewerker in dienst van GRIP 
(thans ProCES) van De Gelderse Roos, waar zij verder werkte aan haar promotie-
onderzoek, waarvan dit proefschrift het resultaat is. Tegelijkertijd startte zij met de 
opleiding tot GZ-psycholoog bij het SPON. Voor de praktijkopleiding zette ze eerst 
twee jaar haar werkzaamheden bij het Ambulatorium voort. Na twee jaar vervolgde ze 
de praktijkopleiding bij De Gelderse Roos, Veluwe Vallei. In december 2009 behaalde 
zij haar registratie als GZ-psycholoog. Sinds juli 2010 werkt zij als programma-
coördinator eerstelijnspsychologie bij het ACSW. Zij volgt tevens de profielopleiding 
tot eerstelijnspsycholoog bij het SPON. 
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